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Abstract 
 
Platinum(IV) complexes are usually inert and stable compounds which can be 
photoactive pro-drugs to produce Pt(II) species with promising anti-cancer 
activity. Studies of the photochemistry of Pt(IV) complexes by time-dependent 
density functional theory (TDDFT) and spectroscopic methods show close 
agreement. Broad exploration of cis/trans geometries, trans influences, the nature 
of the OR
−
 and (pseudo)halogen ligands, electron-withdrawing/donating/ 
delocalizing substituents on the N-ligands, and intramolecular H-bonds shows that 
(1) the design of platinum(IV) complexes with intense bands shifted towards 
longer wavelengths (~330 nm) can be achieved by introducing intramolecular H-
bonds involving the OH ligands and 2-hydroxyquinoline or by iodido ligands, (2) 
mesomeric electron-withdrawing substituents on pyridine result in low-energy 
absorption with significant intensity in the visible region, and (3) the distinct 
makeup of the molecular orbitals in electronic transitions for cis/trans-{Pt(N3)2} 
isomers result in different photoproducts. In general, the comparison of the 
optimised geometries shows that Pt(IV) complexes with longer Pt−L bonds are 
more likely to undergo photoreduction with longer-wavelength light. Complex 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-nitropyridine)] was first synthesised. 
The experimental UV-Vis spectrum in aqueous solution correlates well with the 
intense band in the computed spectrum whereas the overlay in the low-energy 
absorption region can be improved by a solvent model. This combined 
computational and experimental study shows that TDDFT can be a design tool to 
tune the coordination environment for optimizing photoactive Pt(IV) compounds 
as anticancer agents without immediate need for synthesis. 
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Additionally, molecular modeling is used to study DNA distortions induced by 
binding metal-containing fragments derived from cis-
diamminodichloroplatinum(II) (cisplatin) and a new class of photoactive platinum 
anticancer drugs. Ligand field molecular mechanics (LFMM) parameters for Pt–
guanine interactions are derived and validated against a range of experimental 
structures from the Cambridge Structural Database, published quantum 
mechanics/molecular mechanics (QM/MM) structures of model Pt-DNA systems 
and additional DFT studies. LFMM gives a good description of the local Pt-
guanine coordination at a fraction of the computational cost of QM/MM methods. 
The force field is then used to develop protocols for ligand field molecular 
dynamics (LFMD) simulations using experimentally characterised bifunctional 
DNA adducts involving both an intra- and an interstrand crosslink of cisplatin as a 
prelude to studying the interaction of trans-{Pt(py)2}
2+
 (P, py = pyridine), the 
major photoproduct of the novel platinum(IV) complex trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (17), with the DNA duplex dodecamer, 
d(C1C2T3C4T5C6G7T8C9T10C11C12)• d(G13G14A15G16A17C18G19A20G21A22G23G24). 
Based on the observed formation of a trans species when 17 is photoreduced in 
the presence of 5’-guanosine monophosphate plus the major-groove binding mode 
of the monofunctional complex cis-{Pt(NH3)2(py)}
2+
, P is proposed to coordinate 
to G7 and G19. This P-DNA adduct has a widened minor groove at one end of the 
platinated site and deepened minor groove at the opposite end, and exhibits a 
global bend of ~67° and an unwinding of ~20°. Brabec et al. subsequently 
demonstrated experimentally that such interstrand GG crosslinks can form as a 
result of the photoactivation of 17 in the presence of DNA. Such cross-links offer 
  
xi 
 
possibilities for specific protein–DNA interactions and suggest possible 
mechanisms to explain the high potency of this photoactivated complex. 
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Chapter 1 
Introduction 
 
 
“All substances are poisonous, there is none that is not a 
poison; the right dose differentiates a poison from a remedy.” 
(Von der Besucht Paracelsus, 1567) 
  
2 
 
The overall scope of this thesis is the implementation and application of 
computational methods for understanding the structures, mechanisms of 
photoactivation, and modes of action of photoactivated anticancer platinum 
complexes to further aid drug design and development. In recent years, the 
significant increase of molecular modeling as an important integral part of 
multidisciplinary efforts in the design and synthesis of new potent 
pharmaceuticals has spurred the interest of scientists with various backgrounds on 
its application. Therefore, in addition to the contribution of computational 
approaches in rational drug design, this thesis has attempted to cover the current 
status of platinum-based drug design, the theoretical methods applicable to the 
research, and the required information for calculating and interpreting the 
experimentally observed properties on the basis of the theoretical results in the 
hope of serving as a useful reference for anyone who works in the 
multidisciplinary field of drug design and discovery and shows a zest for 
computer-aided drug design of metallopharmaceuticals.  
Chapter 1 presents a collection of overviews of platinum-based anticancer drugs, 
strategies in drug design and development, fundamental photochemical principles, 
and the design of photoactive platinum complexes as prodrugs. Chapter 2 provides 
an introduction to computational methods for modelling and designing molecules. 
Chapters 3, 4, and 5 cover my novel contributions. Chapter 3 presents a 
computational approach to tuning the photochemistry of Pt(IV) anticancer agents. 
In Chapter 4, the first application of ligand field molecular mechanics (LFMM) 
for modelling of platinum–DNA complexes is described. Chapter 5 focuses on the 
application of the novel LFMM parameters developed in Chapter 4 in simulations 
of a variety of platinum–DNA cross-links. The final Chapter 6 presents a 
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perspective on drug design and suggests future work to advance the rational 
design of metal-based anticancer complexes. 
1.1 Platinum-Based Anticancer Drugs 
The discovery of the anticancer activity of cisplatin (cis-[PtCl2(NH3)2]) and its 
clinical introduction in the 1970s is an important landmark in the history of 
successful treatment of cancers. Despite the introduction in the 1980s of 
carboplatin, a second-generation analogue that is safer but shows a similar 
spectrum of activity to cisplatin, the pace of further improvements slowed for 
decades. However, recent key advances in the elucidation of the mechanisms of 
action of the drugs and of tumour resistance to the drugs, the approval of new 
platinum-based agents (e.g. oxaliplatin), and clinical studies using platinum drugs 
in combination with resistance modulators or new molecularly-targeted drugs, 
have lead to a surge in interest in developing new anticancer platinum drugs.
1
 
1.1.1 Serendipitous Discovery 
The interest in platinum-based antitumor drugs has its origin in the 1960s, with the 
accidental discovery by Rosenberg of the inhibition of cell division by Pt 
complexes. Detailed chemical analysis identified two active complexes — trans-
diamminetetrachloroplatinum(IV) (trans-[Pt(NH3)2Cl4]) and cis-
diamminetetrachloroplatinum(IV) (cis-[Pt(NH3)2Cl4]) — as the molecules causing 
filamentation due to cell growth without proper division. The trans isomer was 
much less active. The active platinum(II) analogue — cis-[Pt(NH3)2Cl2], which 
went on to be cisplatin, was made en route to synthesising the Pt(IV) complexes, 
and it also was active in forming filaments.
2
 As it turned out, the group had 
rediscovered a known platinum coordination complex, known as Peyrone’s 
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chloride, that was originally synthesised and described in 1845.
3
 Followed by 
confirmatory in vivo tests in London, cisplatin underwent clinical testing in US. A 
very short time after the original ‘bench’ discovery, the first patients were treated 
in 1971. Approval of cisplatin for the treatment of testicular and ovarian cancer by 
the US Food and Drug Administration (FDA) was granted in 1978. Today, 
cisplatin is one of the most widely utilised antitumor drugs in the world. Its 
discovery initiated a new chapter of research in medicinal inorganic chemistry and 
has led to the synthesis and biological testing of over 3000 cisplatin analogues,
4
 
and study on other nearby elements from the periodic table (e.g. ruthenium, 
palladium, and gold). Despite its highly effective treatment in testicular and 
ovarian cancers, cisplatin has several disadvantages that include severe toxicity 
such as nephrotoxicity, neurotoxicity, and emetogensis.
5
 Tremendous efforts in 
the design of new platinum drugs were aimed at making chemotherapy safer to 
patients. The development of new platinum-based drugs has encountered many 
twists and turns over the past three decades (see timeline in Figure 1-1). At 
present, only four platinum complexes are registered as marketed drugs (cisplatin, 
carboplatin, oxaliplatin, and nedaplatin in Table 1-1.)
6
 
1.1.2 How Does Cisplatin Work? 
Upon administration, the relatively high concentration of chloride ions (~100 mM) 
maintains cisplatin in a neutral state. Inside the cell, the lower ambient chloride 
ion concentrations (~4-20 mM) facilitates the activation of cisplatin by stepwise 
aquation, and subsequent reaction with various cellular targets, most notably 
 5 
 
5
 
Figure 1-1. Milestones in the development of platinum drugs for cancer therapy. Reproduced from reference 1 with permission from Nature 
Publishing Group. 
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Table 1-1. Marketed platinum drugs (5FU = 5-fluorouracil; LV = leucovorin). 
Adapted from reference 1,6. 
Drug Approval year Dose-limiting toxicity 
 
 
Cisplatin 
Metastatic testicular 
cancer  
Metastatic ovarian 
cancer  
Transitional bladder 
cancer  
1978 
 
1978 
 
1993 
Nephrotoxicity 
Neurotoxicity, ototoxicity 
Nausea and vomiting 
 
 
Carboplatin 
Ovarian cancer  
(palliative after previous 
chemotherapy)  
Ovarian cancer, first 
line  
1989 
 
 
1991 
Myelosuppression 
(thrombocytopenia  
and neutropenia) 
Nausea and vomiting (but 
less than  
with cisplatin) 
 
Oxaliplatin 
Accelerated approval, 
metastatic colorectal 
cancer (second line 
with 5FU with LV) 
Colorectal cancer 
(previously untreated or 
adjuvant treatment with 
5FU with LV) 
2002 
 
 
 
2004 
Neurotoxicity (sensory 
peripheral 
neuropathy) 
Nausea and vomiting 
 
Nedaplatin 
Approval in Japan, 
cervical cancer, and 
non-small and small cell 
lung cancer  
1995 myelosuppresion 
 
DNA. The interaction between platinated DNA and nuclear proteins induces 
signal transduction pathways which lead to DNA-damage recognition and repair, 
cell-cycle arrest, and apoptosis or necrosis.
6,7
 Experimental characterisation of the 
types of platinum–DNA adducts formed shows the presence of approximately 
65% 1,2-d(GpG), 25% 1,2-d(ApG), and 5-10% 1,3-d(GpNpG) intrastrand cross-
links as major components, although interstrand cross-links and monofunctional 
adducts have also been identified (Figure 1-2).
6
 In all cases, platinum is bound to 
the N7 position of purine bases (Figure 1-2). Formation of cisplatin adducts 
significantly alters the structure of the target DNA by bending, unwinding, and 
 
a b c 
d e 
 
a b c 
d e 
 
a b c 
d e 
 7 
 
destabilising the duplex. The structural details of platinum-DNA adducts are 
available from X-ray, NMR and molecular mechanics simulation.
8-17
 Although 
these DNA adducts formed by platinum drugs exhibit some degree of structural 
similarity, arising from coordination to the N7 atom of the purine base, it is clear 
that each distorts the duplex DNA in a distinctive manner.
11,18
 These nuances may 
activate distinctive DNA-damage recognition and cellular processes, which 
possibly mediate cytotoxicity and anticancer properties of the compounds via 
different mechanisms of action.
1,6,7
 
 
Figure 1-2. Platinum preferential binding at N7 sites of purine bases and 
bifunctional cisplatin-DNA adducts: 1,2-d(GpG), 1,2-d(ApG), and 1,3-d(GpNpG) 
intrastrand as well as interstrand cross-links. 
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Platinum-based drugs disrupt DNA synthesis by mechanisms common to all 
actively dividing cells, regardless of whether they are cancerous or not, which 
generates severe side effects. In addition, the large volume of damaged cells 
further cause altered cellular transport, enhanced repair of distorted DNA, 
overexpression of DNA-damage recognition proteins and decreased apoptosis 
contributing to tumour resistance to platium drugs. 
6,19
  Thus, a thorough 
understanding of the mechanism of action of platinum-based anticancer agents 
and the design of drugs with increased selectivity are of great importance for 
significant clinical advantages over the current drugs.  
1.2 Rational Design of Platinum Anticancer Drugs 
1.2.1 Structure-Activity Relationship 
All Pt compounds that have entered clinical trials so far adhere to the structure-
activity relationships summarized by Cleare and Hoeschele.
20
 These relationships 
state that for a Pt complex to show antitumor activity, the Pt(II) or Pt(IV) complex 
should have a cis geometry with the general formulas of cis-[PtX2(Am)2] or cis-
[PtX2Y2(Am)2], where X is the leaving group and Am is an inert amine with at 
least one N–H moiety. The leaving group, X, should be an anion with intermediate 
binding strength to platinum and have a weak trans effect to avoid labilizing the 
amine. Complexes with labile leaving groups such as ClO4
−
 or NO3
−
 are highly 
toxic, while complexes with inert leaving groups are generally inactive. The 
guidelines have dominated platinum drug design for decades and remained valid 
until relatively recently. However, it has become quite evident that mere 
analogues of cisplatin or carboplatin will probably not offer any substantial 
clinical advantages over the existing drugs. A number of compounds that violate 
 9 
 
the structure-activity relationships, yet show antitumor activities, have been 
discovered. Efforts have also been directed toward the rational design of 
compounds with specific characteristics that make chemotherapy safer for patients, 
in particular, lessening severe side effects, increasing oral bioavailability, and 
overcoming drug resistance.
5
 
1.2.2 Strategies in the Development of New Platinum Anticancer Agents 
Herein, the generalized rationale underlying the development of the current 
platinum anticancer drugs is summarised.
1
 Modification of the structure of the 
leaving groups (e.g. carboplatin) appears to alter the physical and pharmacokinetic 
properties and thus influence tissue and cellular distribution of the platinum 
coordination complexes, but it is unlikely to modify pharmacological properties. 
In contrast, modification of the amine carrier ligands (e.g. oxaliplatin) could lead 
to different pharmacokinetics and structurally different DNA lesions possibly 
associated with a different spectrum of activity. Substitution of the more stable 
cyclobutanedicarboxylate for the two chlorides results in less toxic carboplatin, 
while replacement of the two ammonia ligands by the sterically-hindered 
diaminocyclohexane leads to oxaliplatin, which retains activity against some 
cancer cells with acquired resistance to cisplatin.
21
 Of the various strategies that 
have been developed to enhance selective targeting of a tumour-killing agent to 
tumours, prodrugs that can deliver platinum in a relatively inactive form and 
subsequently be released and activated at the tumour site appear to have particular 
potential. Improved delivery of platinum drugs with liposomal-based or polymer-
based vehicles is an attractive strategy and has been in clinical trials.
22-24
 However, 
creating delivery systems that target specific sites to achieve good release and 
 10 
 
activation is challenging. On the other hand, a photoactive agent in combination 
with light provides a promising avenue to achieve accurate targeting.
25,26
  
1.3 Photochemical Principles 
Light is a form of energy that exhibits both wave-like and particle-like properties. 
The intensity of light is associated with the number of photons per unit time; the 
energy (E) of the photons is related to the frequency (ν) of the radiation by the 
expression: 
                                                                                                                 (1-1) 
where h is Planck’s constant. An increase in the intensity of radiation will 
therefore only increase the number of species excited and not the energy available 
to each individual species. Energy levels are quantized; i.e. species can exist only 
in certain defined, discrete energy states. A direct result of the quantization of 
energy levels is that for each individual species, only specific energies and, 
therefore, frequencies of radiation can be absorbed or emitted. The characteristic 
line and band spectra of chemical species are a consequence of this behaviour. 
When a species absorbs a quantum of radiation, it becomes excited. How the 
species assimilates that energy — in rotational, vibrational, or electronic modes — 
depends on the wavelength of the incident radiation. As the differences in 
quantized energy levels for vibrational energy and those for rotational energy are 
respectively smaller by nearly 10
2
 and 10
4
 times than those for the electronic 
energy, absorption at low energies associated with infra-red radiation usually only 
leads to transitions between rotational or vibrational states of the species. The 
electronic transitions require energies in the visible and ultraviolet regions of the 
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electromagnetic spectrum and are accompanied by simultaneous changes in the 
vibrational and rotational states.  
The excited state of a species can exhibit a dramatically altered reactivity from the 
ground state. Not only does the species possess more energy, but it can also 
participate in different reactions as a result of the new electronic arrangement. The 
energies of electronic excitation are of the same order of magnitude as the bonds 
in a species. Furthermore, the energies correspond roughly with typical activation 
energies of reactions, and the excitation energy can help a species to either 
partially or completely overcome an activation barrier. The arrangement of the 
electrons in a species is fundamental in defining what reactions the species can 
and cannot undergo, so that a change in the spatial distribution of electrons can 
have a major effect on reactivity.
27
 
1.3.1 Selection Rules for Optical Transitions 
A photon has an intrinsic spin angular momentum corresponding to s = 1. The 
change in angular momentum of the electron must compensate for the angular 
momentum lost upon the absorption of the photon. Thus, an electron in a s orbital 
(l = 0) cannot make a transition into an d orbital (l = 2) because not enough 
angular momentum can be lost by the absorption of the photon. Similarly, an s 
electron cannot make a transition to another s orbital, because there would then be 
no change in the electron's angular momentum to make up for the angular 
momentum lost by the photon. It follows that some spectroscopic transitions are 
allowed, meaning that they can occur, whereas others are forbidden, meaning that 
they cannot occur. Selection rules are statements about which transitions are 
allowed and give an indication of the feasibility of a transition from one state to 
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another in terms of the quantum number. They are derived by identifying the 
transitions that conserve angular momentum when a photon is emitted or absorbed 
but give no indication of the absolute intensities of those transitions.  
The selection rules can be summarised as follows.  
(1) ΔS = 0 
(2) In atoms, for one-electron transitions,  
       ΔL = ±1 
       ΔJ = 0, ±1, but J= 0  J= 0 
(3) For diatomic and linear polyatomic molecules, 
        ΔΛ = 0, ±1 
The total electronic orbital angular momentum L of an n-electron atom is defined 
as the vector sum of the orbital angular momenta of the individual electrons:  
     
 
                                                                                                             (1-2) 
The total electronic spin angular momentum S of an atom is defined as the vector 
sum of the spins of the individual electrons:  
     
 
                                                                                                             (1-3) 
The total electronic angular momentum J of an atom is the vector sum of the total 
electronic orbital and spin angular momenta:  
J = L + S                                                                                                              (1-4) 
The value of Λ is the sum of the quantum number for the component of the total 
orbital angular momentum of an individual electron around the internuclear axis. 
There are two selection rules concerned with changes in symmetry. First, only 
+↔+ and −↔− transitions are allowed. Second, the Laporte selection rule for 
molecules and atoms with a centre of inversion states that: the only allowed 
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transitions are transitions that are accompanied by a change of parity; that is, u ↔ 
g transitions are allowed, but g ↔ g and u ↔ u transitions are forbidden.27,28  
1.3.2 Franck-Condon Principle 
 
 
Figure 1-3. (a) The idea of the Franck-Condon principle is that the most intense 
vibronic transition is from the ground vibrational state to the vibrational state 
lying vertically above it. Transitions to other vibrational energy levels also occur, 
but with lower intensity; (b) In the quantum mechanical picture of the Franck-
Condon principle, the molecule undergoes a transition to the upper vibrational 
state with wavefunction that has the greatest overlap integral with the vibrational 
wavefunction of the vibrational ground state of the lower electronic state. Adapted 
from reference 28. 
 
Because nuclei are so much heavier than electrons, an electronic transition takes 
place very much faster than the nuclei can respond. Consequently, electron 
density is rapidly moved into new regions of the molecule via vertical transition. 
The initially stationary nuclei suddenly experience a new force field, and in 
response they begin to swing backwards and forwards from their original 
positions which were maintained during the rapid electronic excitation. Thus, the 
(a) 
 
(b) 
 
Nuclear coorninates Nuclear coorninates 
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equilibrium nuclear positions in the initial electronic state become stationary 
turning points in the final electronic state (Figure 1-3a). 
Figure 1-3b provides a quantum mechanical view of the Franck-Condon principle. 
When the molecule is in the lowest vibrational state of its lowest electronic state, 
the most probable positions of the nuclei are at their equilibrium separation, Re. 
The electronic transition is most likely to take place when the nuclei have this 
separation in the excited states represented by the upper curve, so that the nuclear 
coordinates undergo the minimal change during the essentially instantaneous 
electronic transition. We may imagine the transition as being up the vertical line in 
Figure 1-3a, vertical transition, due to the assumption of constant nuclear 
coordinates during the transition. 
The quantum mechanical formulation of the Franck-Condon principle is that the 
intensity of a vibronic transition is proportional to the square of the overlap 
integral between the vibrational wavefunctions of the two states involved in the 
transition.  The vibrational wavefunction shows maximum amplitude at the level 
marked *, which is thus the most probable state for the transition. Other nearby 
states of the nuclei being at the separation Re have appreciable probabilities at 
various degrees. Hence, transitions occur to all the vibrational states in this region, 
but most intensely to the state with the strongest peaks of vibrational 
wavefunction near Re. 
The relative horizontal position of the two potential energy curves determines the 
vibrational structure of the spectrum and the mechanisms of the photoactivated 
chemical reactions. Electronically excited states usually have more antibonding 
character than ground states, and thus the upper curve tends to be displaced to 
longer equilibrium bond lengths. 
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1.3.3 Photochemistry of Coordination Complexes 
For metal complexes, excitation leads to electronically- and vibrationally-excited 
states with the same multiplicity as the ground state. Figure 1-4 is a schematic 
localised molecular orbital (MO) diagram for an octahedral transition metal 
complex. The electronic transitions to the excited states are classified according to 
the character of the orbitals involved in the electronic transition. This is a 
simplified classification in some cases. Orbitals may have mixed metal/ligand 
character depending on the nature of the metal-ligand bond and electronic 
transitions may involve more than two orbitals at a time. There are principally 
four types of electronic transitions: 
 
Figure 1-4. Simplified molecular orbital diagram of electronic transitions for a 
low-spin d
6
 metal complex with octahedral coordination (strong crystal field is 
assumed). Each black arrow (↑ or ↓) represents an electron with its associated spin. 
Coloured arrows (↕) represent the electron involved in each electronic transition. 
In the singlet state, excited electrons are spin-down (↓), while in the triplet state 
they are spin-up (↑). Adapted from reference 29. 
 
Ground State
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Metal-centred (MC) transitions. Electronic transitions occurring between the 
metal d orbitals are known as ligand-field (LF) or d-d transitions. These are 
orbitally (Laporte)-forbidden, and can also be spin-forbidden if the spin state 
changes. As a result, these transitions are often weak (extinction coefficients ~ 1–
1000 M
−1
 cm
−1
 for orbital-forbidden; 0.01–10 M−1 cm−1 for spin-forbidden) and 
can be masked by more intense, formally allowed charge-transfer transitions. 
Since MC transitions typically populate excited states with antibonding character, 
they often lead to bond lengthening and favour ligand substitution. Photochemical 
lability is thus commonly a feature of complexes in which a MC excited state is 
lowest in energy. 
Metal-to-ligand charge transfer (MLCT) transitions. Electrons migrate from 
the metal d orbitals to the ligand orbitals. 
Ligand-to-metal charge transfer (LMCT) transitions. Electrons move from 
orbitals of the ligand to the d obitals of the metal. MLCT and LMCT transitions 
give rise to stronger absorption (typical extinction coefficients ~ 10–50,000 M−1 
cm
−1
) and can bring about redox reactions and also cause homolytic bond 
cleavage, reducing the metal and producing radicals. Generation of radicals under 
biological conditions can cause damage to cellular components. 
Ligand-centred (LC) transitions. Electron transitions occurring between orbitals 
of two ligands are known as interligand (IL) transitions. These often occur in 
large delocalised systems.  
The excited states can undergo a series of physical radiationless processes 
including intersystem crossing (ISC), internal conversion (IC) vibrational 
relaxation, intramolecular vibrational redistribution and solvation dynamics 
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(reorganisation of solvent shells), which ultimately lead to the ground-state 
electronic structure. Radiative processes such as fluorescence (singlet-singlet) and 
phosphorescence (triplet-singlet) result in a return to the ground state with 
emission of light of longer wavelength than for the excitation. The efficient 
intersystem crossing promoted by the metal ion prolongs the lifetime of triplet 
states to the timescale of 50 ns – 1 μs, much faster than that of classical organic 
compounds (ms), with relatively high emission quantum yield. The main 
absorption and emission processes can be summarised by a Jablonski diagram 
(Figure 1-5).
29,30
  
 
Figure 1-5. Jabłonski energy diagram. The principal physical processes triggered 
by light excitation of a d
6
 metal complex are represented by dashed (radiationless) 
and solid (radiative) lines. Adapted from reference 29. 
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The combination of light and metal complexes has been used in medicine. 
Phototherapy of cancer, i.e. the treatment of a tumour with a drug and light, is 
particularly attractive as it provides site-specific activation of the photodrug, and 
thus allows for local treatment of the tumour and minimise the side effects of 
chemotherapy. Recent advances in laser and fiber optic technologies have made it 
possible to reach specific tissues in the body with light of highly defined intensity 
and wavelength, extending the applicability of this method beyond easily 
accessible cancer cells. A key parameter of the approach is the wavelength of the 
light. For efficient phototherapy, light with wavelengths between 300 and 900 nm 
is generally preferred, as shorter wavelengths have limited depth of penetration 
into human tissue and can cause severe damage to tissue, and longer wavelengths 
lack sufficient energy for chemical transformation.  
Photodynamic therapy (PDT) is used clinically to selectively damage easily 
accessible cancer cells (e.g. from the skin, neck and head, oesophagus, and 
bladder) by using a photosensitising drug and light. Upon irradiation, the 
photosensitiser, typically a porphyrin, becomes excited and this energy is 
transferred to ground state triplet oxygen (
3
O2) to create highly reactive singlet 
oxygen (
1
O2) that reacts rapidly with cellular components to cause damage leading 
to cell death. However, this oxygen-dependent mechanism for cytotoxicity is a 
major drawback of PDT as many malignant and aggressive cancer cells are 
hypoxic. It is thus highly desirable to develop photochemotherapy that is not 
dependent on oxygen.
25,31
  
1.4.1 Pt(IV) Prodrugs  
 19 
 
  
Figure 1-6. Photoactivation of Pt(IV) complexes as a prodrug strategy for 
metallopharmaceuticals; (a) a general scheme of prodrug activation by 
photoreduction; (b) photosubstitution and photoisomerization are competing 
photoreaction pathways, which can generate different reactive species upon 
reduction. Adapted from reference 32. 
 
The general kinetic inertness of Pt(IV) complexes compared to Pt(II) complexes 
has been widely exploited in the design of potential prodrugs. The Pt(IV) 
compound satraplatin with improved oral activity has been abandoned recently in 
phase III clinical trials for the treatment of hormone-refractory prostate cancer 
because its effectiveness was not better than current Pt drugs. Substitution 
reactions of Pt(IV) complexes under physiological conditions are very slow or do 
not take place at all. Therefore, intracellular reduction to Pt(II) oxidation state is 
widely accepted to be essential for anticancer activity. This reduction might be 
achieved by cellular reducing agents or by irradiation with light, enabling site-
specific activation of the drugs. However, in addition to photoreduction, the 
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hν 
occurrence of a mixture of photosubstitution and photoisomerization makes the 
photopathways of Pt complexes difficult to predict and a careful analysis of the 
photoproducts imperative (see Figure 1-6).
25
 Ultimately, the aim is to design Pt(IV) 
anticancer drugs that specifically target cancer cells, and to have control over 
ligand-exchange kinetics, and selective activation by light to allow for temporal 
and spatial control of drug delivery and activation. 
1.4.2 Photoactivated Platinum Anticancer Drugs 
 
 
Figure 1-7. Possible mechanism for photoactivation of platinum(IV) diazido 
complexes. 
 
Trans-dihydroxido platinum(IV) prodrugs containing two azido ligands in trans or 
cis positions relative to each other are nontoxic in the dark but show cytotoxicity 
toward various human cancer cell lines upon photoactivation via a oxygen- 
independent mechanism.
33,34
 In particular, a Pt(IV) diazido complex containing 
pyridine trans to ammonia, trans,trans,trans-[Pt(N3)2(OH)2(py)(NH3)], is up to 80 
times more cytotoxic than cisplatin in ovarian cancer cells upon irradiation but 
inactive and stable toward biological reductants in the dark.
35
 One photoactivation 
pathway for these complexes (among several possibilities) involves ligand-to-
metal charge transfer from the azido ligands to Pt(IV), resulting in reduction to the  
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Figure 1-8. (a) [
1
H,
15
N] HSQC NMR spectra of 
15
N-labeled ptohoactive Pt(IV) 
complex, trans,trans,trans-[Pt(N3)2(OH)2(py)(NH3)], and 2 mol equiv of 5'-GMP 
after 1 min and 30 min of irradiation; (b) time dependent decrease in 
concentration of trans,trans,trans-[Pt(N3)2(OH)2(py)(NH3)]  and formation of 
[Pt
II
(5'-GMP-N7)(N3)(NH3)(py)]
+
 and trans-[Pt
II
(5'-GMP-N7)2(NH3)(py)]
2+
; (c) 
quantification of in vitro DNA repair synthesis using an extract from the repair-
proﬁcient HeLa cell line. Cisplatin was taken as 100%. Adapted from reference 32. 
 
reactive Pt(II) species with liberation of two unstable azideradicals, which rapidly 
decompose in water to form N2 gas (Figure 1-7). Aquation of the Pt(II) compound 
and subsequent binding to DNA (and possibly proteins) leads to its cytotoxic 
effect. Studies on calf thymus DNA platination have shown that the rates of 
photodecomposition closely correlate with the rates of irreversible DNA 
platination, indicating direct reaction of photolysis products with DNA at notably 
faster rates than cisplatin, for which the platination rate is determined by slow 
hydrolysis steps. Studies in the presence of 5'-GMP have shown that rapid 
photoreduction results in the formation of the mono-adduct [Pt
II
(5'-GMP-
N7)(N3)(NH3)(py)]
+
 and bis-adduct trans-[Pt
II
(5'-GMP-N7)2(NH3)(py)]
2+ 
(Figure 
1-8). The observation suggests stepwise dissociation of the two azides rather than 
PtIV 
Pt
IV
 complex 
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concerted reductive elimination of both azides as a result of photoreaction of 
Pt(IV) complexes. Several biological assays such as different levels of p53 protein 
and caspase activity and distinctive crosslinks upon DNA platination pointed to an 
unusual mechanism of action which is clearly different from cisplatin. Moreover, 
DNA repair synthesis of the platinated lesion induced by photoplatination was 
considerably lower compared to cisplatin or transplatin (Figure 1-8).
35
 
A novel platinum(IV) diazido complex trans,trans,trans-[Pt(N3)2(OH)2(py)2] 
lately discovered in our group is stable in solution and can be photoactivated with 
a low-dose (5 J cm
−2
) of visible light (420 nm) to give potent, cytotoxic effects in 
a number of cell lines. In the presence of 5'-GMP, the major photoproduct is 
trans-[Pt(py)2(5'-GMP)2]
2+
 as confirmed by 
1
H and 
195
Pt NMR spectroscopy.
36
  
Photoactivation promotes the rapid formation of such bis-guanine adducts 
whereas in thermal reactions involving trans diamine complexes such trans cross-
links are formed very slowly if at all. The unusual nature of such trans-GG 
crosslinks formed on DNA after photactivation of trans-diazido Pt(IV) complexes 
may contribute to their high potency towards cancer cells.
35
 
1.4.3 Sequence-Dependent Kinetics and Thermodynamics of Reactions 
between Platinum Complexes and DNA
37
 
The reaction between DNA and platinum complexes (such as cisplatin) is often 
multistep, consisting of aquation, electrostatic preassociation, nucleophilic 
substitution of one aqua ligand by a DNA guanine, and crosslink formation. 
Quantiﬁcation of monoadducts and diadducts after reaction between salmon testes 
DNA and [PtCl2(
3
H-en)] as a function of incubation and postincubation time 
suggests that both the rate of formation of the monoadducts and the rate of their 
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closure to diadducts are sequence-dependent.
38
 Herein, I summarise the recent 
studies on the sequence-dependent selectivity of nucleobases in DNA. A better 
understanding of how various forms of polynucleotides affect the stepwise 
interaction with metal-based complexes is essential for the design of drugs to 
target specific DNA sequences or structures. 
1.4.3.1 Why Does Cisplatin Prefer Guanine over Adenine? 
In early competition studies with nucleosides and nucleotides, guanine bases are 
often found to be the preferred DNA binding sites of cisplatin. Experimental 
kinetic
39
 and theoretical
40,41
 studies suggest that hydrogen bonding can partly 
account for the guanine over adenine preference of cis-[Pt(NH3)2(H2O)2]
2+
 and 
cis-[PtCl(NH3)2(H2O)]
+
 and, furthermore, the calculated free energies of 
activation show that cis-[Pt(NH3)2(H2O)2]
2+
 discriminates much more strongly 
between guanine and adenine than does cis-[PtCl(NH3)2(H2O)]
+
.
40
 
1.4.3.2 How Is the Reactivity of an Individual Guanine Affected by the 
Sequence Context in Duplex DNA? 
Experiments suggest that monoadduct formation proceeds under kinetic control 
rather than under thermodynamic control. To explain sequence-selectivity of cis-
[Pt(NH3)2(H2O)2]
2+
 binding to duplex DNA, a kinetic model has been proposed 
based on HPLC studies.
42
 According to this model, the neighbouring bases 
intervene (i) by affecting the molecular electrostatic potential at the site of the N7 
lone-pair of guanine, and (ii) by exerting different steric hindrances for the 
platinum complex to approach the N7 atom of guanine. Hydrogen bonding from 
platinum ligands, initially considered as the most likely cause of the sequence 
selectivity, has been shown to intervene in a rather sequence-unspeciﬁc manner by 
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calculations that reveal the strongest hydrogen bond in the transition state forms 
between a water ligand of platinum and the 5'-phosphate group.43 This may 
explain why the reactivity of complexes cis-[PtL(NH3)2(H2O)]
n+
 (n = 1, 2) 
increases in the order Cl
−
 < NH3 < OH
−
 < H2O matches closely the increasing 
hydrogen-atom donating capacity.
44
 In addition, kinetic studies of monoadducts 
with cis-{PtCl(NH3)2}
+
 bound to a speciﬁc guanine (G*) in the centre of a DNA 
duplex give an impressive demonstration of how the aquation rate depends on the 
nature of the ﬂanking bases.37,45,46  
1.4.3.3 Why Are Interstrand Cross-Links the Minor DNA Products Formed 
by Cisplatin? 
In addition to structure of the cisplatin–DNA interstrand crosslinks, how the 
sequence affects the kinetics of their formation is important for understanding the 
mechanisms of the drugs. Surprisingly fast closure of the aqua monoadducts 
formed at d(GC)2 sequences of duplex oligonucleotides to interstrand crosslinks 
(t1/2 ≈ 1 min at pH 4.5 and 20 °C),
45,47
 suggests that the slow formation of 
interstrand crosslinks after DNA platination with cis-[PtCl2(NH3)2] is due to slow 
aquation of the chlorido monoadducts rather than a slow crosslinking reaction. 
Additionally, the 3'-cytosine has been shown to slow down the reactivity of the 
adjacent guanine in monoadducts formation (i) by lowering the negative potential 
at the N7 atom of the adjacent guanine, and (ii) by sterically hindering the access 
to the N7 of guanine with the 4-amino group of cytosine.
42
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1.4.4 Structure, Function and Targeting of G-quadruplexes 
Figure 1-9. G-quartet with metal ion (e.g. K
+
) coordination to GO6. Adapted from 
reference 48. 
  
G-quadruplex nucleic acids can be formed by the spontaneous folding of DNA or 
RNA sequences that have repeat tracts of the kind AGnTm, into structures 
comprising stacked G-quartets held together by loops arising from the sequences 
occurring between the G-tracts, especially in the presence of a monovalent ion of 
the correct size, such as Na
+
 or K
+
 (Figure 1-9 and 1-10).
48
 Quadruplex-forming 
sequences occur in particular at the ends of eukaryotic chromosomes, in promoter 
regions and/or in both 5′ and 3′ untranslated regions of a number of genes.49  
Stabilization or disruption of quadruplex structures within their genomic 
environments can lead to a range of biological effects. Promoter quadruplex 
formation and stabilization can result in inhibition of the transcription of a 
targeted gene, and formation of telomeric quadruplexes can inhibit the end-
 K+ 
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capping and catalytic functions of the telomerase enzyme from maintaining 
telomere integrity in cancer cells. G-quadruplex structures are, thus, the subject of 
considerable interest for the development of small-molecule ligands, and are also 
the targets of a wide variety of natural proteins.
49
 More than 118 structures have 
been deposited in the protein data bank (January 2011).
50
 
 
 
Figure 1-10. Visualizations of G-quadruplexes from PDB 1KF1. Ball = metal ion; 
white = DNA backbone; blue, yellow, and orange = Guanine. 
51
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Figure 1-11. Structures of three quadruplex-binding molecules.  
 
Small molecules which bind to G-quadruplexes have been largely based on 
polycyclic planar aromatic compounds with at least one substituent terminating in 
a cationic group that enable them to intercalate effectively between planar G-
quartets and generally bind more tightly to backbone phosphates of nucleic 
acids.
49
 Some good quadruplex-binding molecules have been developed, such as 
those depicted in Figure 1-11. They include the trisubstituted acridine compound 
BRACO-19,
52
 macrocycle telomestatin found in the bacterium Streptomyces 
anulatus,
53
 and a platinum molecular square [Pt(en)(4,4'-dipyridyl)]4.
54
 A 
particular challenge is for a given ligand to have high selectivity for any chosen 
one over other quadruplex structures, as well as to have low affinity for duplex 
DNA, which generally far outnumbers any G-quadruplexes present in the 
genome.
49,55
 Structural information has revealed the presence of several distinctive 
topologies for telomeric quadruplexes, dependent on the nature of the cations 
present, and on length and sequence of the loops.
48,56
 
Platinum Supermolecular Square Telomestatin 
BARCO-19 
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1.5 Computational Approaches to Modeling Photoactivation and 
Platinum–DNA Cross-links 
It is rare to see a natural product like taxol become a drug without any 
modification. The use of computational methods has shown advantage in the 
structure refinement and the prediction of pharmacological properties and of drug-
receptor binding. The following section provides a collection of overviews of 
various theoretical methods used to study platinum anticancer complexes in this 
thesis. More advanced computational techniques are described in Chapter 2. 
1.5.1 Time-dependent Density Functional Theory to Study Photochemistry 
and Molecular Spectroscopy 
An extension of density functional theory (DFT) for excited states, time-
dependent DFT (TDDFT), enables quantitative prediction of electronic absorption 
spectra for transition metal complexes. The results discussed in a recent review 
indicate that the agreement of TDDFT with experiment is not as good for 
transition metal complexes as has been observed for small molecules such as N2, 
CO, CH2O, and furan, where an accuracy of 0.1–0.2 eV has often been obtained. 
The best TDDFT methods for absorption spectra of transition metal complexes 
often appear to have errors of a few tenths of an eV. The applied functional and 
the geometry of the system are important for the accuracy of TDDFT.
62, 63
 
For spectra in solution, considerable solvent shifts have been observed. Although 
various solvation models are available to include solvation effects in the TDDFT 
applications, the accuracy of solvation models in combination with TDDFT needs 
to be carefully evaluated.
62, 63
 It is also important to note that the TDDFT module 
in current software suites such as the Amsterdam Density Functional (ADF)
57
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package is relatively new and not extensively tested for a wide range of 
applications. Therefore, one needs to build experience about aspects that may 
affect the accuracy of TDDFT results. In particular, it is advised to apply the 
zeroth-order regular approximation (ZORA)
58,59
 relativistic corrections for 
molecules containing heavy nuclei and use an asymptotically correct exchange-
correlation potential such as the statistical average of the orbital dependent 
potentials (SAOP)
60
. 
1.5.2 Previous Work on Photoactivated Pt(IV) Pyridyl Azido Acetato 
Complexes 
The Pt(IV) complexes trans, cis-[Pt(bpy)(OAc)2(N3)2] (1), trans, cis-
[Pt(phen)(OAc)2(N3)2] (2), trans, trans, trans-[Pt(OAc)2(N3)2(py)2] (3) were 
synthesised, and X-ray, NMR and UV-vis spectroscopy and TDDFT in the 
Gaussian 03 (G03) program
61
 were used to study their structural and 
photochemical properties. The B3LYP functional
62,63
 in conjunction with the 
LanL2DZ basis set
64
 and effective core potential for the Pt atom and the 6-31G** 
basis set
65
 for the other atoms, and the conductor-like polarisable continuum 
model method (CPCM)
66-68
 with water as solvent were used to calculate the 
electronic structure and the excited states.  
These complexes with aromatic amines undergo photoactivation with both UVA 
(365 nm) and visible green light (514 nm) and exhibit greater absorption at longer 
wavelengths (ε = 9756 M-1 cm-1 at 315 nm for 1; ε = 796 M-1 cm-1 at 352 nm for 2; 
ε = 16900 M-1 cm-1 at 307 nm for 3, in aqueous solution) than previously reported 
Pt(IV) azide complexes. The calculated and experimental absorption spectra are 
displayed in Figure 1-12. Additional UV-Vis spectrum for complex 1 was 
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simulated using scalar relativistic TDDFT with the asymptotically correct XC 
potential derived from SAOP in the ADF program
57
. The computed spectra 
correlated with the experimental measurements, and the results show that TDDFT 
can be a useful tool to study the photochemistry of Pt(IV) complexes.  
 
Figure 1-12. Calculated (blue line) and experimental (black line) absorption 
spectra of 1–3 in aqueous solution. The computed excited states are shown as 
vertical bars with heights equal to the extinction coefﬁcients. Adapted from 
reference 69. 
1 
 
 
 
 
 
 
2 
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1.5.3 Molecular Modelling for Nucleic Acids 
With signiﬁcant progress in the past decade in the development of efficient 
methods for treating the long-range electrostatic interactions, empirical molecular 
mechanical force ﬁelds, and molecular dynamics (MD) simulation methods, 
current MD simulation is not only capable of reproducing experimental 
observations in general, but also can provide insight into the structure, energetics, 
and dynamics of nucleic acids. These force fields were mainly parameterised from 
experimental and quantum mechanical results on small molecular fragments that 
make up proteins and nucleic acids (see Chapter 2, Section 2.2 for more detailed 
description of force fields and parameterisation). Among available force fields, 
CHARMM and AMBER have been the most widely used. The performance of 
various force fields in the simulation of nucleic acids is provided in Section 2.2.4.  
1.5.4 Molecular Modelling for Platinum–DNA Interactions  
Herein, theoretical approaches to study platinum–DNA interactions are introduced. 
As computational models are often compared with experimental structures, 
cisplatin–DNA structures solved by NMR spectroscopy and X-ray crystallography 
as well as via quantum mechanics/molecular mechanics (QM/MM) methods are 
summarised. 
1.5.4.1 Progress in the Application of Force Fields to Platinum–DNA 
Complexes 
The diversity of structure makes inorganic molecules more difficult to model than 
their organic counterparts. A variety of force fields have been developed for the 
modelling of platinum–DNA complexes. The discrepancy between force field 
results and crystal structures of small molecules and oligonucleotide complexes as  
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Figure 1-13. Deformation of Pt out of the plane of the guanine base. Adapted 
from reference 70. 
 
well as geometries obtained by ab initio quantum mechanical calculations 
regarding the degree of bending of the Pt–N7 bond out of the plane of the 
coordinated purine base (δ, Figure 1-13) has been extensively discussed.70 The 
parameters for the modelling of DNA interactions were developed by using 
torsional constraints or out-of-plane deformation terms to ensure the Pt atom 
remained within the plane of the coordinated purine. Ab initio calculations show 
that the assumption of planarity of nucleic acid bases leads to an overestimation of 
the platinum out-of-plane bending force constant.
71
 They questioned whether the 
purine ring is stiff enough to withstand large out-of-plane bending of the Pt–N7 
bond without puckering of the five-membered ring containing N7. The calculated 
force constants for puckering of the base and out-of-plane deviation of the Pt atom 
indicate that the purine bases are likely to undergo significant puckering. In the 
majority of platinum–DNA interactions, deviations from planarity are small and, 
therefore, the limitations in this aspect of the modelling are probably not 
significant, but modelling of highly strained systems may not be reliable. An 
explicit coupling between the geometry and the occupancy of d-orbitals can be 
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achieved by adding a ligand field energy term to the force field energy function, 
giving a more sophisticated approach to model transition metal complexes known 
as ligand field molecular mechanics (LFMM).
72
  
1.5.4.2 Quantum Mechanics/Molecular Mechanics Approach 
Hybrid quantum mechanics/molecular mechanics (QM/MM) methods have been 
widely applied to model local electronic events in large biomolecular systems. 
The basic idea is to describe the chemically active region such as platinated sites 
by electronic structure methods, as accurately as needed, while treating the rest by 
empirical force ﬁelds methods. This is the QM/MM approach based on a mixed 
Hamiltonian of the form: 
                                                                                              (1-5) 
HQM is the ab initio Hamiltonian, and HMM represents the classical Hamiltonian. 
In this way, large systems can be modelled in a computationally efficient manner. 
The main problems with QM/MM approach is deciding how the two regions 
should interact, as described by the interaction Hamiltonian HQM/MM. It is crucial 
to treat the QM/MM interface in an accurate and consistent way. 
In general, there are three levels of HQM/MM. The lowest level of the interaction is 
called mechanical embedding model, where only the bonded and steric energies of 
the two parts are considered, but the electronic interaction of the two regions is 
not included. This is not a widely applied model because the wave function of the 
QM region does not respond to structural changes in the MM region. In electronic 
embedding model, the atoms in the MM regions are allowed to polarize the QM 
region. Partial charges on the MM atoms can be incorporated into the QM 
Hamiltonian, and thus the QM atoms feel the electric potential caused by all the 
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MM atoms. As a result, the geometry of MM atoms can affect the QM region. In 
polarisable embedding model, the QM atoms are also allowed polarise the MM 
region. Thus, the electric field generated by the QM region influences the atomic 
charges and dipoles of the MM atoms. This model requires a polarisable force 
field and a double iterative procedure to compute the electric fields in both the 
QM and MM parts by a self-consistent protocol. This level of description 
demands a much larger computational cost, so it is not commonly used. Most 
QM/MM methods use the electronic embedding model.
73
 
QM/MM data from Platts
74
 used to compare with the LFMM results in Chapter 4 
were computed by the ONIOM (own-n-layered integrated molecular orbital 
molecular mechanics) method, which, in general, uses mixing methods of 
different accuracy (e.g. two different inner QM layers and an outer MM layer). 
The structure of QM/MM simulation from Carloni
75
 for the comparison of the 
resulting structure of the LFMD in Chapter 5 was obtained by electronic 
embedding model.  
1.5.4.3 Molecular Dynamics Simulation on Platinum–DNA Complexes 
Computer simulation methods enable us to model biological systems in 
laboratory-relevant conditions and predict their properties through generating 
representative configurations of these small replications in such a way that 
accurate values of structural and thermodynamic properties can be obtained with a 
feasible amount of computation.
76,77
 Simulation techniques also enable the time-
dependent behaviour of atomic and molecular systems to be determined, 
providing a detailed picture of the way in which a system changes from one 
conformation or configuration to another. Simulation techniques are widely used 
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in some experimental procedures, such as the determination of protein structures 
from X-ray crystallography.  
A 5 ns MD simulation of the DNA duplex d(GCCG*G*ATCGC)• 
d(GCGATCCGGC) with a cis-{Pt(NH3)2}
2+
 fragment crosslinking the two G* 
guanine bases was carried out using AMBER 98 force field
78
 with reduced 
improper torsion angle terms that take into account purine puckering to 
parameterise the bending of the Pt-N7 bonds out of the guanine planes
71
, and the 
results correlated with NMR data determined for the same adduct.
12
 To resolve the 
differences between X-ray
79
 and NMR
10
 structures of 
d(CCTCTG*G*TCTCC)•d(GGAGACCAGAGG) containing a cisplatin 
coordinated to the two G* guanine bases, QM/MM simulations with the platinated 
unit treated by DFT and the rest of DNA by AMBER98 force field
78
 were 
performed to study the same Pt–DNA adduct. The calculations were initiated with 
the X-ray structure of the platinated DNA, and during the 2-ns simulation the 
structure has shown closer resemblance to the solution structure obtained by 
NMR.
75
 
1.5.4.4 Experimental and QM/MM Structures for Cisplatin–DNA Complexes 
The structures of 1,2-intrastrand cisplatin–DNA complexes with the sequence 
d(C1C2T3C4T5G6*G7*T8C9T10C11C12)• d(G13G14A15G16A17C18C19A20G21A22G23G24) 
where the -G6*G7*- site has been modified by cisplatin are available in NMR 
(PDB 1A84)
10
, X-ray at 2.6 Å  resolution (PDB 1AIO)
79
, and QM/MM 
calculation
75
. In AIO, however, T3 was replaced by a 5-bromo-2'-deoxyuridine-5'-
monophosphate to solve the crystal structure. The main structural features are 
summarised as follows. For NMR and X-ray structures, (i) DNA axis bend angles 
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are 78°, and 39°/55° (two independent molecules), respectively, (ii) minor groove 
width/depth are 9.4-12.5 Å /1.4 Å  and 9.5-11.0 Å /3.0 Å , respectively, and (iii) the 
displacements of Pt atom from G6*/G7* are 0.8/0.8 Å  and 1.3/0.8 Å , respectively. 
The QM/MM simulation started from the X-ray structure, and the resulting 
structure shows an increase of axis bend to an intermediate value between the X-
ray and NMR structures. During the simulation, the structure of the platinated 
DNA rearranged significantly toward the NMR structure. 
The structure of interstrand cisplatin–DNA complexes with the sequence 
[d(C1A2T3A4G5*C6T7A8T9G10)]2 cross-linked at the G*C:G*C site was 
determined by NMR (PDB 1DDP)
80
 and that with the sequence 
d(C1C2T3C4G5*C6T7C8T9C10)•d(G11A12G13A14G15*C16G17A18G19G20), where G* 
denotes the location of platinated nucleotides was solved by X-ray diffraction at 
1.63 Å  resolution (PDB 1A2E)
9
. The NMR structure exhibits a duplex bending of 
14° toward the minor groove and a helix unwinding of 38°, while the X-ray 
structure shows a bend of 47° toward the minor groove and an unwinding of 70°. 
Note that the comparison of the structures needs to relate to the structural 
parameters used in Curve
81
 program. 
1.6 Advances in Current Status of in Silico Design of Photoactive 
Platinum Anticancer Complexes in the Thesis 
Experimental and/or theoretical studies on photoactive platinum complexes and 
their mechanisms of action have been reported. However, no computational 
studies have been carried out to systematically tune the coordination environment 
to achieve desirable photochemical properties, and the elucidation of the cytotoxic 
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mechanism has been impeded by the difficulty of obtaining structures of platinum 
photoproducts with DNA/proteins via X-ray crystallography or NMR.  
In this thesis, I first utilise TDDFT with the aim of designing platinum(IV) 
complexes with absorption bands shifted towards longer wavelengths. This is 
achieved via a broad exploration of trans influences, the nature of OR
−
 and 
(pseudo)halogen ligands, electron-withdrawing/donating/delocalizing substituents 
on the N-ligands, and intramolecular H-bonds. Secondly, LFMM parameters for 
Pt–guanine interactions are derived to model platinated DNA. Thirdly, the force 
field is used to develop protocols for LFMD simulations of known bifunctional 
DNA adducts involving both an intra- and an interstrand crosslink of the 
anticancer drug cisplatin. The fourth objective is to simulate a DNA lesion 
involving the photoproduct of the novel platinum(IV) complex trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (1) and suggest possible mechanisms to explain the high 
potency of this photoactivated complex.  
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Chapter 2 
Methods and Computational Details 
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This chapter provides an overview of the theoretical methods and techniques 
applied in this work. The first section provides an introduction to time-dependent 
density functional theory. Secondly, an overview of molecular mechanics, ligand 
field molecular mechanics, and molecular dynamics simulation is given. Thirdly, 
the ligand field molecular mechanics approach for modelling metal complexes is 
presented. Computational details are provided in the following section. Finally, 
the techniques used to analyse the results of molecular dynamics simulation are 
summarised. 
2.1 Time-dependent Density Functional Theory 
Time-dependent DFT (TDDFT) extends ground-state density functional theory 
(DFT) to the dynamical description of atomic and molecular electronic excitations 
and is an efficient computational tool for the study of molecular spectroscopy.
82,83
 
TDDFT can be viewed as an alternative formulation of time-dependent quantum 
mechanics, where the fundamental variable is no longer the many-body wave 
function but the one-body electron density. With this method, the time evolution 
of electronic systems can be simulated, which allows changes in molecular 
properties over time under the influence of applied time-dependent fields to be 
studied. Within TDDFT two main types can be distinguished: (i) If the external 
time-dependent potential is ‘strong’ (e.g. when matter interacts with intense laser 
fields), a full solution of the time-dependent Kohn-Sham equations has to be 
performed. (ii) For a ‘small’ external potential (e.g. for the calculation of 
photoabsorption spectra), the complete numerical solution of the time-dependent 
Kohn-Sham equations can be avoided by the use of linear response theory. 
2.1.1 Basic Equations of TDDFT and Linear Response Theory 
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TDDFT linear response theory is one of the most widely used electronic structure 
method for calculating vertical electronic excitation energies.
84
 The estimated 
accuracy of the best TDDFT methods for transition metal complexes, where errors 
are often of several tenths of an eV, is lower than for simple molecules like N2, 
CO, and CH2O, with errors of the order of 0.1–0.2 eV. According to the theorem 
of Runge and Gross
85
, the time evolution of the electron density ρ(r1,t) of a many-
electron system at the initial time t=0 can be represented by a definite 
wavefunction Ψ(x1 ,...,xN ,t=0) (xi are the electron coordinates). That is, given the 
initial state of the wavefunction, the density ρ(r1,t) at all later time determines the 
potential νext(r1,t) uniquely up to a purely time-dependent function. With the 
potential νext(r1,t), the wavefunction Ψ(x1 ,...,xN,t) of the evolving system can 
therefore become a functional of the time-dependent electron density, 
Ψ(x1 ,...,xN,t)=Ψ([ρ],t). In other words, there is a one-to-one correspondence 
between ρ(r1,t), νext (r1,t), and Ψ(x1 ,...,xN,t): 
ρ(r1,t) ↔ νext (r1,t) ↔ Ψ(x1 ,...,xN,t)                                                                     (2-1) 
In the Kohn-Sham (KS) approach of TDDFT,
86
 the density ρ can be expressed in 
the orbital form: 
                  
 
  
                                                                                     (2-2) 
by the sum of the densities of the KS orbitals ϕi, the first N solutions of the time-
dependent one-electron KS equations (in atomic units) 
  
 
 
                      
 
  
                                                               (2-3) 
The orbitals ϕi (r1,t) evolve under the influence of the KS potential νs, which 
consists of the external potential νext, the standard Hartree potential νCoul of the 
electrostatic electron repulsion and the exchange-correlation (xc) potential νxc: 
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                                                                                       (2-4) 
The time-dependent KS Equation (2-3) can be used to simulate the full time 
evolution of the density. However, if the external potential is small, the behaviour 
of the system can be described by first-order perturbation theory. The linear 
response approach considers a linear density response of the ground-state density 
to an external time-dependent perturbation δνext(r1,t), for instance, an oscillating 
electric field δνext(r1,t) switched on at time t0: 
                                                                                                    (2-5) 
The time-dependent KS system obeys the time-dependent one-electron 
Schrödinger equation 
  
 
 
                     
 
  
         
                                 (2-6) 
where    are orbital energies corresponding to KS molecular orbitals ϕi. Through 
Fourier transformation, the linear density response for the frequency-dependent 
density response δρ(r1,ω)  to the potential change δνs(r2,ω) can be expressed as 
           
                                                                               (2-7) 
and  
               
  
             
           
         
     
 
 
         
             
     
         
             (2-8) 
   and    being the Kohn-Sham unoccupied and occupied molecular orbitals 
corresponding to the Kohn-Sham energies εj and εi, respectively. By defining δPij 
as 
           
    
                                                                                            (2-9) 
the density change is given as:  
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The    in Equation (2-8) can be written as 
                                       
 
       
  
 
       
   
 
         
 
                           
        
       
     
 
                                               (2-11) 
(from here we use i and j for the occupied orbitals, whereas a and b are used for 
the virtual ones). Then the elements    
     in the density response function 
become: 
   
     
       
       
    
                                                                                         (2-12) 
Insertion of Equation (2-13) as well as the changes of external potential and of the 
potential of electron-electron interaction, Hartree and xc, into Equation (2-9) 
yields a more detailed equation: 
    
     
         
         
    
      
                           
                     (2-13) 
(notice that we have now introduced the spin index σ and τ) where the coupling 
matrix consists of Hartree and xc parts: 
             
                         
             
 
   
    
                      
             (2-14) 
with the xc kernel being the functional derivative of the xc potential      with 
respect to the spin-density    
   
            
   
           
          
                                                                           (2-15) 
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Rearranging Equation (2-13) and separating its free terms leads to the following 
matrix equation for the density response 
               
                 
           
                                           (2-16) 
where            are the following matrix elements 
                                            ,                                      (2-17) 
         
           
       
                                                                                          (2-18) 
Excitation energies in response theory are characterized as the poles of the 
response functions. At the true excitation energies ωk, a finite external 
perturbation νext(r1, ωk) leads to an infinite change in the density. For Equation (2-
16) to hold, the matrix in the square brackets must to have a zero eigenvalue at ωk. 
The following eigenvalue equations for the excitation energies ωk can be derived: 
      
                                                                                                          (2-19) 
where 
    
  
    
  
  ,                                                                                          (2-20)  
so that its matrix elements are 
                           
                                            (2-21) 
The eigenvectors Fk can be used to calculate the corresponding oscillator strengths 
of the excitations. 
2.1.2 The xc Potential 
From the equations described in the previous section, it is evident that the KS 
orbital energies and the MO shapes are important for the xc potential and the 
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response properties such as excitation energies. Since the exact form of the xc 
potential      is not known, various approximations are in use. The local-density 
approximation (LDA) and the generally applied generalized gradient 
approximations (GGA) are the standard approximations in TDDFT. However, the 
LDA and GGA Kohn-Sham potentials have two main drawbacks. First, they are 
too shallow in the molecular region. Thus, the energies of unoccupied orbitals 
close to zero energy cannot shift up much and excitations to these levels tend to be 
underestimated in LDA or GGA potentials. Second, the KS potentials for LDA 
and GGA do not have correct Coulombic asymptotics −1/r. The much too fast 
exponential decay of these approximate potentials distorts the shape of diffuse 
unoccupied orbitals, and hence gives errors in intensities.  
A new approximate xc potential,    
    , constructed by the statistical average of 
(model) orbital potentials (SAOP)
60
 brings a significant improvement in the 
calculated molecular static isotropic polarizabilities (    
       
      
     
   ).
87
 The more sophisticated SAOP potential     
     employs a modified 
potential of van Leeuwen and Baerends,     
   , as one of its components,60 and 
uses different model potentials,      
   , for the different occupied KS orbitals,    , 
and combines them into a single xc potential with the statistical average over the 
orbitals: 
   
                
       
 
 
         
 
      
                                                                            (2-22) 
The orbital potentials      
    are obtained with the following equation: 
     
         
           
 
    
            
           
 
     
                            (2-23) 
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    has the proper Coulombic asymptotics (i.e. −1/r) in the outer region, and the 
potential     
     of Gritsenko, van Leeuwen, van Lenthe, and Baerends (GLLB)88 
correctly describes the atomic shell structure in the inner regions. Therefore, 
    
     provides a balanced approximation to the KS potential      in all regions. 
2.2 Molecular Mechanics: Empirical Force Field Methods 
Molecular mechanics calculate the energy of a system only as a function of the 
nuclear positions without considering the electronic motions, and is thus often 
used to perform calculations on systems of biological interest that typically 
involve macromolecules in their condensed phase environment. In addition, to 
study the inherent dynamical nature of biomolecules and the mobility of their 
environments, energy calculations of a significant number of conformations are 
required. Molecular mechanics is based on empirical energy functions with 
relatively simple terms to describe the underlying physical interactions that direct 
the structure and dynamic properties of molecules and can therefore fulfill the 
demands required by computational studies of biological systems. Molecular 
mechanics, in some cases, can provide properties that are as accurate as even the 
highest-level quantum mechanical calculations, at a fraction of the computational 
cost. However, to model molecular properties that depend upon the electronic 
distribution, careful parametrisation is essential. 
2.2.1 A Simple Molecular Mechanics Force Field 
Most force fields designed to model the total potential energy can be interpreted 
by a relatively simple four-component picture of the intra- and inter- molecular 
forces within the system.
89
 The intramolecular terms are associated with 
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covalently connected atoms, and the intermolecular terms represent the 
noncovalent or non-bonded interactions between atoms. The total potential energy 
of a chemical system,        can be described as a function of the positions (r) of 
N particles in the following equations: 
       
   
 
         
 
  
   
 
         
 
            
                   
  
 
             
        
 
                           
   
   
 
  
  
   
   
 
 
  
    
       
       
 
                                (2-24) 
The various contributions are illustrated in Figure 2-1. The first term in Equation 
(2-24) models a bond between two atom types A and B using a harmonic potential 
that gives the increase in energy as the bond length li deviates from the reference 
value li,0. The second term is a summation over every valence angle formed 
Figure 2-1. Illustration of the four principle contributions to a molecular 
mechanics force field: bond stretching, angle bending and torsional terms and 
non-bonded interactions. 
 
 
 
 
 
 
 
θ 
ω 
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between three atoms A–B–C in which A and C are both bonded to B in the 
molecule, modelled here by a simple harmonic approximation. The third term is a 
torsional potential that models how the energy changes by rotation around a bond. 
The fourth contribution is the non-bonded term that describes interactions between 
all pairs of atoms (i and j) that are in different molecules or that are in the same 
molecule but separated by at least three bonds. A basic force field expression 
usually models the non-bonded term using a Coulomb potential for electrostatic 
interactions and a Lennard-Jones potential for van der Waals interactions. 
More sophisticated force fields may have a number of additional components, but 
they invariably contain these four energy terms. An advantage of this 
representation is that it is easier to understand how changes in the force field 
parameters affect its performance. This is helpful for the parameterisation as the 
various terms can be attributed to changes in specific internal coordinates such as 
bond lengths, bond angles, the rotation of bonds or movements of atoms relative 
to one another. 
2.2.2 Force Field Parameterisation 
Parameterisation of a force field is by no means a trivial task. A force field can 
contain a large collection of functional forms and associated constants, even for 
calculations on only a small molecular system. Creating a new force field entirely 
from scratch takes tremendous effort. It can be a complicated and time-consuming 
process even to model a new class of molecules by adding a few parameters to an 
existing force field. It is noteworthy that the performance of a force field is often 
particularly sensitive to a few of the parameters, and thus it is wise to spend more 
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time optimising these parameters rather than the values which do not greatly affect 
the results. 
The first step in the parameterisation process is to select the data (e.g. 
conformations and vibrational frequencies) that one wishes the force field to 
reproduce. In the cases that experimental data are not available or difficult to 
obtain, quantum mechanics calculations are often used to provide the data for the 
parameterisation of molecular mechanics force fields. This significantly extends 
the range of chemical systems that can be modelled by the force-field approach.
89
 
2.2.3 Force Field Models for Liquid Water 
Proper condensed phase simulations require that the non-bonding interactions 
between different solvents and solutes of the system under study be properly 
balanced. The first step in obtaining this balance is to model the solvent–solvent 
interactions. Despite its small size, water is one of the most challenging systems to 
model accurately. Many different water models have been proposed. As there may 
be a very large number of water molecules present, most of the force fields used to 
simulate liquid water use effective pairwise potentials with no explicit three-body 
terms or polarisation effects. The TIP3P
90
 model, one of the most common water 
models in biomolecular simulations, uses pairwise Coulombic and Lennard-Jones 
expressions for the interaction between molecules and a total of three interaction 
sites for the electrostatic interactions with the partial positive charges on the 
hydrogen atoms exactly balanced by an appropriate negative charge located on the 
oxygen atom in a rigid geometry. A Lennard-Jones function with simply a single 
interaction point per molecule centred on the oxygen atom is employed to model 
the van der Waals interaction between two water molecules. No van der Waals 
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interactions involving the hydrogen atoms are computed. The simple water 
models are usually parameterised by calculating various thermodynamic and 
structural properties (e.g. the density, dipole moments, radial distribution function, 
heat capacity, diffusion coefficient, and dielectric constant) using molecular 
dynamics or Monte Carlo simulations and then modifying the parameters until the 
desired level of agreement between experiment and theory is achieved.
89
 
Depending on the properties of water to reproduce in a system, an appropriate 
model needs to be selected with care. 
2.2.4 Force Fields for Nucleic Acids 
Both widely applied force fields, AMBER94
91
 and CHARMM22
92
, can reproduce 
many static properties of nucleic acids and yield stable unconstraint MD structures 
in physiological conditions. CHARMM27
93,94
 has corrected the overstabilisation 
of A forms relative to B forms of DNA in CHARMM22. AMBER99
78
 has 
improved sugar pucker phases, endocyclic torsion chi values, and overall helical 
twist, but fails to show B-DNA to A-DNA transitions under conditions expected 
to stabilise A-DNA. In contrast, this transformation is observed with AMBER94. 
Although perform well in simulations in the 10-ns range, AMBER94 and 
AMBER99 have been reported to overpopulate the α/γ backbone in the gauche+ , 
trans geometry which, may introduce severe distortions in DNA in long 
simulation. parmbsc0
95
, a new AMBER force field, has improved the description 
of α/γ conformers and can be used to study nucleic acids in a greater time scale. A 
cautionary note regarding the relative performance of the force fields is that 
modifications to a given force field do not necessarily improve all properties. It is 
also noteworthy that the comparison to experimental structure values tends to be 
biased by poorly refined NMR structures or crystal packing artifacts.  
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In solution, the DNA duplex is a highly charged polyanion stabilised by a range of 
cations. Counterions and solvation conditions play important roles in 
conformational properties and function of DNA, and thus a proper description of 
the ions around DNA is essential for accurate modeling of the dynamical structure 
of DNA in MD simulations.
96
 The results for MD simulations of DNA dodecamer  
together with water molecules and Na
+
 ions show that the internal structural 
parameters of DNA are well converged around 5 ns, yet the relaxation times of 
ion motions are much longer.
97
 
2.2.5 Force Fields for Metal Coordination Complexes 
The diversity of geometries and the presence of highly delocalised bonds make 
inorganic molecules more difficult to model than their organic counterparts. 
Figure 2-2. Valence angles at central atom for various regular geometries. 
Reproduced from reference 72 with permission. 
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Common structures of metal complexes include tetrahedral and square planar for 
four coordination, square pyramidal and trigonal bipyramidal for five coordination, 
and octahedral and trigonal prismatic for six coordination. Carbon coordination 
chemistry is straightforward. As the three common geometries — tetrahedral, 
trigonal planar and linear — are each associated with a single angle — 109.5◦, 
120◦, and 180◦, respectively, the reference value,     , in Equation (2-24) for the 
bond angle term is clear. In contrast, for common coordination geometries like 
octahedral and trigonal bipyramidal, there are multiple reference angles for the 
same A–M–A triad (Figure 2-2). The increased number of ligands combined with 
the multitude of possible geometries significantly increases the problem of 
assigning suitable functional forms for each of the energy terms. Hence, the first 
hurdle encountered in molecular mechanics for transition metal systems is how to 
describe the angular geometry at the metal centre when using a force field 
expression like Equation (2-24). The situation can be much more challenging for 
irregular four-, five- and six-coordinate species particularly when valence 
electronic effects such as the Jahn-Teller effect play a significant role in 
determining the molecular structure.
98
 A Urey-Bradley
92
 treatment of the bonding 
about the metal can often give quite reasonable geometries; here, there are no 
angle-bending terms at the metal but terms due to pairs of atoms bonded to the 
metal. Alternatively, ligand field molecular mechanics (LFMM)
99
 — a more 
sophisticated approach that includes an explicit treatment of d-electron effects — 
has been developed and successfully applied to the modelling of various transition 
metal complexes. 
2.3 Ligand Field Molecular Mechanics  
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Ligand field molecular mechanics (LFMM)
72,98-101
 is designed to model the 
electronic effects of the valence d and s electrons in transition metal compounds. 
These effects can lead to severe distortions away from the ideal geometries 
predicted by simple VSEPR theory. The stereochemical activity of d electrons 
manifests in a range of structural distortions of ionic coordination complexes 
typified by the Jahn–Teller elongations of six-coordinate d9 Cu2+ species. 
Modelling these effects requires an additional term in the potential energy which 
describes the ligand field stabilisation energy (LFSE). The LFSE is explicitly 
incorporated into the LFMM method which has been applied to a range of 
complexes of Cu
2+
, Ni
2+
, Co
3+
, Ru
2+
, and Pt
2+
. A single set of LFMM parameters 
for a given metal–ligand interaction is able to model different coordination 
numbers and geometries, spin states and bond lengths. 
72,98,100,102
  
2.3.1 The Angular Overlap Model 
 
Figure 2-3. Schematic representation of the five d orbitals. Note change in axis 
frame directions for dxy and dyz. 
 
The shapes of the d-orbitals are central to the qualitative and quantitative aspects 
of ligand field theory (LFT) (Figure 2-3). Certain magnetic and spectroscopic 
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features arise from the electrons in the d-shell which play a crucial role in the 
chemistry of the transition elements. 
 
 
Figure 2-4. Definition of AOM parameters in terms of local M–L bonding. 
Reproduced from reference 72 with permission. 
 
Although valence bond theory and crystal field theory (CFT) adequately account 
for a large number of features, they have serious limitations when describing the 
bonding in coordination compounds and rationalizing and predicting their 
properties.
103
 The concept now most widely used to study the general chemistry of 
the transition metals is a simple molecular orbital (MO) approach, often referred 
to as Ligand Field Theory (LFT). The notions inherent in the simple MO approach 
form the basis of a potent method of describing metal–ligand bonding in terms of 
local σ and π bonding interactions while retaining the empiricism of the ligand 
field approach. It is known as the angular overlap model (AOM).
104
 The AOM 
defines the total ligand field potential as a sum of individual, local M–L σ and π 
bonding contributions as illustrated in Figure 2-4, rather than in terms of the 
symmetry of the complex as a whole. The AOM parameters eσ, eπx, and eπy may 
 54 
 
be derived from spectroscopic measurements or fitted to the results of quantum 
mechanical calculations .
100
  
2.3.2 The LFMM Method 
LFMM uses a generalized ligand field calculation of the d-orbital energies to 
estimate the ligand field stabilisation energy (LFSE). The LFSE depends on the 
complex, the d configuration and the spin state and can have a marked effect on a 
range of structural and thermodynamic properties of metal complexes. Since MM 
is inherently bond centered, the most convenient form of ligand field model is the 
angular overlap model (AOM) outlined above.
104
 Each M-L interaction is 
parameterized in terms of local bonding modes of  or  symmetry, with each 
assigned its own parameter (Figure 2-4).
100
 The full ligand field potential is then 
constructed by summing the contributions from each bonding mode over all 
ligands and diagonalizing the resulting matrix. The LFSE and its gradients are 
then merged with a more-or-less conventional MM scheme. The total potential 
energy,      , can be modeled by simple contributions from bond stretching, Estr, 
angle bending, Ebend, torsional twisting, Etor, and non–bonding interactions, Enb, 
where the latter may include both van der Waals and electrostatic terms. The core 
concept of the ligand field molecular mechanics (LFMM) method is the addition 
to the conventional potential energy expression of a new term specifically 
designed to describe the effects of the ligand field stabilization energy (LFSE): 
        Σ Estr  Σ Ebend  Σ Etor + Σ Enb + LFSE                                          (2-25) 
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Figure 2-5. Schematic reprecsentation of division into coordination and ligand 
regions and force ﬁeld terms which span the two. Reproduced from reference 72 
with permission.  
 
In other words, LFMM merges conventional MM for the ‘organic’ parts of a 
transition metal complex with an AOM treatment of the LFSE for the metal 
centre. Each molecule is divided into two overlapping regions as illustrated in 
Figure 2-5 for a [M(en)2]
n+
 complex (en = ethylenediamine). The coordination 
region contains the metal and its bonded donor atoms (e.g. the MN4 unit) and the 
ligand region includes everything except the metal atom (e.g. the ethylenediamine 
ligands). The LFMM model focuses on the coordination region and is used to treat 
the LFSE, M–L bond stretching (via a Morse function), and L–M–L angle 
bending (via an explicit L-L repulsive term). The program, ‘d orbital molecular 
mechanics in the Molecular Operating Environment’ (DommiMOE)101,105, has 
been designed to take advantage of existing force fields implemented in MOE, 
e.g., MMFF
106-110
, AMBER
111
 and CHARMM
112
, which treat all the interactions 
in the ligand region. 
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2.4 Molecular Dynamics Simulation Methods  
Molecular dynamics (MD) simulation, which provides detailed microscopic 
modelling on the atomic scale by numerically solving Newton's equations of 
motion, is an excellent approximation for a wide range of systems and is thus a 
powerful tool in chemistry, physics, biology, and materials science. This 
technique enables the natural time evolution of the system which allows the 
structural, dynamic, and thermodynamic properties of substances to be predicted 
directly from the underlying interactions between the molecules, providing every 
detail of how a many-particle system changes from one conformation to 
another.
113, 114, 89
 
2.4.1 Basic Statistical Mechanics of Molecular Dynamics 
Computer simulation generates information at the microscopic level (atomic and 
molecular positions, velocities etc.) and the conversion of this very detailed 
information into macroscopic properties (pressure, internal energy etc.) is the 
province of statistical mechanics. Herein, the aspects of the subject which are 
within the scope of this thesis are summarised.
89,113
 
A Hamiltonian, H, in a classical system is a function of both coordinates r and 
momenta p. The Hamiltonian for the system can be expressed as the sum of 
kinetic energy, K(p), and the potential energy, U(r), 
                    
  
   
                                                      (2-26) 
where pi is the momentum of particle i, and mi the mass of particle i. A 
microscopic state of the system can therefore be characterised by the set of values 
{r, p}. For a system containing N atoms, 3N positions and 3N momenta are 
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required to define the state of the system. The 6N-dimensional space defined by 
by both coordinates r and momenta p is known as the phase space of the system. 
For a system with fixed number of particles, volume and temperature, the 
probability density is given by the Boltzmann distribution function: 
       
                 
 
                                                                                  (2-27) 
where the canonical partition function, Z, is an integral over all phase space of the 
Boltzmann factors                  , and kB is the Boltzmann constant. 
Partition function allows us to compute thermal averages of any dynamic variable 
A(r, p) of interest (positions, the total energy, the kinetic energy etc.) and, 
therefore, is the key feature in statistical mechanics. These averages over every 
possible state of the system: 
                             
 
  
                                                          (2-28) 
are called ensemble averages. Alternatively, to calculate the average values of 
properties, averaging over the whole phase space all at once can be replaced by 
following the motion of a single point through phase space. That is, in this 
approach, the motion of a single point through phase space is followed as a 
function of time, and the averages, known as time averages, simply involve 
computing those points during the time evolution: 
                 
 
 
               
 
 
                                                       (2-29) 
where τ is the duration of the simulation. If τ is sufficiently long, the value of the 
integral in Equation (2-29) approaches the ‘true’ average value of the property. 
Compared to the ensemble average, the time average is easier to obtain.  
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The ergodic hypothesis, one of the fundamental axioms of statistical mechanics, 
states that for an infinitely long trajectory the ensemble average is equal to the 
time average:  
   
   
                                                                                                  (2-30) 
In other words, the ergodic hypothesis assumes that when simulated time becomes 
long enough, eventually all of phase space will be explored and thus quantities by 
time averaging and by ensemble averaging become equal. The system has to reach 
equilibrium for this hypothesis to sustain. 
2.4.2 Newtonian Molecular Dynamics
114
 
In molecular dynamics, configurations of the system connected in time are 
generated by a numerical integration of Newton's laws of motion. As a result, a 
trajectory that specifies how the positions and velocities of the particles in the 
system evolve as a function of time is recorded. Newton’s equation of motion 
states that 
          
    
   
                                                                                          (2-31) 
where Fi is the force on particle i, mi is the mass of particle i, ai is its acceleration, 
and ri is the coordinate.  
In order to generate the trajectory, a numerical procedure for integrating the 
differential equation to solve Newton’s equation of motion is required. A standard 
approach to solve ordinary differential equations like Newton’s equation of 
motion is a finite difference method. The essential concept is that the integration 
can be broken down into many small steps with a fixed time interval Δt. Given the 
molecular coordinates and velocities at time t, the molecular coordinates and 
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velocities at a later time t+Δt can be calculated to a sufficient degree of accuracy. 
The equations are solved step by step. The choice of time step ∆t will depend on 
the characteristics of the simulated molecules, and ∆t will be significantly 
(typically an order of magnitude) smaller than the typical time of the fastest 
motion studied in order to model such a motion with sufficient accuracy. 
For algorithms using finite difference methods, the positions can be approximated 
as a Taylor expansion: 
                      
 
 
        
 
 
        
 
  
                (2-32) 
where v(t) is the velocity (the first derivative of the positions with respect to time),  
and a(t) is the acceleration (the second derivative), b(t) is the third derivative, and 
so on. With rn and rn+1 to indicate the position at step n (at time t) and at the next 
step, n+1 (at time t+∆t), respectively, and recalling Equation (2-31), Equation (2-
32) can be written as:  
             
 
 
 
  
 
                                                                    (2-33) 
2.4.2.1 Verlet Integrator 
The Verlet algorithm
115
 is one of the simplest method for integrating the equations 
of motion in a molecular dynamics simulation. The Verlet integrator employs two 
Taylor expansions, a forward expansion (t+∆t) and a backward expansion (t−∆t): 
             
 
 
 
  
 
                                                                  (2-34a) 
             
 
 
 
  
 
                                                                  (2-34b) 
Summing these two expansions, an algorithm for propagating the position with an 
error of order        is obtained: 
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                                                                    (2-35) 
Subtracting Equation (2-34b) from Equation (2-34a) gives a complementary 
algorithm for propagating the velocities accurate to order       : 
   
         
   
                                                                                         (2-36) 
The advantages of the Verlet algorithm are (i) implementation is straightforward 
and the storage requirements are modest, comprising two sets of positions (rn and 
rn+1) and the accelerations a(t), (ii) fast since only a single force evaluation per 
integration cycle is required, and (iii) time reversibility. The disadvantages of the 
Verlet algorithm are (i) the positions rn+1 are obtained by adding a small 
term,          to the difference of two much larger terms, 2rn and rn-1 and this 
may lead to large numerical errors, (ii) vn can be computed only if rn+1 is already 
known and the velocity propagation is only accurate to order O(∆t2) (an accurate 
estimate of the velocity is required to compute the kinetic energy and the 
instantaneous temperature), and (iii) it is not self-starting (the new positions, rn+1, 
are computed from the positions at the current, rn, and the previous, rn-1, time 
steps), and a lower order Taylor series expansion is often used to initiate the 
propagation. 
2.4.2.2 Velocity Verlet Integrator 
The velocity Verlet algorithm
116
 has been developed to improve the velocity 
evaluation in the basic Verlet integrator. This algorithm gives positions, velocities, 
and accelerations all at the same time t and minimizes round-off errors by the 
following form: 
             
 
 
 
  
 
                                                                            (2-37a) 
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                                                                              (2-37b)   
The advantages of the velocity Verlet algorithm are (i) it is simple and 
numerically stable, and (ii) it is a more accurate equation for the velocities and 
consequently the kinetic energy compared to the Verlet algorithm. The main 
disadvantage of this method is the slightly higher computational cost compared to 
the simpler Verlet or leap-frog algorithms.  
2.4.3 Setting up and Running a Molecular Dynamics Simulation 
To start a molecular dynamics simulation, we first need to decide which energy 
model is to be used to describe the interactions within the system and specify the 
conditions of the run (e.g., number of particles, initial temperature). Secondly, we 
need to initiate the integration by selecting initial values of the system (typically a 
set of initial coordinates {r(0)} and a set of initial velocities {v(0)}). Following 
the assignment of an initial configuration is an equilibration phase, during which 
the system evolves from the starting configuration. Thermodynamic and structural 
properties must be monitored carefully during this stage until stability is achieved. 
At the end of the equilibration proper comes the production phase, during which 
simulation averages can be computed. Finally, the simulation is analysed. 
2.4.3.1 Assigning Initial Values 
The initial configuration of the system can often affect the results of a simulation, 
and thus it needs to be selected with care. For simulations of systems at 
equilibrium it is important to choose a starting configuration close to the structure 
that we are aiming to simulate. The initial coordinates {r(0)} can be obtained from 
experiments such as X-ray crystallography and NMR measurements, from 
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computer models generated by a variety of modelling techniques or from a 
combination of the two. However, some preparation steps are often required 
before most structures can be used as starting configurations in a MD simulation. 
For instance, the coordinates for hydrogen atoms are often not available in 
structures determined by X-ray. The addition of these coordinates to the initial 
structure is required to initiate the simulation. The available algorithms for 
assigning protonation states generally lie in two categories. Geometric methods 
place hydrogen atoms based upon optimization of hydrogen bond networks, 
whereas electrostatic methods determine the hydrogen coordinates based upon 
electrostatic effects considerations and often require the calculation of pKa values. 
The Protonate3D methodology in Molecular Operating Environment (MOE)
117
 
adds protons to macromolecules by selecting a protonation state for each chemical 
group with minimum total free energy of the system, and the results show good 
overall agreement with high resolution X-ray structures. With the provision of all 
the coordinates, the initial structure can be further refined by energy minimization 
in order to relieve local stresses caused by nonbonded overlaps, and to relax bond 
length and bond angle distortions in the experimental structure. These stresses 
often result from the empirical nature of the energy function and the average 
nature of the experimentally obtained structures. 
For a molecular dynamics simulation, initial velocities (vx , vy , vz ) may be chosen 
randomly from the Maxwellian velocity distribution at a temperature T: 
        
 
     
 
   
    
    
    
                                                                   (2-38) 
This initial assignment is not at equilibrium; moreover, high velocities may be 
accidentally assigned to a localized cluster of atoms, leading to unstable 
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simulation. It is good practice to initiate a simulation by heating up the system 
step-by-step to avoid this problem. Velocities are first assigned at a low 
temperature, which is then gradually increased until the simulation reaches the 
desired temperature. We can use equipartition theorem to define an instantaneous 
temperature, T(t), at time t in terms of the mean kinetic energy by: 
     
 
      
       
     
                                                                                (2-39) 
where Ndof is the number of unconstrained degrees of freedom in the system (Ndof 
= 3N − n, where N is the number of atoms and n is the number of constraints). We 
can adjust a mean kinetic energy to match a desired temperature T0 by scaling the 
velocities with a factor of [T0/T(t)]
½
. 
2.4.3.2 Selecting the Integration Time Step 
The size of the time step ∆t greatly affects the magnitude of the error in 
integration algorithms. A small time step means better integration quality; 
however, it also means that more integration steps are needed to cover the same 
amount of phase space. There is a trade-off between simulating the correct 
trajectory and covering the phase space. In general, it is advantageous to use a 
large time step that will give accurate dynamics. An appropriate time step should 
be approximately one-tenth the time of the highest frequency motion in the 
modelled system. 
Table 2-1. Suggested time steps for the different types of motion in various 
systems. Adapted from reference 89. 
System  Types of motion  Suggested time 
step (s) 
Atoms  
Rigid molecules  
Flexible molecules, rigid bonds  
Flexible molecules and bonds  
Translation  
Translation and rotation  
Translation, rotation, torsion  
Translation, rotation, torsion, vibration  
       
        
        
      or         
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The typical motions together with suggested time steps in various systems are 
shown in Table 2-1, which can be used to choose an appropriate time step. For 
flexible molecules, the fastest motions are the stretching vibrations of the bonds 
between hydrogen atoms and heavy atoms with frequencies about 3000 cm
−1
 (10 
fs =          ). This extremely small time step limits the time scale of 
molecular dynamics simulations. 
Sophisticated algorithms that allow use of longer time steps to enable longer 
simulations have been developed. A basic rationale is to remove the fastest 
motions from the numerical integration and treat them properly in some other way, 
such that the next fastest molecular motion can be used to decide the time step. 
The most commonly used algorithm to account for the hydrogen coordinates is 
SHAKE.
118
 In the SHAKE algorithm, the hydrogen coordinates have been 
adjusted iteratively until the deviation of the current length dk(t) of the kth bond 
from its reference bond length   
  satisfied to within a given tolerance value ε: 
         
    
     
                                                                               (2-40) 
In other words, SHAKE uses an iterative scheme that adjusts the coordinates of 
hydrogen atoms after each integration step in order to simultaneously satisfy all 
the constraints. This procedure may be iterated until sk is smaller than ε for all 
values of k. It is most useful when we simulate large molecules. 
2.4.3.3 Stability of Integration 
When a simulation has picked up errors along the way, it becomes unstable. It is 
therefore important to maintain the accuracy and stability of the simulation for the 
duration of interest. The integration error will either cause an unstable simulation 
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to crash, if one is lucky, or continues till its designated termination but give 
inaccurate trajectories that deviate considerably from true trajectories.  
Quantities that are expected to be conserved during the simulation can be used to 
measure the stability of the simulation. To be considered conserved, an adequate 
fluctuation ratio for the total energy, E (the Hamiltonian) in Equation (2-26) is: 
  
 
                       
  
 
                                                                      (2-41) 
The total linear momentum P and the total angular momentum L also become 
conserved after equilibration. However, for simulation schemes with constant 
adjustments of velocities, momentum conservation can no longer be used for 
probing the stability of the simulation. Furthermore, Newton’s equation is time 
reversible. This means it should be able to retrace back its original trajectory in 
phase space (when the sign of the time step ∆t is changed to −∆t). However, 
numerical errors will cause any two trajectories that are initially very close to 
diverge from one another although it is still possible to keep a stable integration 
that exhibits time reversibility for short periods of time. 
2.4.3.4 Boundaries 
In order to simulate macroscopic properties, it is essential to apply appropriate 
boundary conditions that mimic the presence of an infinite bulk surrounding the 
model system and minimise surface effects. This can be achieved by periodic 
boundary conditions. Imagine a cubic box of particles which is replicated 
infinitely in all directions such that the central box in three dimensions is 
surrounded by 26 identical cubes, which are again surrounded by 98 boxes, etc. 
The coordinates of the particles in the periodic image boxes can be obtained 
simply by adding or subtracting integral multiples of the box sides. If a particle 
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leaves the central box through the right wall during the simulation, then its image 
will enter the box through the left wall from the neighbouring box. Thus, the 
number of particles in the central box remains constant. 
Periodic boundary conditions are widely applied in computer simulations, but we 
should always be aware that they may lead to spurious correlations not present in 
a truly bulk system. For systems where longer-range electrostatic interactions play 
important roles, it is important to use a cutoff distance less than half the periodic 
box length to ensure that a given particle interacts only with the nearest periodic 
image of any other particles. 
Alternatively, the simplest way to incorporate explicitly solvent molecules in 
simulations is to surround the molecule with a ‘skin’ of solvent molecules. If the 
skin is sufficiently deep, it is equivalent to model a solute molecule inside a ‘drop’ 
of solvent. The number of solvent molecules required in this approach is usually 
significantly fewer compared to the analogous periodic boundary simulation. 
Boundary effects can be transferred from the molecule-vacuum interface to the 
solvent-vacuum interface such that a realistic treatment of the solute may be 
achieved. 
2.4.3.5 Long-Range Forces 
As mentioned in the foregoing section, the charge-charge interaction, which 
decays as r
−1
, will extend beyond the boundary of a box and thus is particularly 
problematic in molecular simulations. It is important to properly model these 
long-range forces when simulating conformations of biological molecules such as 
polynucleotide chains. Among a variety of methods developed to handle long-
range forces, the Ewald summation
119
 has been used successfully to liquid 
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simulations and is a standard for macromolecular simulations.
113
 In this method, a 
particle interacts with all the other particles in the central simulation cell and with 
all of their images in an infinite array of periodic cubes.  
The idea of the Ewald summation is to split the interaction, which converges 
extremely slowly, into two series, each of which converges much more rapidly. 
The first contribution is obtained by surrounding each point charge with a 
neutralising charge distribution of equal magnitude but of opposite sign centred at 
the position of the point charge. The conversion of the sum over point charges to a 
new sum of the interactions between the charges plus the neutralising distributions 
leads to zero net charge. The interaction between the screened point charges is 
short-ranged and converges very rapidly. A smooth charge distribution is now 
added to the system which exactly offset the first neutralising distribution. The 
second summation can be evaluated in reciprocal space, and also converges much 
more rapidly than the original point-charge sum. Nevertheless, one needs to bear 
in mind that the Ewald method is not without problems. It tends to reinforce 
artefacts resulting from imposing periodic boundary conditions and is 
computationally rather expensive to implement.  
2.4.3.6 Simulation Protocol 
Every molecular dynamics simulation comprises several steps. A simulation 
protocol refers to these steps all together. The main steps common to most MD 
simulation protocols are: (i) preparation of the initial configurations such as 
addition of hydrogen atoms, energy minimization, and specification of initial 
velocities, (ii) gradual increase on the velocities to the desired temperature, (iii) a 
relatively long dynamic simulation that may take from tens of picoseconds to 
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several hundred picoseconds to bring the system to equilibrium from the starting 
configuration and to ensure that the simulation is stable, (iv) the dynamic 
simulation after the equilibration phase called production, where the trajectory 
generated can be stored for further analysis, and (v) analysis of the resulting 
trajectories.  
2.4.4 Molecular Dynamics in Various Ensembles 
The original MD technique was performed in the constant NVE ensemble. It is 
important to perform simulations in other ensembles relevant to experimental 
conditions, such as the canonical (constant-NVT) ensemble associated with a 
Helmholtz free energy or the isothermal-isobaric (constant-NPT) ensemble 
associated with a Gibbs free energy. Herein, I outline the most widely used 
methods of MD simulations under conditions of constant temperature or constant 
pressure. 
2.4.4.1 Constant Temperature MD 
An obvious approach to maintain the temperature of a system during an MD 
simulation is to rescale the velocities at each time step by a factor of [T0/T(t)]
½
, 
where T(t) is the temperature at time t defined in Equation (2-39) and T0 is the 
desired temperature. A further refinement of this approach is to couple the system 
to a heat bath at a temperature T0 using velocity scaling.
120
 The bath can supply or 
remove heat from the system like a source of thermal energy, such that the 
velocities can be rescaled at each step and the rate of change of temperature is 
proportional to the difference in temperature between the bath and the system: 
     
  
 
 
 
                                                                                                  (2-42) 
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where τ is a coupling parameter, which determines the strength of the coupling to 
the heat bath. The change in temperature between successive time steps can be 
expressed as: 
   
  
 
                                                                                                  (2-43) 
The velocities can thus be scaled by a factor λ: 
     
  
 
 
  
    
    
   
                                                                                  (2-44) 
If τ is large, the coupling is weak. With the decreasing τ, the coupling will be 
stronger. When the coupling parameter equals the time step (τ = δt) the algorithm 
is equivalent to the simple velocity scaling method. For the time step of 1 fs, the 
coupling parameter of 0.4 ps (δt/τ ≈ 0.0025) is suggested as an appropriate value. 
However, these two methods do not generate rigorous canonical averages and do 
not correspond to exact canonical ensembles. 
In the stochastic collisions method, the molecules of the system interact with the 
particles of a heat bath at a specified temperature.
121
 A particle is randomly 
selected at intervals and its velocity is obtained from the Maxwell-Boltzmann 
distribution in Equation (2-38) corresponding to the desired temperature T0. The 
mean frequency with which each particle experiences a stochastic collision, ν, 
chosen from a Poisson distribution: 
                                                                                                         (2-45) 
where        is the probability that the next collision will take place in the time 
interval δt.  
Another approach to isothermal MD simulation is to treat the dynamics of a 
system in contact with a thermal reservoir by considering the thermal reservoir as 
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an integral part of the system and introducing an additional degree of freedom, 
denoted s, that represents that reservoir.
122,123
 In a simulation of this extended 
system, energy is allowed to flow back and forth from the reservoir to the system, 
and each state of the extended system corresponds to a unique state of the real 
system. The velocities of the atoms in the real system are related to the time-
derivatives of position by: 
    
   
  
                                                                                                            (2-46) 
where ri is the position of particle i in the simulation and vi is considered to be the 
velocity of the particles in the real system. The time step δt' is associated with the 
time step in real system δt by: 
                                                                                                                  (2-47) 
The reservoir has potential energy (f + l)kBT lns, where f is the number of degrees 
of freedom (3N − 3 if the total momentum is fixed) and T is the desired 
temperature. The kinetics of the reservoir can be expressed as (Q/2)(ds/dt)
2
, where 
Q is the thermal inertia parameter with dimensions of energy   (time)2 which 
determines the coupling between the reservoir and the real system and thus 
controls the temperature fluctuations. The time-scale variable s, its conjugate 
momentum ps and the parameter Q are introduced to express the Hamiltonian of 
the extended system of the N particles plus additional degrees of freedom: 
       
  
 
    
 
 
         
  
 
  
                                                    (2-48) 
The time step in real time can fluctuate as the value of the additional degree of 
freedom s changes. To avoid fluctuating time intervals in the simulation, a slightly 
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different set of equations have been derived with no involvement of the time-
scaling parameter s. During the simulation, the following quantity is conserved: 
        
  
 
   
 
         
   
 
                                                            (2-49) 
where ξ (= ps/Q.) is the thermodynamic friction coefficient. It should be stressed, 
however, that this       is no longer a Hamiltonian. The adjustable parameter Q 
regulates the energy flow between the system and the reservoir. A small value of 
Q corresponds to a low thermal inertia of the bath and results in poor equilibration 
and rapid temperature fluctuations. However, a large value of Q results in slow 
energy exchange, and in the limit of infinite Q, conventional MD is regained. It 
may be necessary to choose Q by performing a series of trial simulations for a test 
system in order to observe how well the desired temperature is maintained. 
2.4.4.2 Constant Pressure MD 
Many experiments are performed under conditions of constant temperature and 
pressure, and so simulations in the isothermal-isobaric (NPT) ensemble are most 
directly relevant to experimental data. For MD simulations at constant pressure 
the volume is considered as a dynamical variable that changes during the 
simulation. Many schemes used for pressure control are analogous to those used 
for temperature control. The pressure can be kept constant by simply scaling the 
volume. The rate of change of pressure can be expressed as:  
     
  
 
 
  
                                                                                               (2-50) 
where τp is the coupling constant, P0 is the pressure of the bath, and P(t) is the 
pressure at time t. The volume of the simulation box is scaled by a factor λ: 
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                                                                                            (2-51) 
This is equivalent to scaling the atomic coordinates by a factor λ1/3, yielding the 
new positions: 
  
                                                                                                                 (2-52) 
This method does not correspond to any ensembles, and therefore it is not possible 
to determine the meaning of fluctuations in any observed quantity.  
Alternatively, the system can be coupled to a ‘pressure bath’, analogous to a 
temperature bath.
121
 An extra degree of freedom V, corresponding to the volume 
of the box, is added to the system. This coupling can be considered as the action 
of a piston on a real system. The piston is associated with a kinetic energy, 
 
 
           where Q is the ‘mass’ of the piston. The potential energy of the 
piston is PV, where P is the desired pressure and V is the volume of the system. A 
piston of small mass leads to rapid oscillations in the box size. A large mass 
results in slow exploration of volume-space, and an infinite mass returns normal 
MD. The extended-system temperature-scaling method employs a scaled time, 
and likewise, in the extended pressure method the coordinates of the extended 
system,   
 , are related to the real coordinates   by: 
  
                                                                                                                (2-53) 
2.5 Quantum Mechanical Calculations 
2.5.1 Computational Details for the Study on Photochemistry of Pt(IV) 
Anticancer Agents  
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The geometries of molecules were optimized with the Amsterdam Density 
Functional 2007 program (ADF)
124
 at the gradient-corrected DFT level using the 
BP86 functional in combination with the uncontracted triple-ζ+polarisation (TZP) 
STO basis sets. A small frozen core was used for efficient treatment of the inner 
atomic shells. Relativistic effects were considered by the zeroth-order regular 
approximation (ZORA)
58,59
. Vibrational frequency calculations confirmed that the 
structures reported are minima on the potential energy surfaces. Ziegler and 
Rauk’s energy decomposition scheme has been used to study the metal-ligand 
bond for selected structures.
125-128
 The lowest fifty singlet electronic excitation 
energies and their corresponding oscillator strengths were calculated by the 
statistical average of orbital potentials (SAOP)
60
 in combination with a TZ2P 
basis sets (i.e. TZP with an additional polarization function) using scalar 
relativistic Time-Dependent Density Functional Theory (TDDFT) as implemented 
in the ADF program. Spin-orbit coupling was evaluated in the Pt(IV) complexes 
to enhance the comparison with available experimental data as previous 
theoretical study has shown that relativistic effects can have a significant effect on 
the simulated electronic spectra of heavy metal complexes.
129
 The results show 
that the main feature of the spectra is similar with or without spin-orbit coupling. 
Electronic transitions were also computed using TDDFT with the Conductor like 
Screening Model (COSMO) for trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] at the 
previously optimized structure in gas phase. COSMO is an approximate approach 
to include solvent effects for reactions in solution. In COSMO the solvent is 
treated as a dielectric continuum, surrounding the molecular cavity of the solute 
molecules. A rigid sphere of the solvent molecules is used to determine how far 
the solvent can penetrate into the region occupied by the solute molecules, the 
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solvent accessible surface of the cavity. The overall surface is partitioned into 
small surface triangles and each triangle is assigned an adjustable point charge, 
which are determined from the charge density and corresponding potential of the 
molecule itself in the SCF procedure and by assuming an ideal conductor where 
the electric potential on the surface disappears. Thus, along with the computed 
charge distribution of the molecule, the energy of the interaction between the 
solvent and the solute molecule can be calculated. The addition of solvent effects 
does not show improvement in terms of the absorption maxima compared to the 
experimental data (Table A1-2, Appendix 1). Thus, all subsequent calculations 
were carried out using scalar relativistic TDDFT at a relatively low computational 
cost and no solvent effects were accounted. The geometry optimization of the 
lowest-lying triplet state of complex 11 was performed using a spin-unrestricted 
BP86/TZP method with a net total spin polarization chosen to be 2. 
The simulated UV spectra were produced by the summation of Gaussian peaks, 
generated for each of the calculated absorption maxima according to: 
          
                                                                                                    (2-54) 
where I is the peak intensity as a function of wavelength (x), A is the calculated 
absorption maximum, b is the wavelength at which the calculated maximum 
occurs and c is the peak width parameter related to the full width at half maximum 
(FWHM) resolution by: 
                                                                                                      (2-55) 
The model was devised to overcome issues inherent in the comparison of 
computed "point spectra" with those generated by experiment. It accounts for 
coalescence of neighbouring peaks, allowing this to be visualised as a function of 
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peak width, but takes no account of dynamic peak width variations arising from 
the different types of electronic states involved in each transition. 
2.5.2 Quantum Mechanical Calculations for New LFMM/MMFF94 and 
LFMM/AMBER94 Charge Schemes 
To estimate partial charges of Pt-guanine complexes, the geometry of a model Pt-
guanine complex was fully optimized using the ADF 2007 program
57
 with the 
BP86 functional
130,131
 in conjunction with the a triple-ζ plus double polarization 
basis set (TZ2P) on all atoms and a scalar ZORA
59
 relativistic and dispersion
132
 
correction. To maintain compatibility with our previous parameterization, 
CHelpG
133
 charges were computed using the previously optimized structure at the 
HF/6-31G(d) level using the Gaussian 03 program
61
 with the LanL2DZ
134
 basis 
set with an extra set of f functions using the exponents determined by Frenking et 
al. for the metal
135
 with Pt given a van der Waals radius of 1.8 Å . 
2.6 Analysis Techniques 
The value of any computer simulation lies in the quality of the information 
extracted from it. The analysis procedure needs to be contemplated before starting 
the simulation, as the goals of the analysis will often determine the general 
character of the simulation. Herein, I give an overview of the techniques that have 
been used to analyse the MD trajectories presented in this thesis.  
2.6.1 Average Structure 
To compare with experimental and/or different MD structures, average MD 
structures of DNA were calculated as below. All x, y, and z coordinates of heavy 
(non-hydrogen) atoms were read in from the specified section of the trajectory. 
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Translation and rotation motions were removed by least-squares fitting to a 
reference structure (usually the initial structure at t = 0). The average x, y, and z 
coordinates were then calculated using Equation (2-56). 
               
              
  
   
  
                                                                      (2-56) 
where Ns is the number of snapshots in the trajectory. 
2.6.2 Root-Mean-Square Deviation 
In order to compare different simulations to one another, or to compare the 
simulation to experimental results, we need to compute average values and 
fluctuations. The most common mathematical expression of a molecule’s motion 
within a trajectory is the root-mean-square deviation (RMSD) of the atoms in the 
system with respect to a reference structure. For a stable system, the RMSD is 
expected to fluctuate about a constant value. The translational and rotational 
motions are first removed by least-squares fitting to a reference structure. The 
RMSD is then calculated by Equation (2-57). 
           
 
  
          
           
           
   
    
   
              (2-57) 
2.6.3 DNA Backbone Conformation Parameters 
The IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) has 
made recommendations for abbreviations and symbols to describe conformations 
of polynucleotide chains. The backbone of a polynucleotide chain comprises a 
repeating unit of six single bonds, P–O5', O5'–C5', C5'–C4', C4'–C3', C3'–O3' and 
O3'–P. The torsion angles related to these bonds are indicated by the symbols α, β, 
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γ, δ, ε, ζ, respectively. The symbols α(i)–ζ (i) are referred to torsion angles of 
bonds within the i
th
 nucleotide unit as illutrated in Figure 2-6 and 2-7.
136
  
 
Figure 2-6. Section of a polynucleotide backbone showing the atom numbering 
and the notation for torsion angles. Reproduced from reference 137. 
 
 
Figure 2-7. Torsion angles for backbone conformations of the ith nucleotide in 
polynucleotide chains. Reproduced from reference 137. 
 
2.6.4 DNA Helicoidal Parameters 
Curves+
138
 is a conformational analysis program for nucleic acids with up to four 
strands and with either standard or chemically modified bases and backbones. 
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Compared to the original Curves algorithm widely used for nucleic acids 
structural studies, this program is algorithmically simpler and computationally 
much faster. In addition, it provides helical and backbone parameters and a full 
analysis of groove widths and depths. Diagrammatic definitions of parameters 
used to describe the geometry of complementary base pairs and sequential base 
pair steps are presented in Figure 2-8 and 2-9. The intra-base pair parameters 
include three translations, shear, stretch and stagger, and three rotations, buckle, 
propeller and opening. Likewise, the inter base pair parameters contains three 
translations, shift, slide and rise, and three rotations, tilt, roll and twist. Therefore, 
Curves+ is used to analyse the local and global structural parameters for nucleic 
acids in Chapter 5. 
 
Figure 2-8. Pictorial definitions of the intra-base pair (left) and inter-base pair 
(right) parameters in Curves+. Images illustrate positive values of the designated 
parameters. Diagram adapted from reference 139.  
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Figure 2-9. Illustration of the base pair reference frame (left) and of the local 
helical frame (right). Images demonstrate positive values of the designated 
parameters. Diagram adapted from reference 139. 
 
2.6.5 Structural Forms of DNA 
 
Figure 2-10. Structures of A-, B-, and Z-forms of DNA. Adapted from reference 
140. 
 
The classical model of double stranded DNA deduced by Watson and Crick is 
known as B-DNA helix. Due to the flexibility of its backbone, DNA can assume a 
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variety of structural forms. Along with B-DNA two other forms, A-DNA and Z-
DNA, are biologically significant (Figure 2-10). The main structural parameters 
for standard A-, B-, and Z-forms of DNA are provided in Table 2-2. 
Table 2-2. Summary of the main structural parameters for standard A-, B-, and Z-
forms of DNA.
141
  
Parameter A-DNA B-DNA Z-DNA 
Shape Broadest Intermediate Narrowest 
Helix sense Right Right Left 
α −85° −47° 60°/160° 
β −152° −146° −175°/−135° 
γ 46° 36° 178°/57° 
δ 83° 156° 140°/95° 
ε 178° 155° −95°/−110° 
ζ −46° −95° −35°/−85° 
Sugar pucker C3'-endo C2'-endo C3'-endo/ C2'-endo 
Glycosidic bond anti anti Alternating anti and syn 
Base roll 12° 0° 1° 
Base tilt 20° 5° 9° 
Base twist 32° 36° 11°/50° 
Helical diameter 25.5 Å  23.7 Å  18.4 Å  
Bases/turn of helix 11 10.4 12 
Rise/base pair 2.3 Å  3.4 Å  3.8 Å  
Major groove Narrow, deep  Wide, deep Flat 
Minor groove Broad, shallow Narrow, deep Narrow, deep 
  
 81 
 
 
 
Chapter 3 
A Computational Approach to Tuning 
the Photochemistry of Pt(IV) 
Anticancer Agents 
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3.1 Introduction 
Since the serendipitous discovery of the inhibition of cell division by cisplatin in 
the 1960s, platinum-based  drugs have been widely used against various 
tumours.
1,5
 Much effort has been devoted to the design of novel Pt anticancer 
drugs to make chemotherapy safer for patients, in particular, lessening severe side 
effects,
142,143
 increasing oral bioavailability,
144,145
 and overcoming drug 
resistance.
146-151
 Platinum-based drugs disrupt DNA synthesis by mechanisms 
common to all actively dividing cells, regardless of whether they are cancerous or 
not, which generates severe side effects. In addition, the large volume of damaged 
cells further cause altered cellular transport, enhanced repair of distorted DNA, 
overexpression of DNA-damage recognition proteins and decreased apoptosis 
contributing to tumour resistance to Pt drugs.
6,19
 Thus, the design of drugs with 
increased selectivity is of great importance for significant clinical advantages over 
the current drugs. 
Prodrugs to improve therapeutic targeting and controlled release at the tumour site 
show promising possibilities for increased selectivity.
152
 Improved delivery of 
platinum drugs with liposomal-based or polymer-based vehicles is an attractive 
strategy and has been in clinical trials.
22-24
 However, creating delivery systems 
that target specific sites to achieve good release and activation is challenging. On 
the other hand, a photosensitizing agent in combination with light provides a 
prominent avenue to achieve accurate targeting.
25,26
  
An approach to platinum based photochemotherapy of cancer is to design 
photoactive Pt complexes which have a strong absorbance at longer wavelengths, 
increased selectivity, and facile metabolism
25,153
. Platinum(IV) complexes are 
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much more inert to reaction in vivo but readily undergo photoinduced reduction 
and ligand substitution. Moreover, photoreduction reactions from excited states 
are more reactive with macromolecules and, therefore, can be used effectively for 
triggering specific interactions between the metal complex and target 
biomolecules (such as DNA, RNA or proteins).
33-35,154-159
 Altering the electronic 
configuration by irradiation can lead to remarkable differences in chemistry, 
including the effects of changes in geometry, dipole moment, redox characteristics 
and acid-base properties, and can bring about reactions that normally do not occur 
under thermal conditions.
27
 Exploration of the factors that control the 
photochemistry of Pt(IV) complexes may thus allow the design of effective 
anticancer agents. 
As irradiation with longer wavelength helps reduce cell damage and deeper 
penetration can be achieved,
160
 the aim of this work is to achieve photoactivation 
of Pt(IV) complexes at longer wavelengths. Trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(py)] (1) is highly phototoxic and, in particular, pyridine is 
suggested to contribute to the potency via a different mechanism of action 
compared to cisplatin.
35
 Therefore, complex 1 has been used as the starting point 
and the template for our theoretical modelling. By tuning cis/trans geometries, 
trans influence, the OR
−
 (R=H, Ac) ligands, (pseudo)halogen (N3
−
, I
−
) ligands, 
electron-withdrawing/donating/delocalizing substituents on pyridine ligands, and 
intramolecular H-bond, the effects of the coordination environment on the 
electronic excitations of Pt(IV) complexes have been explored (Figure 3-1). The 
present study has also evaluated the influence of various chemical modifications 
on (i) the electronic excitations of the intense absorption band (normally at shorter 
wavelength) and of low-energy absorption band (the “tail” normally at longer 
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wavelength), (ii) the molecular orbitals involved in the electronic transitions in the 
UV-Vis bands, and (iii) the nature of bonding. In addition, trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(4-nitropyridine)] has been synthesised and characterised by 
Yao Zhao in order to compare its absorption properties with the calculations. A 
theoretical study of ground and excited state properties of photoactive Pt(IV) 
diazido was reported while this thesis was in preparation.
161
 Our results on the 
replacement of OH
−
 ligand by aromatic OR
−
 and the formation of azidyl radicals 
N3• upon photoreduction largely agree with those reported in this work, but our 
present study focuses on a systematic survey of various chemical influences on the 
photochemistry of Pt(IV) complexes in intense band and low-energy absorption in 
order to provide guidelines for future synthesis of this class of compounds. 
Relevant computational details were given in Chapter 2. 
3.2 Influence of Various Chemical Modifications 
The electronic excitations of Pt(IV) complexes are evaluated by the influence of 
various chemical modifications with reference to complex 1 (see Figure 3-1). 
Calculated excitation energies for the intense band are in good agreement with 
experimental measurements with errors less than 0.3 eV. Electronic trans 
influences are well-understood ground-state phenomena,
103
 but relatively little is 
known about their effects on photophysical properties. OR
−
 and halogen ligands 
have a large effect on the rate of reduction,
162
 and thus it is interesting to study 
their influence on electronic transitions in Pt(IV) complexes. As earlier 
reports
25,162,163
 showed that Pt(IV) complexes with OAc
−
 or halogen ligands are 
often easily reduced in cells and are less likely to have a noticeable difference 
between light and dark toxicity, in this study the design with trans OH
−
 and trans 
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N3
−
 groups is preferred. Pyridine with its range of possible substituents is a useful 
ligand for structure-property studies, including the photochemistry of Pt(IV) 
compounds. All these unique chemical properties lead us to the current 
construction of the theoretical models in this work. Figure 3-3 summarises the key 
features of the computed intense and lowest energy absorptions under the 
influence of various chemical modifications given above. Figure 3-4 displays 
simulated UV spectra of selected Pt(IV) complexes. 
 
3.2.1 Comparison between Experimental and Calculated Structures and 
Absorption. 
The fully optimized structures of cis, trans, cis-[Pt(N3)2(OH)2(NH3)2], and its all 
trans isomer show that bond lengths and angles are in good agreement with the 
respective experimental values, with a root-mean-square deviation (RMSD) of 
Figure 3-1. Various chemical modifications to explore the photochemistry of a 
potent photocytotoxic platinum complex, trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(pyridine)] (1). Changes in the coordination geometry and 
trans influence were considered. Substitutions (R) on the imine ligands, OR and 
(pseudo)halogen ligands were also included in the calculation. The substitutions 
on the imine ligands vary from withdrawing/donating groups/quinoline to 
intramolecular H-bonding involving OH ligand 
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0.046 Å  for Pt−L bonds and 0.9° for L−Pt−L angles (Table A1-1, Appendix 
1).
34,164
 The computed absorption maximum for the complex cis, trans, cis-
[Pt(N3)2(OH)2(NH3)(py)] (2) (py = pyridine) (273 nm, Table 3-2) is 20 nm shorter 
than that of its all trans isomer complex 1 (293 nm, Table 3-1). The same trend 
was observed for the cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] (271 nm, Table 3-1) and 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] (295 nm, Table 3-1), which is consistent 
with the previously reported experimental data, 256 nm and 285 nm respectively 
(Table 3-1).
34
 The comparison of the simulated and experimental UV-Vis spectra 
reveals smaller discrepancy in the intense band (λmax) for complex 1 and trans, 
trans, trans-[Pt(N3)2(OH)2(NH3)(quin)] (13) (quin = quinoline) (Table 3-1 and 
Figure 3-2) compared to cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] and trans, trans, 
trans-[Pt(N3)2(OH)2(NH3)2]. The high electron density of pyridine and quinoline 
may increase the accuracy of the modelled frontier orbitals.
165
 In addition to the 
electronic excitation energies, the computed intensity of absorption is consistent 
with the UV-Vis spectrum.
34,164
 
Table 3-1. Experimental and calculated absorption properties (intense band) of 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)2], cis, trans, cis-[Pt(N3)2(OH)2(NH3)2], 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] (1), and trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(quin)] (13) 
λmax, nm 
ε (M1 
cm1) 
Tra Composition 
Energy/eV 
(nm) 
Oscillator 
Strength 
Assignment 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] 
285 
(18900) 
11 
HOMO−3LUMO (46%) 
HOMO−6LUMO (24%) 
HOMO−3LUMO+1 (19%) 
4.21 (295) 0.341 LMCT/ LLCT 
19 HOMOLUMO+3 (67%) 5.24 (237) 0.192 LLCT 
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cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] 
256 
(13700) 
13 
HOMO−5LUMO+1 (64%) 
HOMO−4LUMO (20%) 
4.47 (277) 0.134 LMCT/ LLCT 
14 
HOMO−4LUMO+1 (39%) 
HOMO−5LUMO (33%) 
4.58 (271) 0.156 LMCT/LLCT 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(py)] (1) 
289 
(18800) 
17 
HOMO−6LUMO (48%) 
HOMO−3LUMO (29%) 
HOMO−3LUMO+2 (14%) 
3.97 (312) 0.119 LMCT/LLCT 
21 
HOMO−6LUMO (46%) 
HOMO−3LUMO (37%) 
4.23 (293) 0.261 LMCT/LLCT 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-nitropyridine)] (11) 
287 
(18200) 
29 HOMO−10LUMO (68%) 3.99 (311) 0.147 LLCT/ MLCT 
30 
HOMO−3LUMO+1 (59%) 
HOMO−5LUMO+1 (13%) 
4.08 (304) 0.311 LLCT/LMCT 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(quin)] (13) 
316 
(17800) and 
294 
(28300) 
20 
HOMO−5LUMO+2 (31%) 
HOMO−4LUMO+2 (17%) 
HOMO−4LUMO (15%) 
3.98 (311) 0.120 LMCT/LLCT 
233 
(42600) 
45 
HOMO−8LUMO+3 (17%) 
HOMO−11LUMO (14%) 
5.27 (235) 0.106 
LMCT/LLCT/ 
MLCT/d-d 
a 
Tr = transition number as obtained in the TD-DFT calculation. 
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3.2.2 Trans Influence 
To investigate the trans influence on photophysical properties in Pt(IV) 
complexes, ligands with strong a trans influence were placed trans to the N3
−
 
ligand, the major reducing/leaving ligand. TDDFT predicts intense bands at 295 
nm and 306 nm for Me2S and H

 ligands trans to azide in cis, trans, cis-
[Pt(N3)2(OH)2(NH3)S(CH3)2] (3) and cis, trans, cis-[PtH(N3)2(OAc)2(NH3)]

 (4), 
respectively, significantly longer wavelengths than in complex 2 (273 nm). 
Comparison of the main absorbance (λmax) for complexes 2, 3 and 4 shows that the 
0 
0.2 
0.4 
0.6 
0.8 
1 
230 280 330 380 430 480 
A
b
s
o
rb
a
n
c
e
 
Wavelength (nm) 
13 expt 
1 expt 
13 TDDFT 
1 TDDFT 
Figure 3-2. Comparison between calculated and experimental UV-Vis spectra for 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(pyridine)] (1) and trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(quinoline)] (13). The oscillator strength of complexes 1 and 
13 has been scaled by 2.5 and 1.8 times, respectively, for the convenience of 
comparison. 
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trans influence has a considerable effect on the electronic excitation energies in 
Pt(IV) compounds (see Figure 3-3 and 3-4 for the comparison with other Pt(IV) 
complexes). 
3.2.3 OR
−
 (R=H, Ac) and Halogen Ligands 
To explore the influence of OR
−
 and halogen ligands, the electronic transitions in 
complexes with OH
−
, OAc
−
, and I
−
 ligands were studied. TDDFT assigns an 
absorption maximum (λmax) at longer wavelength, 318 nm for trans, trans, trans-
[Pt(N3)2(OAc)2(NH3)(py)] (5) and 320 nm for trans, trans, trans-
[Pt(N3)2I2(NH3)(py)] (6), compared to complex 1 (293 nm). The excitation 
energies decrease in the order OH

 > OAc

 ~ I

. This result indicates that the 
energy required for a Pt(IV) complex with OH

 to populate an electronic state to 
the potential energy surface at an energy above the transition states of 
photoreduction to Pt(II) complexes is higher than the complex with OAc

 or I

. 
On the other hand, it was reported that the Standard Hydrogen Electrode adjusted 
reduction potentials for cis, trans, cis-[Pt(NH3)2(X)2(Cl)2] are in the order of: OH

 
> OAc

 > Cl

.
162,163
 It is interesting to note that the excitation energies follow the 
same trend with the energy difference between the products and reactants in 
reduction for Pt(IV) complexes with OR
−
 and halogen ligands. The replacement of 
the N3
−
 ligands in complex 5 by I
−
 ligands (complex 7 in Figure 3-3) result in the 
red shift of the intense band at 333 nm. Meanwhile, the "tail" of the absorbance 
extends from 506 nm in complex 1 to 744 nm in complex 6 and to 732 nm in 
complex 7. The trend of the influence on the simulated spectra of the studied 
complexes is displayed in Figure 3-4. 
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3.2.4 Substituents on Pyridine, Quinoline, and Intramolecular Hydrogen 
Bonding 
To elucidate the relationship between electronic effects on the pyridine ring and 
photophysical properties of Pt(IV) complexes, electron-withdrawing (via 
inductive or resonance effect), electron-donating and electron-delocalizing 
substituents on pyridine have been considered. OR
−
 and halogen ligands show a 
critical influence on electronic transitions. However, the relatively higher energies 
of the unoccupied frontier orbitals in Pt(IV) complexes with OAc
−
 or halogen 
ligands often lead to rapid reduction in cells. The lower excitation energies can be 
achieved by either increasing the energies of the occupied frontier orbitals or 
decreasing the energies of the unoccupied frontier orbitals, and thus, the design of 
photoactivated Pt drugs with greater absorption at longer wavelengths can be 
better achieved by the latter approach. This concept leads to the exploration of 
Pt(IV) complexes with an intramolecular hydrogen bond between 2-
hydroxypyridine/2-hydroxyquinoline and the hydroxyl group. In general, electron-
withdrawing functional groups on pyridine red shift not only the absorption 
maxima by 13 nm but also the lowest energy absorption by 38332 nm, while 
intramolecular hydrogen bonding involving the OH ligands and 2-
hydroxyquinoline red shifts the main absorption by 2432 nm and extends the 
lowest energy absorption toward the red region by 40100 nm.  
The calculated wavelengths of intense bands for complexes trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(2-cyanopyridine)] (8), trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(2,6-difluoropyridine)] (9), and trans, trans, trans-
[Pt(N3)2(OH)2(NH3)(2-nitropyridine)] (10) are 306 nm, 305 nm and 307 nm, 
respectively, which reveal that electron-withdrawing by induction and resonance 
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have a subtle influence on the electronic excitation energies of Pt(IV) compounds. 
Surprisingly, trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-methoxypyridine)] (12) 
shows a maximum at 308 nm, similar to complexes with electron-withdrawing 
groups on pyridine. Comparison of the predicted bands of complexes 8, 9, 10, and 
12 indicates that electron-withdrawing/donating substituents on pyridine slightly 
extend the main absorption to longer wavelength. In complex 13, the band centred 
at 311 nm suggests that stabilization of the unoccupied frontier orbitals by 
electron delocalization decreases the energies of electronic transitions to a similar 
extent as electron-withdrawing/donating groups. Moreover, the calculated intense 
bands of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-hydroxyquinoline)] (15) and of 
trans, trans, trans-[Pt(N3)2(OH)2(2-hydroxyquinoline)2] (16), 317 nm and 325 nm 
respectively, are red shifted compared to complexes 8, 9 , 10, 12 and 13 which 
shows that intramolecular hydrogen bonding involving OH ligands can have a 
marked effect. On the other hand, it is interesting to note that the low-energy low-
intensity spectroscopic absorption extends from the green region of the spectrum 
for complex 1 (506 nm) to the red region for complexes 16 (606 nm), 8 (625 nm), 
and 10 (858 nm), yet is blue shifted by 30 nm for complex 12. The trend of 
electronic transitions for the Pt(IV) complexes is showed in Figure 3-3 and 3-4. 
The results for trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-nitropyridine)] (11) will 
be analyzed and discussed later in Section 3.5.  
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Figure 3-3. Calculated wavelength of the intense band and lowest energy 
absorption for platinum complexes with various chemical modifications 
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Figure 3-4. Simulated absorption spectra of selected Pt(IV) complexes 1, 2, 3, 5, 
7, and 16. The oscillator strength has been scaled by 2.5 times for the convenience 
of comparing with experimental absorption of complex 1. 
 
3.3 Orbitals Analyses 
In addition to exploring the energies of electronic transitions upon different 
chemical modifications, it is highly desirable to understand qualitatively how the 
structural changes in Pt(IV) complexes relate to spectroscopic absorption. By 
identifying and examining the most important orbitals that control the electronic 
excitation this correlation and thus mechanisms of photoactivation can be 
elucidated. The results for electronic transitions of the intense band and electronic 
transitions of low-energy absorption are summarized in Table 3-2 and Table 3-3, 
respectively. The major orbital contributions to the main absorption are visualized 
in Figure 3-5. 
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3.3.1 Electronic Transitions of the Intense Band 
The key transitions are a mixture of ligand-to-metal charge transfer (LMCT), 
where electron density migrates from the OR
−
 and (pseudo)halogen ligands to the 
metal, and ligand-to-ligand charge transfer (LLCT), where electrons move 
between OR
−
 and (pseudo)halogen ligands. In comparison with complex 1 (293 
nm), the cis isomer, complex 2 (273 nm), has a lower nonbonding orbital of N3 
character resulting in the higher energies of the transitions. The trans influence 
tends to increase the probabilities of electronic transition from N3 trans to Me2S 
and slightly lower the energies of the unoccupied orbitals compared to complex 2.  
Figure 3-5. Prominent molecular orbital diagram of the main absorption for 
selected platinum complexes. Orbital energies are given in eV. Full symbols 
correspond to vacant orbitals; empty symbols correspond to occupied orbitals. 
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Table 3-2. Calculated absorption properties (intense band) of Pt(IV) complexes 
(continued on following pages). 
Tr
a
 Composition 
Energy/eV 
(nm) 
Oscillator 
Strength 
Assignment 
cis, trans, cis-[Pt(N3)2(OH)2(NH3)(pyridine)] (2) 
26 
HOMO−5LUMO+2 (47%) 
HOMO−4LUMO (18%) 
4.50 (276) 0.133 LMCT/LLCT 
27 
HOMO−4LUMO+2 (35%) 
HOMO−5LUMO (25%) 
HOMO−5LUMO+2 (10%) 
4.54(273) 0.205 LMCT/LLCT 
cis, trans, cis-[Pt(N3)2(OH)2(NH3)S(CH3)2] (3) 
12 
HOMO−4LUMO+1 (29%) 
HOMO−4LUMO (28%) 
HOMO−3LUMO+1 (11%) 
4.20 (295) 0.255 LMCT/LLCT 
13 
HOMO−5LUMO+1 (61%) 
HOMO−5LUMO (19%) 
4.48 (277) 0.114 LMCT/LLCT 
cis, trans, cis-[PtH(N3)2(OAc)2(NH3)]

 (4) 
13 HOMO−2LUMO+1 (72%) 4.05 (306) 0.103 LMCT/LLCT 
17 
HOMO−8LUMO (45%) 
HOMO−8LUMO+1 (17%) 
HOMO−5LUMO+1 (14%) 
HOMO−6LUMO+1 (13%) 
4.50 (276) 0.113 LMCT/LLCT 
trans, trans, trans-[Pt(N3)2(OAc)2(NH3)(pyridine)] (5) 
24 
HOMO−4LUMO (31%) 
HOMO−4LUMO+1 (28%) 
HOMO−5LUMO+2 (13%) 
3.89 (318) 0.243 LMCT/LLCT 
 
HOMO−7LUMO (22%) 
HOMO−7LUMO+1 (17%) 
4.27 (291) 0.148 LMCT/LLCT 
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HOMO−8LUMO+1 (17%) 
trans, trans, trans-[Pt(N3)2I2(NH3)(pyridine)] (6) 
31 
HOMO−6LUMO+1 (33%) 
HOMO−7LUMO (21%) 
HOMO−10LUMO (18%) 
3.87 (320) 0.221 
LMCT/LLCT/ 
MLCT/d-d 
32 
HOMO−6LUMO+1 (27%) 
HOMO−7LUMO+1 (19%) 
HOMO−10LUMO (16%) 
3.93 (315) 0.292 
LMCT/LLCT/ 
MLCT/d-d 
35 
HOMO−10LUMO (48%) 
HOMO7LUMO (11%) 
4.24 (293) 0.199 
LMCT/LLCT/ 
MLCT/d-d 
 trans-trans-trans[Pt(I)2(OAc)2(NH3)(pyridine)] (7) 
25 
HOMO−4LUMO (31%) 
HOMO−9LUMO (27%) 
HOMO−10LUMO (22%) 
3.73 (333) 0.197 
LMCT/LLCT 
 
34 
HOMO−10LUMO (43%) 
HOMO−4LUMO (21%) 
HOMO−11LUMO (13%) 
4.28 (290) 0.349 
LMCT/LLCT/ 
MLCT/d-d 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-cyanopyridine)] (8) 
22 
HOMO−3LUMO+1 (69%) 
HOMO−3LUMO+3 (12%) 
4.05 (306) 
 
0.333 LMCT/LLCT 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2,6-difluoropyridine)] (9) 
23 
HOMO−3LUMO (43%) 
HOMO−3LUMO+2 (33%) 
HOMO−6LUMO       
(15%) 
4.07 (305) 
 
0.344 
LMCT/LLCT 
 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-nitropyridine)] (10) 
28 
HOMO−3LUMO+1 (37%) 
HOMO−5LUMO+2 (23%) 
4.03 (307) 0.229 
LMCT/LLCT/ 
MLCT 
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trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-methoxypyridine)] (12) 
17 
HOMO−3LUMO (46%) 
HOMO−7LUMO (34%) 
4.03 (308) 0.184 LMCT/LLCT 
20 
HOMO−3LUMO+3 (64%) 
HOMO−3LUMO (19%) 
HOMO−7LUMO (12%) 
4.26 (291) 0.123 LMCT/LLCT 
42 
HOMO−5LUMO+2 (51%) 
HOMO−9LUMO+1 (21%) 
5.39 (230) 0.168 
LMCT/LLCT 
MLCT/d-d 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-hydroxypyridine)] (14) 
13 
HOMO−3LUMO (41%) 
HOMO−4LUMO (13%) 
4.00 (310) 0.253 
LMCT/LLCT 
MLCT/d-d 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-hydroxyquinoline)] (15) 
17 
HOMO−4LUMO (43%) 
HOMO−5LUMO (25%) 
HOMO−6LUMO+1 (15%) 
3.91 (317) 0.259 
LMCT/LLCT 
MLCT/d-d 
38 
HOMO−5LUMO+3 (18%) 
HOMO−1LUMO+3 (15%) 
5.06 (245) 0.138 LLCT 
 trans, trans, trans-[Pt(N3)2(OH)2(2-hydroxyquinoline)2] (16) 
29 
HOMO−7LUMO+1 (35%) 
HOMO−4LUMO+1 (21%) 
3.81 (325) 0.159 
LMCT/LLCT/ 
MLCT/d-d 
a 
Tr = transition number as obtained in the TD-DFT calculation. 
The profile of electronic transitions in Figure 5 reveals that electrons in cis 
isomers tend to move from orbitals of the (pseudo)halogen ligands to the d 
orbitals of the metal, whereas those in all trans isomers are more likely to transfer 
from both OR and (pseudo)halogen ligands to the d orbitals of the metal and thus 
lead to different photoproducts. The NMR spectra for the photolysis of trans, 
 98 
 
trans, trans-[Pt(N3)2(OH)2(NH3)2] and cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] 
reported previously correlate with the calculations.
33,34,159
 It will be necessary to 
study a series of cis-trans isomers and the makeup of the important molecular 
orbitals in future work for a complete understanding of the mechanisms that give 
rise to different photopathways and photoproducts. 
OAc

 and I

 ligands in Pt(IV) complexes significantly lower the energies of the 
LUMO and LUMO+1 and lead to a red shift with the main absorption around 320 
nm in complexes 5 and 6. The fairly long wavelength of complex 7 (333 nm) is 
mainly due to the higher occupied orbital of I

 as leaving ligands yet the energies 
of unoccupied orbitals are similar to those in complexes 5 and 6. Otherwise, 
quinoline and electron-withdrawing substituents on pyridine tend to lower the 
energies of the unoccupied orbitals of complexes 12, 8, 9, and 10 to a similar level 
and result in lower energy absorption from 305 to 311 nm, whereas the electron-
donating methoxy substituent on aromatic amines reduces the energies of 
transitions, with a absorption maximum at 308 nm, by increasing the contribution 
from the frontier orbitals closer to the HOMO and LUMO. 
3.3.2 Electronic Transitions of Low-energy Absorption 
The TDDFT results in Table 3-3 show that the "tail" of the absorbance extends 
from the green region for complex 1 (506 nm) to the red region for complexes 8 
(625 nm) and 10 (858 nm) which indicates that electron-withdrawal by resonance 
effect has a larger influence on reducing the energy of the LUMO in Pt complexes 
compared to electron-withdrawal by the inductive effect and electron-donating 
substituents on py (544 nm for complex 9, 476 nm in complex 12).  
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Selected frontier orbitals for complex 10 generated by Molekel v. 5.3
166
 are 
presented in Figure 3-5. The main contributions for low-energy absorption are 
from the nonbonding orbitals for azide ligands (HOMO−2 and HOMO) to the 
LUMO, which comprises antibonding orbitals on the pyridine nitro group. Some 
familiar trends are observed in complexes 8 and 16, which feature unusually low 
energy absorption. Electron-withdrawing groups tend to increase the likelihood of 
ligand-to-ligand charge transfer (LLCT), where electrons move from leaving 
groups to py/quin, leading to a different mechanism of photoreaction. Likewise, 
the calculated low-energy absorption for complexes 6 and 7 with iodide ligands 
are 744 nm and 732 nm, respectively. The results are consistent with the UV-Vis 
spectra of iodide-containing complexes obtained in previous studies.
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Comparison of the energies of the frontier orbitals in complex 1 reveals that the 
energy of the LUMO in complex 6 is lowered whereas the energy of the HOMO 
in complex 7 is raised resulting in a smaller gap between HOMO and LUMO, and 
thus longer wavelength absorption can be achieved. 
Table 3-3. Calculated low-energy absorption properties of Pt(IV) complexes. 
Tr
a
 Composition 
Energy, 
eV (nm) 
Oscillator 
Strength 
Assignment 
(1) trans, trans, trans-[Pt(N3)2(OH)2(NH3)(pyridine)] 
1 HOMOLUMO (100%) 2.45 (506) 0.0 LMCT 
5 
HOMO−2LUMO (71%) 
HOMO−1LUMO+1 (28%) 
2.93 (423) 0.007 LMCT/LLCT/ 
MLCT/d-d 
(2) cis, trans, cis-[Pt(N3)2(OH)2(NH3)(pyridine)] 
1 HOMOLUMO (96%) 2.52 (492) 0.0 LMCT 
2 HOMOLUMO+1 (96%) 2.64 (469) 0.007 LLCT 
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(3) cis, trans, cis-[Pt(N3)2(OH)2(NH3)(S(CH3)2] 
1 HOMOLUMO (100%) 2.37 (523) 0.0 LMCT/LLCT 
2 HOMO−1LUMO (50%) 
HOMO−2LUMO (48%) 
2.65 (468) 0.003 
 
LMCT/LLCT 
(5) trans, trans, trans-[Pt(N3)2(OAc)2(NH3)(pyridine)] 
1 HOMOLUMO (96%) 2.17 (572) 0.001 LMCT 
7 HOMO−2LUMO+1 (39%) 
HOMO−1LUMO+1 (28%) 
HOMO−1LUMO (18%) 
2.79 (445) 0.052 LMCT 
(6) trans, trans, trans-[Pt(N3)2I2(NH3)(pyridine)] 
1 HOMOLUMO (98%) 1.67 (744) 0.0 LMCT/LLCT 
7 HOMO−5LUMO (54%) 
HOMO−1LUMO+1 (37%) 
2.20 (564) 0.007 LMCT/LLCT 
(7) trans-trans-trans[Pt(I)2(OAc)2(NH3)(pyridine)] 
1 HOMOLUMO (99%) 1.69 (732) 0.0 LMCT/LLCT 
8 HOMO−1LUMO+2 (99%) 2.46 (504) 0.002 LLCT 
 (8) trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-cyanopyridine)] 
1 HOMOLUMO (100%) 1.98 (625) 0.0 LLCT 
4 HOMO−2LUMO (98%) 2.46 (504) 0.003 LLCT 
(9) trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2,6-difluoropyridine)] 
1 HOMOLUMO (99%) 2.28 (544) 0.001 LMCT 
4 HOMO−1LUMO+1 (98%) 2.45 (506) 0.005 MLCT/LLCT 
(10) trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-nitropyridine)] 
1 HOMOLUMO (99%) 1.45 (858) 0.002 LLCT 
3 HOMO−2LUMO (96%) 1.94 (639) 0.014 LLCT 
 (12) trans, trans, trans-[Pt(N3)2(OH)2(NH3)(quinoline)] 
1 HOMOLUMO (97%) 2.37 (524) 
 
0.0 LMCT 
6 HOMO−2LUMO+1 (84%) 2.90 (428) 0.015 
 
LLCT 
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(14) trans, trans, trans-[Pt(N3)2(OH)2(NH3)(2-hydroxyquinoline)] 
1 HOMOLUMO (88%) 2.27 (546) 
 
0.0 LMCT/LLCT 
7 HOMO−2LUMO+1 (98%) 2.88 (431) 0.001 LMCT/LLCT 
(15) trans, trans, trans-[Pt(N3)2(OH)2(2-hydroxyquinoline)2] 
1 HOMOLUMO (98%) 2.05 (606) 0.002 LMCT/LLCT 
2 HOMO−1LUMO (93%) 2.19 (565) 0.007 LMCT/LLCT 
a 
Tr = transition number as obtained in the TD-DFT calculation. 
3.4 Structures and Bonding Characteristics 
The structural features and Pt-L bond lengths of the computed Pt(IV) complexes 
are listed in Figure A1-1 (Appendix 1) and the results of Pt-Npy bond analysis are 
shown in Table 3-4 (see Section 3.4.2). The relationship between the 
structures/bonding characteristics and photophysical properties provides insight 
into the pathway of photoreaction and may help the design of more efficient 
photoactive anticancer compounds.  
3.4.1 Relationship between Calculated Structures and Wavelength of 
Simulated Intense Absorption Band 
Due to the various Pt-binding atoms and the cis/trans geometries, the structures of 
our model Pt(IV) complexes needs to be compared with care (see Figure A1-1, 
Appendix 1). Nevertheless, in comparing the structural features by groups of the 
various chemical modifications or by complexes with the same types of atoms 
coordinated to Pt, the correlation between structures and the absorption maxima, 
λmax can be revealed. Firstly, for cis/trans isomers, the λmax of complex 1 (293 nm) 
is longer than that of complex 2 (273 nm). The average Pt−N3 bond distances of 
2.09 Å  in complex 1 longer (caused by stronger trans influence of N3
−
 ligands 
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compared to NH3 and py) than the corresponding values for complex 2 (2.05 Å ) 
are computed, yet the average Pt−O bond lengths in the two isomers are about 
2.05 Å . Secondly, the same trend 4 (306 nm; 2.15 Å ) > 3 (295 nm; 2.07 Å ) > 2 
(273 nm; 2.05 Å ) is observed for λmax and the average Pt−N3 bond distances, yet 
the average Pt−O bond lengths are about 2.07 Å , 2.05 Å , 2.05 Å , respectively. 
Ligands with a stronger trans influence elongate the Pt−L bond for the ligands in 
the trans position, which accounts for the longer Pt-N3 bond lengths of S−Pt−N3 
in complex 3 (2.08 Å ) and of H−Pt−N3 in complex 4 (2.25 Å ) compared to that of 
py-Pt-N3 in complex 2 (2.05 Å ). On the other hand, ligands with a strong trans 
influence tend to decrease the energy gap between the occupied and unoccupied 
frontier orbitals in the platinum complexes, leading to a slightly red-shifted 
intense band in the absorption spectrum (Figure 3-5). In addition, the comparison 
of the average Pt−Npy/quin, Pt−N3, and Pt−O bond lengths as well as λmax values in 
complex 16 (~2.14, 2.10 and 2.05 Å ; 325 nm), complex 5 (~2.08, 2.10, and 2.09 Å ; 
318 nm), and complex 1 (~2.07, 2.09, and 2.05 Å ; 293 nm) shows that the Pt−L 
bond distances tend to be longer for complexes with absorption maxima at longer 
wavelength. The relatively shorter Pt−O bond lengths in complex 16 may result 
from the weaker trans influence of OH
−
 ligands involving intramolecular H-bonds. 
It is also worth noting that the λmax values of complexes 814 are between 
304~311 nm and, interestingly, the similar average Pt−N (~2.052.07 Å ), Pt−N3 
(~2.092.10), and Pt−O (~2.05 Å ) in complexes 814 are predicted. In general, 
the comparison of the optimised geometries shows that Pt(IV) complexes with 
longer Pt−L bonds lengths (particularly for the leaving groups) are more likely to 
undergo photoreduction with longer-wavelength light. 
3.4.2 Energy Decomposition of the Ptpy/quin Bond 
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To explore the effect of geometry, OR

 and (pseudo)halogen ligands, and various 
pyridine substituents on the photochemistry of Pt(IV) complexes and on the nature 
of the Pt-N bond, the Pt-Npy and Pt-Nquin bond energy can be decomposed into 
contributions from the strain energy, Estr , and the interaction energy, Eint ; i.e., 
E = Estr + Eint. The former is the energy required to deform the equilibrium 
structures of the metal fragment and py/quin toward their respective geometries in 
the Pt(IV) complexes. Eint is the interaction energy between the in-complex 
metal and py/quin fragments. It can be further partitioned into three components: 
(1) the Pauli repulsion between the (non-overlapping) charge clouds of the 
py/quin and metal fragments at their in-complex positions, EPauli, (2) the 
electrostatic interaction between the two fragments, Eelec, and (3) the stabilising 
orbital interactions accompanying relaxation of the electron density, Eorb. Thus, 
Eint = EPauli + Eelec + Eorb. As illustrated in Table 3-4, relative to complex 1 
the largest total interaction energies are observed for complex 14, with an 
intramolecular H-bond (45.4 kcal/mol) and complex 12, with an electron-
donating substituent (40.3 kcal/mol). Electrostatics provides a 30-60 kcal/mol 
larger stabilizing contribution to the Pt-Npy and Pt-Nquin bond than do orbital 
interactions. The ratio of the orbital to the electrostatic contributions, Eorb/Eelec , 
indicates the relative covalent vs ionic character of the Pt-Npy and Pt-Nquin bond. 
For Pt(IV) complexes with no intramolecular H-bond, the covalent/ionic ratio, Rci, 
is between 0.56 and 0.63. The Pt-Npy and Pt-Nquin bond for complexes with an 
intramolecular H-bond between OH on the py/quin ring and an OH
−
 ligand 
exhibits more covalent bond character (Rci = 0.750.80). The strain energy is 6.8 
kcal/mol smaller for complex 2 (10.0 kcal/mol) with a cis geometry, yet it is 
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1020 kcal/mol larger for complex 5 (31.0 kcal/mol) with acetate and complexes 
14 (27.6 kcal/mol) and 15 (36.5 kcal/mol) with intramolecular H-bonding 
compared to complex 1 (16.8 kcal/mol). In terms of bonding stability, these 
results may make useful suggestions for the synthesis of Pt(IV) complexes. 
Table 3-4. Energy decomposition of the Pt-Npy
b
 and Pt-Nquin
c
 bond in selected 
Pt(IV) complexes. 
 1 2 5 8 9 12 13 14 15 
          
ΔEstr(py) 0.7 1.0 0.4 1.6 1.4 1.2 0.8 9.7 12.0 
ΔEstr(pt) 16.1 9.0 30.5 20.6 21.3 16.5 20.7 18.0 24.5 
ΔEstr 16.8 10.0 31.0 22.2 22.7 17.7 21.5 27.6 36.5 
ΔEPauli 167.6 157.0 159.5 162.2 133.9 178.82 166.3 223.8 215.6 
ΔEelst -137.4 -127.6 -131.4 -130.2 -101.4 -148.7 -134.8 -170.1 -158.9 
ΔEorb -84.0 -71.9 -82.0 -79.8 -63.6 -88.1 -83.8 -126.8 -127.4 
ΔEint -53.7 -42.5 -53.9 -47.7 -31.1 -58.0 -52.3 -73.0 -70.7 
ΔEsum -36.9 -32.5 -23.0 -25.5 -8.4 -40.3 -30.8 -45.4 -34.2 
ΔEorb/ΔEelst 0.61 0.56 0.62 0.61 0.63 0.59 0.62 0.75 0.80 
a 
Energies in kcal/mol. 
b
py = pyridine. 
c
quin = quinoline 
 
3.5 Photophysics of trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-
nitropyridine)] (11) 
Tissue-penetration of light is wavelength-dependent. Complexes activated with 
light of longer wavelength (600800 nm)160,167 allow treatment of larger tumours 
in photochemotherapy. In the calculated UV-Vis spectrum of trans,trans,trans-
[Pt(N3)2(OH)2(NH3)(4-nitropyridine)] (11), there is a low-energy low intensity 
absorption band around 664 nm (Figure 3-7) induced by the electron-withdrawing 
nitro group, which mainly corresponds to a ligand(azide)-to-ligand(4-nitropyridine) 
charge-transfer transition. Complex 11 was thus synthesised by Yao Zhao in order 
to compare its UV-Vis spectrum with the computed results and investigate the 
photoreaction pathway promoted by the electron-withdrawing substituent. 
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3.5.1 Experimental Study 
200 300 400 500
0.0
0.5
1.0
A
b
s
o
rb
a
n
c
e
Wavelength  / nm  
350 400 450 500 550
0
200
400
600
0
10
20
30
40
50
 
E
x
ti
n
c
ti
o
n
 c
o
e
ff
ic
ie
n
t 
 
/M
-1
 c
m
-1
Wavelength / nm
 
 
P
s
e
u
d
o
 q
u
a
n
tu
m
 y
ie
ld
 
/1
0
-4
 
Figure 3-6. (a) UV-Vis spectra recorded for 11 in H2O upon irradiation of 365 nm 
(light dose 0, 0.7, 2.1, 4.2 J/cm
2
). (b) Pseudo quantum yield ϕ (red, circles) of 
action spectrum (wavelength-dependent photodecomposition) for 11, in 
comparison with extinction coefficient ε (blue, squares). The data points are the 
average of two experiments. Data supplied by Yao Zhao. 
Complex 11 trans,trans,trans-[Pt(N3)2(OH)2(NH3)(4-nitropyridine)] was 
synthesised and characterised by 
1
H, 
13
C, 
195
Pt NMR and ESI-MS. In order to 
compare with the calculated spectrum, the UV-Vis spectrum for complex 11 in 
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aqueous solution was recorded, Figure 3-6a. In the experimental spectrum, there is 
an absorbance maximum at 287 nm, which is assigned to be a ligand(azide)-to-
metal charge-transfer (LMCT) transition. The absorption intensity at >400 nm is 
very small and no absorption was observed above 540 nm. When the sample was 
irradiated with a specific wavelength of light (e.g., 365 nm), the major absorption 
band decreased, indicating the loss of azide groups (Figure 3-6a). For the purpose 
of investigating the relationship between the wavelength of irradiation and 
photodecomposition of 11 in aqueous solution as monitored by UV-Vis 
spectroscopy, an “action spectrum” was measured36,168 (Figure 3-6b). The action 
spectrum recorded the rate of photodecomposition of the molecule upon the 
exposure to light of wavelength 365 to 540 nm. The pseudo quantum yield ( ) 
(ratio of the number of photo reactions to the number of incident photons) was 
determined (Figure 3-6b). The photolysis of complex 11 (pseudo quantum yield ) 
upon irradiation from 365 nm to 520 nm correlated closely with the UV-Vis 
spectrum (extinction coefficient). Over 540 nm, the photolysis was too small to 
detect with our experimental conditions. The irradiation with light of 600 nm, 633 
nm, 660 nm and 700 nm was also carried out individually, but no 
photodecomposition was observed (data not shown). These experiments were 
carried out by Yao Zhao. 


 107 
 
3.5.2 Computed Spectra and Comparison with Experiment 
A comparison of calculated and experimental spectra of complex 11 is shown in 
Table 3-1, Table 3-3, and Figure 3-7. Both spectra show absorption maxima in the 
UV region, which can be assigned to mixed LLCT/LMCT/MLCT (N3, OH→N3, 
Pt and py, Pt→4-nitropyridine) and LLCT/MLCT (py, Pt→4-nitropyridine) 
transitions by TDDFT. In the investigation of low-energy absorption, TDDFT 
predicts two small peaks at 430 nm (LLCT/MLCT; N3, Pt, OH→4-nitropyridine) 
and 664 nm (LLCT; N3→4-nitropyridine), whereas UV-Vis spectrum shows no 
absorption beyond 540 nm.  
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Figure 3-7. Comparison between calculated excited-state transitions and UV 
absorption for trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-nitropyridine)] (11). The 
oscillator strength has been scaled by 1.84 times for the convenience of comparing 
with experimental absorption. Representive frontier orbitals are shown on the 
right. Insert: magnification of the spectra from 300-800 nm. Experimental data 
supplied by Yao Zhao. 
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The spectrum of complex 11 was therefore recomputed by TDDFT with the 
Conductor like Screening Model (COSMO)
169
 of solvation, and the overlay with 
the experimental spectrum shows an improvement in terms of intense bands and 
low-energy absorption. In particular, the two small peaks at 430nm and 664 nm 
for the low-energy absorption were flattened and two blue-shifted peaks at 376 nm 
and 531 nm are predicted instead. This increase in energy is mainly due to the 
stabilization of the occupied frontier orbitals and destabilization of LUMO by 
solvent effects and the resulting larger energy gap between HOMO−3/HOMO−7 
and LUMO (Figure 3-7). This result matches closely the experimental UV-Vis 
and action spectrum. It is worth to note that the minimum absorption wavelength 
of complex 11 is ca. 20 nm longer in the action spectrum than that of 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (< 520 nm) in the previous study.
36
 This 
demonstrates that the electron-withdrawing group by resonance effect can extend 
the absorption to longer wavelength. The photophysical behavior has been shown 
experimentally to depend on solvent polarity.
170
 The measurement of the low-
energy low-intensity absorption in less polar solvents or in gas phase may be 
extended to longer wavelength in closer agreement with the gas phase prediction 
of TDDFT. 
 
ground state 
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Figure 3-8. The computed geometries of the ground state and the lowest-lying 
triplet state for trans, trans, trans-[Pt(N3)2(OH)2(NH3)(4-nitropyridine)] (11). 
 
In addition, the lowest-lying triplet states of transition metal complexes have been 
shown experimentally to make prominent contributions to the photodissociation 
process.
171
 The geometry of the lowest-lying triplet state of complex 11 was thus 
optimised and is displayed in Figure 3-8. Relative to the singlet ground state, the 
two Pt−N3 bond lengths are significantly elongated from 2.098 Å  and 2.097 Å  to 
2.387 Å  and 2.343 Å  in the triplet state (Figure 3-8). Mulliken population 
analysis
172
 shows that the two nitrogen atoms of azide coordinated to Pt have spin 
density of 0.23 and 0.28 e. The results of the calculation correlate with the release 
of azido ligands as N3• radicals observed experimentally.
159
 
3.6 Conclusions 
In this work, the photochemistry of Pt(IV) complexes has been investigated in 
terms of the coordination environment in relation to electronic excitation energies 
by DFT and TDDFT. The main findings and the biological relevance of this work 
lowest-lying triplet state 
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are as follows: (1) Calculated excitation energies for the intense band according to 
TDDFT with the SAOP functional are in good agreement with experimental 
observations; the theory has been shown to be a useful tool to portray 
spectroscopic absorption, to further assist the design of Pt(IV) complexes to 
achieve photoactivation at longer wavelength, and to study the mechanisms of 
photoreaction (vide infra). (2) Electronic transitions for cis-{Pt(IV)(N3)2} isomers 
tend to arise from the orbitals of the (pseudo)halogen ligands to the d orbitals of 
metal, whereas those for all trans isomers are more likely to arise from both OR 
and (pseudo)halogen ligands to the d orbitals of the metal and thus lead to 
different photoproducts. (3) Electron-withdrawing/donating substituents on 
pyridine tend to slightly red shift the wavelength of the main absorption compared 
to the unsubstituted (e.g. complex 1) by up to 15 nm. However, electron-donating 
substituents on pyridine reduce the energies of transitions by increasing the 
contribution from frontier orbitals closer to the HOMO and LUMO while 
quinoline and electron-withdrawing substituents on pyridine achieve absorption at 
longer wavelength by lowering the energies of the unoccupied orbitals. (4) The 
design of photoactivated Pt drugs with slower reduction rates and greater 
absorption at longer wavelengths can be better achieved via lowering the energies 
of the unoccupied frontier orbital of Pt complexes. Intramolecular hydrogen 
bonding involving the OH ligand and 2-hydroxyquinoline red shifts the main 
absorption by 2432 nm and extends the lowest energy absorption toward the red 
region by 40100 nm. Moreover, mesomeric electron-withdrawing groups (CN 
and NO2

) on pyridine also show low-energy absorption with significant intensity 
in the visible region. (5) The Pt(IV) complexes with longer calculated Pt−L bond 
lengths tend to absorb light of longer wavelengths. (6) A comparison of the 
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computed and experimental UV-Vis spectra of complex 11 shows that the 
prediction of low-energy absorption in solution can be improved by using a 
solvent model, whereas the absorption maximum is little affected. The absorption 
of the complexes in clinical treatment may lie between the results of the TDDFT 
with and without a solvent model depending on the solvent-accessibility in the 
tissues. (7) The structural and spin density analysis of the lowest-lying triplet state 
for complex 11 suggests the release of azido ligands as N3• radicals is possible, 
which is consistent with the experimental data. 
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Chapter 4 
Ligand Field Molecular Mechanics 
Modelling of Platinum–DNA 
Interactions 
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4.1 Introduction 
Computational approaches can provide insights that are not fully accessible 
experimentally. However, quantum mechanics (QM) is too expensive for large 
systems like proteins and DNA which contain significant numbers of atoms. 
Hence, classical techniques such as molecular mechanics (MM) and molecular 
dynamics (MD) are usually used for macro-biomolecules.
70,113
 MD simulations 
can generate a trajectory that provides atomic details of the time evolution of the 
system. MD is based on a simple function of nuclear positions via empirical force 
fields and has a successful record in the study of proteins and nucleic acids. 
However, MD simulations of metal-containing systems present significant 
challenges since molecular mechanics ignores electronic motions, yet d electrons 
can have a potent effect on the structure and properties of coordination complexes. 
In response, QM/MM is being increasingly used for biomolecules with metal 
centers, although the computational cost of the QM part remains a major 
bottleneck. Alternatively, the flexibility and precision of quantum mechanics at 
the speed of molecular mechanics can be achieved by ligand field molecular 
mechanics (LFMM) which has been applied to the modeling of electronically 
‘difficult’ metal ions such as d9 Cu(II) and both spin states of d8 Ni(II) centres for 
which conventional MM does not provide a general approach.
72,98,100
  
Conventional force fields have been applied to Pt-guanine binding using torsional 
constraints or out-of-plane deformation terms to ensure the Pt atom remains 
within the plane of the coordinated purine. However, ab initio calculations
71,173
 
suggest the platinum out-of-plane bending force constant is overestimated. Here, I 
first develop new LFMM parameters for guanine bound to platinum via N7, 
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which, in combination with previous work on modeling of the trans influence in 
Pt(II) complexes,
173
 reproduces experimental bond lengths and bond angles of 
small platinum complexes.  
4.2 Results of Pt-guanine LFMM Parameterisation 
 
To determine the angular coordination of L–Pt–L interactions and model 
intermolecular interactions, partial charges for coordinated guanines are required. 
These were derived by adding the change in CHelpG partial atomic charges 
between isolated and Pt-coordinated guanine to the standard MMFF94
106-110
 or 
AMBER94
91
 FF partial charges for uncoordinated guanines (computational details 
in Section 2.5.2). Figure 4-1 displays the complex, cis-[Pt(NH3)2(Cl)(dGuo)]
+
, 
Figure 4-1. Model compound, cis-[Pt(NH3)2(Cl)(dGuo)]
+
, used to derive the new 
charge scheme for Pt-binding guanines. 
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 Figure 4-2. New LFMM/MMFF94 and LFMM/AMBER94 charge schemes for 
N7-platinated deoxyguanosine (dGuo(Pt)
+
), derived from CHelpG charges of the 
model compound, cis-[Pt(NH3)2(Cl)(dGuo)]
+
, in Figure 4-1. 
 
used for developing the new LFMM/MMFF94 and LFMM/AMBER94 charge 
scheme (see Figure 4-2 and Table A2-1 in Appendix 2). There charges were 
employed for coordinated guanines in this work. The charge on Pt, qPt, can be 
computed from the total charge transferred by all the ligands to Pt(II) , ΔQ: 
qPt = 2 – ΔQ                                                                                                        (4-1) 
Having fixed the partial charge scheme, LFMM requires Morse function 
parameters for Pt–L bond stretching (r0, α, D0), and ligand–ligand repulsion 
parameters (ALL) for L–Pt–L angle bending. The Cambridge Structure Database
174
 
(CSD) was searched for X-ray structures of complexes that could be used to 
optimize new Pt-guanine parameters. Fifteen complexes were selected and, in 
conjunction with the existing LFMM parameters for Pt-NH3 and Pt-Cl,
173
 Pt-
guanine parameters were optimized to reproduce experimentally observed 
structures with a target deviation in all Pt–L bond lengths of less than 0.05 Å  and 
G–Pt–G bond angles of less than 3° (Table 4-1). The Morse function is of the 
following form: 
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                                                                                (4-2) 
where r0= 2.241 Å , α= 1.728 Å
−1
, D0= 60 kcal/mol were obtained in the 
parameterization. The LFMM parameters for platinum complexes are available in 
Table A2-2 in Appendix 2. Apart from cis-diammine-bis(9-ethylguanine)-
platinum(II) (DEGXA0) where LFMM places one of the ammine ligands 0.075 Å  
further from the metal than observed experimentally, the only apparent major 
discrepancy is with diammine-(deoxy-guanylyl-guanylyl-N
7
,N
7'
)-platinum(II) 
(DETLIX). Two of the five CSD entries are included in Table 4-1, DETLIX01
175
 
and DETLIX20
176
, which shows fairly large variations of what should be the same 
bonds. This leads to the conclusion that the differences between LFMM and 
experiment are largely attributable to the quality of the experimental data. Several 
disorder issues are reported in the other structures. Further justification for our 
assertion comes by comparing LFMM results with previously reported QM/MM 
data.
74
 The LFMM Pt–L bond lengths and G–Pt–G bond angles for square-planar 
platinum complexes and DNA fragments accurately reproduce QM/MM (Table 
A2-3, Appendix 2), while overlays of selected molecules confirm that the 
agreement extends to entire systems (see Table 4-1). The largest absolute 
difference between LFMM and QM/MM Pt-L contacts is 0.03 Å  with the average 
error ~0.02 Å . In addition to structural features, LFMM parameters have been 
used for a vibrational analysis of cis-[Pt(NH3)2(Cl)(dGuo)]
+
 (Figure 1) which was 
compared to the BP86/TZ2P results. The computed values of the low energy 
LFMM frequencies are comparable with the respective quantum mechanical 
values (Table A2-4, Appendix 2). While the detailed atomic motions vary 
somewhat, the similarity of the energies suggests that the LFMM and DFT force 
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constants are comparable and that the subsequent LFMD trajectories should be 
realistic. 
This initial parameter development employed the MMFF94 force field since it has 
a richer set of ligand types. However, for DNA simulations, I wish to use the 
AMBER force field. Fortunately, transferring LFMM parameters from MMFF94 
to AMBER is straightforward, as shown previously and involves only some minor 
adjustments of the partial charges and renaming of the atom types.
77
  
Table 4-1. LFMM-Optimized (color by element; Pt in magenta) and Experimental 
(cyan) Pt–L Bond Lengths (in Å ) for Pt2+ Complexes containing Guanine 
.Structure (CCDC ref no)  LFMM  Experiment Δ(LFMM − EXP) 
JAQCUZ 
 
 
N1 
N9 
Cl1 
Cl2 
2.022 
1.985 
2.304 
2.304 
2.025 
2.007 
2.306 
2.291 
-0.003 
-0.022 
-0.002 
0.013 
SEWDUV 
 
 
N4 
N9 
Cl1 
Cl2 
2.021 
2.021 
2.317 
2.317 
2.026 
2.005 
2.292 
2.269 
-0.005 
0.016 
0.025 
0.048 
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HEKJAI 
 
 
N3 
N1 
N2 
Cl1 
2.037 
2.028 
2.024 
2.272 
2.001 
2.037 
2.050 
2.294 
0.036 
-0.009 
-0.026 
-0.022 
TUWTAG 
 
 
N5 
N5A 
N1 
N1A 
2.011 
2.011 
2.037 
2.037 
1.993 
1.993 
2.035 
2.035 
0.018 
0.018 
0.002 
0.002 
TUWTEK 
 
 
N18 
N23 
N3 
N4 
2.014 
2.014 
2.038 
2.038 
2.041 
1.989 
2.052 
2.030 
-0.027 
0.025 
-0.014 
0.008 
ZODGII 
 
 
N12 
N13 
N1 
N2 
2.001 
2.001 
2.042 
2.042 
2.011 
1.985 
2.059 
2.034 
-0.010 
0.016 
-0.017 
0.008 
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JUJFID 
 
 
N6 
N6E 
N1 
N1E 
2.011 
2.011 
2.037 
2.037 
2.019 
2.020 
2.033 
2.032 
-0.008 
-0.009 
0.004 
0.005 
CUHJOE 
 
 
N6 
N10 
N1 
N3 
2.003 
2.013 
2.039 
2.044 
2.017 
2.025 
2.035 
2.052 
-0.014 
-0.012 
0.004 
-0.008 
DEGXA0 
 
 
N6 
N11 
N1 
N2 
2.013 
2.003 
2.044 
2.039 
1.963 
2.010 
1.969 
2.046 
0.050 
-0.007 
0.075 
-0.007 
CUHJIY 
 
 
N7 
N9 
N4 
N8 
2.013 
2.003 
2.039 
2.044 
2.023 
2.029 
2.046 
2.040 
-0.010 
-0.026 
-0.007 
0.004 
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GUOAPT20 
 
 
N6 
N11 
N1 
N2 
2.011 
2.009 
2.045 
2.046 
1.993 
2.018 
2.088 
2.070 
0.018 
-0.009 
-0.043 
-0.024 
DETLIX01 
 
 
N37 
N42 
N47  
N48 
2.008 
1.996 
2.031 
2.037 
1.936 
2.090 
2.086 
2.035 
0.072 
-0.094 
-0.055 
0.002 
DETLIX20 
 
 
N28 
N33 
N25 
N26 
1.992 
2.030 
2.070 
2.043 
2.020 
2.054 
2.008 
2.061 
-0.028 
-0.024 
0.062 
-0.018 
LOSYOH 
 
 
N21 
N26 
N31 
N17 
1.994 
2.007 
2.012 
2.034 
2.030 
2.011 
2.004 
2.045 
-0.036 
-0.004 
0.008 
-0.011 
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KARYEI 
 
 
N5 
N10 
N1 
N12 
 
 
2.010 
2.004 
2.049 
2.030 
2.008 
2.017 
2.041 
2.020 
 
0.002 
-0.013 
0.008 
0.010 
 Rmsd 
(Å ) 
  0.028 
 
4.3 Discussion 
In this work, novel LFMM parameters for DNA simulations of Pt(II) bound to the 
N7 position of guanines have been developed. The LFMM approach differs from 
conventional MM by explicitly taking into account the ligand field stabilization 
energy (LFSE). By parameterizing the ligand field in terms of the bond-centered 
angular overlap model, a sophisticated description of metal-ligand bonding is 
possible which captures most of the essential physics around the metal centre. For 
low-spin d
8
 Pt(II) systems such as those studied here, the square-planar geometry 
of the platinum fragment is generated automatically rather than imposed by 
artificial forces. Also, the computational efficiency of LFMM allows relatively 
extensive molecular dynamics simulations from which a detailed description of 
global DNA parameters can be extracted. Compared to QM/MM, LFMD appears 
to afford closely comparable accuracy but at a small fraction of the computational 
cost.  
4.3.1 Accuracy of LFMM 
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The new LFMM parameters are able to reproduce crystal and QM/MM structures 
in terms of Pt–L bond lengths and Gua–Pt–Gua bond angles for square-planar 
platinum–DNA complexes, except for one system (CSD code DETLIX01: 
polymorph I and DETLIX20: polymorph II, see Table 4-1). The existence of 
different crystal forms is presumably a result of differences in the conditions of 
crystallization. However, the relatively large difference of over 0.16 Å  in Pt–
N(guanine) bond lengths in DETLIX01 is clearly at odds with the rest of the data 
in Table 4-1, which suggest a fairly narrow range of Pt-N7 distances. The 
difference might be due to the tightly-packed aggregate comprised of four 
crystallographically independent molecules held together by an extensive network 
of hydrogen bonding and intermolecular base-base stacking interactions reported 
for the structure of DETLIX01. However, on average, the experimental Pt–NH3 
and Pt–N7 bond lengths are 2.04 Å  and 2.00 Å , respectively,175 which are in good 
agreement with the corresponding LFMM values and a difference of 0.16 Å  in the 
Pt-N distances seems anomalously large. I conclude that there is probably an error 
in the DETLIX01 sturcture.  
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Chapter 5 
Ligand Field Molecular Dynamics 
Simulations of Platinum–DNA Cross-
links: a Distinctive Trans DNA 
Conformation Formed by a 
Photoactivated Platinum Complex 
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5.1 Introduction 
The new LFMM parameters developed in Chapter 4 should provide a reliable 
basis for modelling the highly strained structures expected for Pt-DNA binding. In 
this Chapter, they are used in simulations of (i) 1,2-intrastrand cisplatin–DNA 
adducts in which cis-{Pt(NH3)2}
2+
 is coordinated to the N7 atoms of adjacent 
guanine bases, (ii) interstrand cisplatin–DNA adducts in which cis-{Pt(NH3)2}
2+
 is 
bound to the N7 position of guanines on both strands of duplex, and (iii) a P–
DNA complex, comprising a trans-[Pt
II
(py)2(dGua)2]
2+
 interstrand cross-link 
formed by binding of the major photoreduction product of the novel platinum(IV) 
complex trans,trans,trans-[Pt
IV
(N3)2(OH)2(py)2] (17) to two nucleobases in DNA. 
Among various platinum–DNA products, 1,2-intrastrand adducts are the major 
DNA products formed by cisplatin and are thought to be important for its 
anticancer activity, while the minor interstrand cross-links prevent DNA strand 
separation and can block DNA replication and/or DNA transcription and can be 
lethal to cells lacking the ability to remove the cross-link.
177
 These systems have 
also been structurally characterized and serve to validate our ligand field 
molecular dynamics (LFMD) protocols. 
The Pt(IV)
 
complex 17 is stable in the dark, but has remarkable cytotoxicity when 
activated with a low-dose (5 J cm
-2
) of visible light (420 nm). In the presence of 
5'-GMP, the major photoproduct is trans-[Pt
II
(py)2(5'-GMP)2]
2+
 as confirmed by 
1
H and 
195
Pt NMR spectroscopy.
36
 Photoactivation promotes the rapid formation 
of such bis-guanine adducts whereas in thermal reactions involving trans diamine 
complexes such trans cross-links are formed very slowly, if at all.
178
 The unusual 
nature of these trans-GG crosslinks formed on DNA after photoactivation of 
 125 
 
trans-diazido Pt
IV
 complexes may contribute to their high potency towards cancer 
cells.
35
  
The detailed molecular mechanisms by which cells process interstrand cross-links 
are not understood. Recently, experiments have shown that formation of 1,2-
d(GpG), and 1,3-d(GpTpG) intrastrand cisplatin–DNA adducts in the nucleosome 
core can alter nucleosome mobility
179
 and/or positioning
180,181
 and compounds 
with higher molecular weights display a greater tendency to target the linker 
region of nucleosomal DNA.
182
 Brabec et al have now demonstrated 
experimentally that the predicted trans-[Pt
II
(py)2(G)2]
2+
 interstand crosslink is 
formed in significant amounts when complex 17 is photoactivated in the presence 
of DNA. Our model for the major platinum–DNA product formed by 
photoactivation of complex 17 is thus based on experimental observations in an 
attempt to contribute to an understanding of the mechanism of action of this novel 
platinum lesion. 
5.2 Calculations 
As AMBER has been extensively applied to simulations of biomolecules and the 
derived partial charges in AMBER94
91
 and MMFF94
106-110
 are in close agreement 
(vide infra), DommiMOE LFMD simulations were carried out at physiological pH 
and a mean temperature of 300 K using the LFMM/AMBER94 force field on (i) a 
1,2-intrastrand cisplatin–DNA dodecamer containing 767 atoms solvated in a 
droplet of 1782 water molecules (~10 Å  thick) and (ii) an interstrand cisplatin–
DNA decamer containing 640 atoms solvated in a droplet of 1531 water 
molecules. To explore the influence of periodic boundary conditions,
113
 the 
LFMM method was ported to DL_POLY2
183
 and the simulation of (iii) the 
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interstrand cisplatin–DNA complex containing 640 atoms solvated now with 3941 
water molecules in a periodic box of dimensions 48x45x56 Å , and, finally, (iv) an 
interstrand P–DNA dodecamer formed by the major photoproduct of complex 17 
with DNA, which contains 781 atoms solvated with 3400 water molecules in a 
periodic box of dimensions 45x45x60 Å . 
5.2.1 LFMD Protocol 
The starting point for the 1,2-intrastrand cisplatin–DNA adduct simulations was 
the solution NMR structure (determined by restrained molecular dynamics 
refinement) of the DNA duplex dodecamer (PDB entry 1A84)
10
 
d(C1C2T3C4T5G6*G7*T8C9T10C11C12)•d(G13G14A15G16A17C18C19A20G21A22G23G24
), containing a cis-GG adduct (where G* denotes the location of platinated 
nucleotides). The starting point for the interstrand adduct simulations was the 1.63 
Å  resolution X-ray structure of the double-stranded DNA decamer (PDB entry 
1A2E),
9
 d(C1C2T3C4G5*C6T7C8T9C10)•d(G11A12G13A14G15*C16G17A18G19G20), 
containing a cisplatin interstrand cross-link. The Protonate3D application in MOE 
was used to assign ionization states and add hydrogens (as described in Section 
2.4.3.1). The structure was immersed in a 10–Å –thick layer of TIP3P water 
molecules of density ~1 g/cm
3
 along with sodium ions used to balance the 
negative charge of each phosphate. The cisplatin/DNA system was frozen and the 
solvent molecule positions were energy-optimized. With cisplatin/DNA still fixed, 
the system was then heated to 300 K in two rounds of 10 ps by coupling to a heat 
bath using the Berendsen algorithm followed by 100 ps simulation to equilibrate 
the water at a temperature of 300 K maintained by a Nosé–Hoover thermostat. All 
atoms were then optimized to give the starting point for LFMD simulations 
followed by 5 ns of production dynamics under NVT condition. All the atoms 
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were propagated according to Newton’s equations of motions with a time step of 2 
×10
-15
 s at a mean temperature of 300 K using a Nosé–Hoover thermostat. Bonds 
involving hydrogen atoms were constrained during the simulations using the 
SHAKE algorithm.
118
 Nonbonded cutoffs      of 10 Å  and an onset       of 8 Å  
(the MOE default) were applied to the nonbonded energy terms with the 
smoothing function: 
s(r) =  
                                                                         
                                 
                                                                        
                                               
where                    
The starting structure for P–DNA complex simulations was generated from the 
2.16 Å  resolution X-ray structure of the DNA duplex dodecamer (PDB 3CO3,
184
 
d(C1C2T3C4T5C6G7*T8C9T10C11C12)•d(G13G14A15G16A17C18G19A20G21A22G23G24). 
This contains a monofunctional adduct of cis-{Pt(NH3)2(py)}
2+
 with a central G 
after replacement of the original metal fragment with the P fragment, trans-
{Pt(py)2}
2+
, and formation of the interstrand trans-[Pt(py)2(dGua)2]
2+
 cross-link 
between the N7 positions of the central guanines on the opposite strands of DNA, 
the metal and its coordinated groups were optimized with the rest of the residues 
frozen. The resulting structure was then reoptimized via multiple rounds of 
simulated annealing at 450 K to give the starting point for NPT simulations 
followed by 6 ns of production with a time step of 2 fs at 300 K and a pressure of 
1 atm maintained by Berendsen baro- and thermostats using DL_POLY. Long 
range interactions were treated by using the Ewald summation method. The 
SHAKE algorithm was employed to constrain all bonds involving hydrogen atoms 
in water molecules. A cutoff of 12 Å  was applied to the nonbonded interaction. 
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The effect of counterions on DNA structural and thermodynamic properties has 
been implicated in diverse experiments. A recent study showed that although 
simulations longer than 60 ns are necessary for ion convergence, the internal 
structural parameters in MD on DNA are well converged at ≈5 ns.97 DommiMOE 
was used to generate input files for DL_POLY simulations. 
5.3 Results 
5.3.1 Droplet LFMD Simulation of 1,2-intrastrand Cisplatin–DNA 
Complexes 
Table 5-1. Comparison between Selected LFMD, QM/MM,
75
 and Experimental 
Pt Bond Distances and Angles and atomic RMSD for 1,2-intrastrand Cisplatin–
DNA Complex PDB 1A84 
 
method 
N7PtN7 
(deg) 
PtN 
(Å ) 
PtN' 
(Å ) 
PtN7 
(Å ) 
PtN7' 
(Å ) 
RMSDs
a
 
(Å ) 
NMR 90.1 2.049 2.050 2.046 2.051  
QM/MM 86 2.11 2.09 2.06 2.03 0.04/1.50/4.20 
DommiMOE 88.9 2.022 2.024 1.986 2.011 0.041/0.554/0.917 
a
RMSDs for Pt–L bond lengths, heavy atoms of {Pt(NH3)2(Gua)2} and heavy 
atoms of whole cisplatin–DNA complex 
 
The DommiMOE simulation of the 1,2–intrastrand cisplatin–DNA adduct started 
from the NMR conformation (PDB code 1A84) to which counterions and water 
molecules were added as described above. The potential energy converges after 
~2500 ps (within 0.2%, Figure A3-1, Appendix 3). The RMSD of the heavy atoms 
from the starting structure initially rose, then plateaued after ~2500 ps, and 
fluctuated around a mean of 3.05 ± 0.11 Å  in the simulation. Thus, the first 2500 
ps of the trajectory were excluded, while the remaining 2500 ps were used in 
computing the average structure, distances, and angles. A comparison between 
LFMD, previous QM/MM results
75
 and experimental data is given in Table 5-1. 
 129 
 
These include three root-mean-square deviations (RMSDs) for, respectively, Pt–L 
bond lengths, the heavy (non-hydrogen) atoms of Pt(II) and its ligands NH3 and 
Gua, and of the entire Pt-DNA system. Figure 5-1 displays an overlay of LFMM 
and experimental structures. Overall, all simulations yield average N7–Pt–N7 
angles and Pt–N distances that are close to those found for the cisplatin binding 
site in the experimental structure. The DommiMOE LFMD RMSD for Pt–L bond 
lengths and heavy atoms of cisplatin–guanine and of cisplatin–DNA complexes 
are 0.041, 0.554, and 0.917 Å , respectively. The QM/MM simulations for the 
same adduct have RMSDs of 0.04, 1.50 and 4.20 Å .
75
 
 
Figure 5-1. NMR structure (green) of the 1,2-intrastrand Cisplatin–DNA 
Complex: PDB 1A84 with the sequence d(C1C2T3C4T5G6*G7*T8C9T10C11C12)• 
d(G13G14A15G16A17C18C19A20G21A22G23G24) where the -G6* G7*- site has been 
modified by cisplatin, superimposed upon the averaged droplet-simulation LFMD 
structure (colored by element; Pt
2+
 in magenta). Pt
2+
 and its directly bounded 
atoms are displayed in ball and stick mode. 
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5.3.2 LFMD Simulation of Interstrand Cisplatin–DNA Complexes 
Table 5-2. Comparison between Selected LFMD and Experimental Pt Bond 
Distances and Angles and RMSD of Geometrical Data for interstrand Cisplatin–
DNA Complex PDB 1A2E  
a
RMSDs for Pt–L bond lengths, heavy atoms of {Pt(NH3)2(Gua)2} and heavy 
atoms of whole cisplatin–DNA complex 
 
Just as for the simulation of the 1,2–intrastrand cisplatin–DNA adduct, the droplet 
simulation of the interstrand cisplatin–DNA adduct started from the X-ray 
configuration (PDB code 1A2E). Again, a reasonable degree of the potential 
energy convergence was obtained after ~2500 ps (within 0.2%, Figure A3-2, 
Appendix 3). After ~2500 ps, the RMSD of the heavy atoms from the starting 
structure fluctuated around a mean of 3.23 ± 0.14 Å  in the simulation. Therefore, 
the average structure was generated using the last 2500 ps of a 5 ns simulation. As 
shown in Table 5-2, the droplet LFMD average N7–Pt–N7 angle and Pt–N 
distances and the root-mean-square deviation (RMSD) of Pt–L bond lengths, the 
heavy atoms of {Pt(NH3)2(Gua)2}, and the heavy atoms of the entire cisplatin–
DNA complex indicate good agreement with the experiment as does the overlay 
of the computed and crystal structures (Figure 5-2, left). The Pt–L bond lengths 
have RMSDs of 0.023 Å  and the heavy atom overlays for {Pt(NH3)2(Gua)2} and 
for the entire complex have RMSDs of 0.265 and 0.494 Å , respectively.  
 
method 
N7PtN7 
(deg) 
PtN 
(Å ) 
PtN' 
(Å ) 
PtN7 
(Å ) 
PtN7' 
(Å ) 
RMSD
a
 
(Å ) 
X-ray 86.8 2.010 1.997 2.000 1.999  
DommiMOE 87.9 2.033 2.037 2.000 2.001 0.023/0.265/0.494 
DL_POLY/LF 90.2 1.963 1.966 1.953 1.950 0.044/0.823/2.488 
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The RMSD for the whole system is very small leading to a concern that the 
droplet protocol might be introducing a surface effect where the system would 
have some difficulty ‘escaping’ from the starting structure. To check if such 
boundary effects lead to any artificial behaviour, a simulation of the same 
interstrand cisplatin–DNA complex was performed with periodic boundary 
conditions using our LFMM implementation in DL_POLY.  
The RMSDs for Pt–L bond lengths, the {Pt(NH3)2(dGua)2}
2+
 fragment and overall 
heavy atoms certainly increase to 0.044, 0.823, and 2.488 Å , respectively, while 
the overlay of computed and X-ray structures (Figure 5-2, right) highlights the 
Figure 5-2. Crystal structure (green) of the cisplatin–DNA complex PDB 1A2E 
with the sequence d(C1C2T3C4G5*C6T7C8T9C10)• 
d(G11A12G13A14G15*C16G17A18G19G20) where G* denotes the location of 
platinated nucleotides, superimposed upon the average LFMD structure (colored 
by element; Pt
2+
 in magenta) derived from simulations with (a) a solute molecule 
inside a ‘drop’ of solvent and with (b) periodic boundary conditions that mimic 
macroscopic bulk system. Pt
2+
 and its directly bounded atoms are displayed in ball 
and stick mode. 
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movement of the backbone during the simulation. Compared to the periodic 
boundary DL_POLY simulation, the solvent droplet LFMD simulation seems to 
be rather ‘stiffer’. Accordingly, the cis-{Pt(NH3)2}
2+
 fragment was removed and a 
6 ns MD simulation was performed to see whether the DNA would straighten out. 
The global bending angle does decrease from 47.2° to 24°, but the distorted 
duplex is unable to return to a B-DNA conformation on this time scale since one 
of the bases has rotated out of alignment with its complementary base (Figure A3-
3, Appendix 3). This leads to the conclusion that while the droplet simulations do 
suffer from surface effects which tend to reinforce the starting structure, they 
behave correctly at a qualitative level, although droplet simulations take longer to 
relax than periodic boundary simulations.  
5.3.3 Periodic Boundary LFMD Simulation of Interstrand P–DNA 
Complexes 
The simulation of the interstrand P–DNA complex (DL_POLY2 with periodic 
boundary conditions) started from the modified X-ray structure (PDB entry 3CO3) 
as described above. The average structure generated from the last 2 ns of a 6 ns 
simulations is displayed in Figure 5-3a and an expanded view of the platinum-
binding site is shown in Figure 5-3b. A detailed analysis of the local and global 
structural parameters for the nucleic acids can be generated using the program 
Curves+
138
 as described in Section 2.6.4. The results for the P-DNA system are 
presented in Figure 5-4. For consistency and to avoid having to make comparisons 
involving both X-ray and NMR data which have known differences (described in 
Section 1.5.4.4),
21, 82
 the comparison focuses on DL_POLY LFMD structures. 
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Coordination of the trans-platinum fragment with bulky hydrophobic pyridine 
ligands to G7 and G19 causes disruption of the T5-A20, C6-G19*, and G7*-C18 
base pairs and a propeller twist of the platinated central base pairs by ~120°, 
resulting in the formation of hydrogen bonds between G19 NH2 and G21 O6, G19 
O6 and A20 NH6, G21 O6 and T5 NH3, and G7 NH2 and 3' oxygen of the sugar 
moiety 6. On the other hand, C6 and C18 are more solvent exposed than in B-
DNA, a feature similar to that found in the X-ray structure of the interstrand cross-
link, PDB 1A2E (Figure 5-3b). The local distortions lead to a global bend of the 
duplex of ~67° and a helix unwinding of ~20°. The larger RMSD of the 
{Pt(py)2(dGua)2} moiety (fluctuating around a mean of 12.54 0.33 Å ) from those 
Figure 5-3. The average LFMD structure derived from simulations of interstrand 
P–DNA complex, an interstrand crosslink on the DNA duplex with the sequence 
d(C1C2T3C4T5C6G7*T8C9T10C11C12)•d(G13G14A15G16A17C18G19*A20G21A22G23G24) 
containing the trans-{Pt(py)2}
2+
 fragment coordinated to G7 and G19, with periodic 
boundary conditions. (a) The P–DNA complex. (b) An expanded view of the 
platinum-binding site. Pt
2+
 and its directly bounded atoms are displayed in ball 
and stick mode. 
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in the starting structure, as compared to the RMSD of the heavy atoms for the rest 
of the complex (fluctuating around a mean of 10.34 0.35), indicates a metal-
binding site which is less rigid than the rest of the DNA. 
Figure 5-4a, 5-4b, 5-4c, and 5-4d summarize the minor groove width (Min-W) 
and depth (Min-D), C5' -C4' -C3' -O3' (δ) torsion angles, and the local inter-base 
pair parameters: rise, tilt, and twist for the two interstrand platinated duplexes in 
this work. Unlike the widened and flattered features on either side of the 
platination site in cisplatin–DNA complexes, the minor groove in the P–DNA 
complex is wide and shallow at one side and narrow and deep on the other. Sugar 
puckers can be inferred from the δ torsion angles. Such an analysis as that of 
Figure 5-4c shows that the P–DNA complex displays a more A-DNA-like C3'-
endo conformation at the platinated site compared to the structure of 1A2E. The 
asymmetric helix unwinding on two strands of P–DNA complex is related to the 
decreasing inter-base twist angles at the metal-binding site (Figure 5-4d). A 
simulation with a different starting configuration may be needed in order to 
demonstrate the reproducibility of this structure. However, as the bulky 
hydrophobic pyridine ligands tend to have very few stable conformations in the 
core of the double helix, the possible starting configurations of P–DNA complex 
have been limited. 
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(d) 
Figure 5-4. Graphical representation of base pair parameters from Curves+ 
analysis as a function of base pair for the two of interstrand platinated duplexes. 
Sequences are presented from residue 2 to 9 and residue 3 to 10 in strand 1 for 
1A2E and P-DNA complex, respectively, to provide an illustrative comparison 
between structures with different DNA sequences in (a) and (b); whereas the 
complementary sequences are presented from residue 20 to 11 and residue 24 to 
13 in strand 2 for 1A2E and P-DNA complex, respectively in (c) and (d). 
  
5.4 Discussion 
5.4.1 Structures of the Platinated Duplex 
The most interesting features of the structural distortions induced in DNA by 
platination are the global bend of the double helix and the deformation of the 
minor groove. Inspection of the overall helix bend angle and the variation in 
minor groove width using the program Curves+
138
 reveals close agreement 
between LFMD and crystal/NMR structures, although this is in part due to the 
droplet simulation protocol. The LFMD simulations yield an overall helix bend 
angle of 82.0° for the 1,2–intrastrand cisplatin–DNA adduct and 67.4° (47.2° with 
periodic boundary conditions) for the interstrand DNA cross-link, similar to those 
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derived from experiments (83.2° and 60.0°, respectively).
9,10
 The calculated 
structure of the intrastrand cross-link adduct shows that the minor groove is 
opened to 7.110.7 Å  over five base pairs, from C4–G21 through T8–A17, in 
agreement with the respective NMR structure (7.111.2 Å ), which is closer to the 
11.0 Å  width of canonical A–DNA than the 5.7 Å  width of B–DNA. The average 
LFMD structure of the interstrand cross-link adduct gives minor groove widths of 
6.511.2 Å  (6.011.7 Å  with periodic boundary conditions and 6.111.1 Å  
experimentally) at both ends of the platinated site, larger than the respective 
values of B–DNA. 
Cisplatin–DNA complexes are stabilized by the formation of a hydrogen bond 
between the ammine-hydrogen of cisplatin and either the O=C6 group of guanine 
or the O=C2 moiety of thymine or an oxygen atom on the 5' -phosphate group. In 
contrast, the pyridine ligands of the P–DNA complex have aromatic C–H donors 
and aromatic π-acceptors which may interact with aromatic groups on proteins. for 
C–H···π-interactions. These weak C–H···π hydrogen-bond-like interactions each 
provide a stabilization energy of about 0.51.0 kcal/mol and may thus play an 
important role in protein–DNA recognition.89 Another notable feature of the P–
DNA complex is that the weak stabilization due to π–π stacking between one of 
the hydrophobic pyridines and T5 results in a relatively flexible local metal-
binding site, which could increase the specificity of protein binding for the 
platination site. 
Inevitably, how well platinum–DNA complexes can be modeled is based on the 
interplay between LFMM for the metal centre and conventional MM for the 
‘organic’ parts. For the latter, the performance of the most popular nucleic acid 
force fields has been evaluated (refer to Section 1.5.3 for the summary) and, in 
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general, simulation is capable of reproducing a variety of nucleic acid structures. 
Here, I acknowledge that the performance with respect to describing intricate 
structural parameters of platinum–DNA complexes using LFMM in conjunction 
with various nucleic acid force fields should be constantly reviewed. 
Brabec et al. subsequently demonstrated experimentally that, in addition to 5'-
CG/5'-CG crosslinks like the P–DNA complex modeled in the present study, 5'-
GC/5'-GC crosslinks and crosslinks between G and the complementary C are 
formed when complex 17 is photoactivated in the presence of DNA. It will be 
interesting to model the latter crosslinks in future work. 
5.4.2 Biological Significance 
The main thrust of this work has been to probe the effect on the structure of DNA 
of generating a trans-{Pt(py)2}
2+
 interstrand crosslink arising from the 
photoreduction of the potent cancer-cell-cytotoxic complex trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (17). The structure of the trans interstrand P–DNA complex 
generated from our simulations exhibits more bending (67°) and less unwinding 
(20°) than an interstrand cisplatin–DNA adduct (bent by 60° and unwound by 81°) 
as well as less bending than a reported transplatin interstrand cross-link (bent by 
26° and unwound by 12°).
177
 The proposed photoadduct bears a closer 
resemblance to the intrastrand cisplatin–DNA adduct, PDB 1A84, (bent by 83.2° 
and unwound by 36°) and is of potential importance in the molecular mechanism 
of action of this photoactivatable complex.  
A quantitative analysis of the influence of nucleosomal core proteins on specific 
drug–DNA interactions using a Taq DNA polymerase stop assay has revealed that 
larger platinum compounds generally display a greater tendency to target the 
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linker region of the nucleosomal DNA and have less access to nucleosomal core 
DNA.
182
 For example, dichloro(N-[3-[(2-aminoethyl)amino]propyl]-9-
aminoacridine-4-carboxamide)platinum(II) with a molecular weight of 603 
produces a higher average linker-core ratio (L/C ratio) of 2.52 compared to 
cisplatin (molecular weight of 300, L/C ratio of 1.32). Upon binding to the linker 
region of the nucleosomal DNA, the platinum modification could (i) enhance the 
binding of histone H1 and the high mobility group (HMG1) protein
185
 and shield 
the damage site from recognition by DNA repair machinery
6,177,185
 by having a 
dramatic effect on the global curvature of the DNA similar to a cisplatin 1,2-
intrastrand lesion, increasing the flexibility of the helix at the local site of the 
interstrand cross-link, (ii) attenuate the negative electrostatic potential of 
backbone phosphates by widening the minor groove at one end of the platinated 
site, and (iii) change the groove landscape by deepening the minor groove at the 
opposite end of the platinated site together with A-DNA-like conformations and 
the above structural factors, and thus affect the formation of base-specific 
hydrogen bonds in the major groove and the electrostatic potential in the minor 
groove, two general mechanisms for protein–DNA recognition.186 The compound 
can also access nucleosomal core DNA. With a striking similarity to the global 
shape of the intrastrand cis-{Pt(NH3)2}
2+
 1,2-d(GpG) cross-link, the trans 
interstrand P–DNA adduct may influence the rotational and translational 
positioning of DNA in nucleosomes.
180
  
In summary, photoactivation promotes the rapid formation of a trans interstrand 
cross-link. Various repair proteins that bind preferentially to platinum intrastrand 
cross-links do not interact with interstrand cross-links. DNA interstrand cross-
links, in general, prevent strand separation, and thus act as a physical barrier to 
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DNA replication and/or DNA transcription, which, in contrast to G2 arrest in the 
cell cycle caused by cisplatin damage,
6
 may block advance through the S phase 
and drive the cells effectively into apoptosis. In addition, the distinctive local and 
global shape and the dynamic features of the P–DNA complex may promote a 
higher affinity for histone H1 and HMG1, which can shield the platinum adducts 
from DNA repair enzymes such as nucleotide excision repair (NER) proteins, 
which mainly recognize and excise intrastrand adducts, and increase the 
cytotoxicity of anticancer agents. Preclinical studies have conﬁrmed that 
modulation of repair pathways can enhance the sensitivity to DNA damaging 
agents.
83
 Moreover, the protein-binding profile of the proposed trans interstrand 
P–DNA complex may be very different from clinically effective platinum drugs, 
and may modulate the binding and assembly of transcription factors such as the 
TATA-binding protein (TBP). TBP recognizes the TATA box of the promoter by 
intercalation between four phenylalanine residues and base pairs of the TATA box 
in the minor groove causing substantial unwinding and bending of DNA. It binds 
to cisplatin adducts with similar affinity and kinetics compared to TATA boxes,
187
 
and therefore affects gene expression. The targeting to cancer cells by site-specific 
photoactivation, reduced DNA repair, cell-cycle arrest in the S phase, and the 
influence on gene expression may all contribute to the high potency and unusual 
mechanism of action of complex 17 with potential for circumventing resistance to 
current Pt drugs. 
5.5 Conclusions 
The ligand field molecular mechanics (LFMM) parameters for Pt(II) complexes 
have been extended to the interaction between the N7 position of guanine to 
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enable ligand field molecular mechanics dynamics (LFMD) simulations of the 
intrastrand and interstrand cisplatin–DNA adducts as well as a P–DNA complex, a 
trans-[Pt(py)2(Gua)2]
2+
 interstrand cross-link formed by binding of the major 
photoproduct of a novel platinum(IV) complex trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (17) to two nucleobases in DNA. The main findings of this 
work are as follows. 
(i) LFMM yields metal-ligand bond distances in good agreement with the 
experimental and QM/MM-optimized small-molecule structures, while LFMD 
accurately reproduces the X-ray and NMR structures of the much larger 
intrastrand and interstrand platinum–DNA complexes at a significantly reduced 
computational cost compared to QM/MM. 
(ii) The unusual nature of the proposed trans interstrand cross-link in P–DNA 
complex promoted by photoactivation of trans,trans,trans-[Pt(N3)2(OH)2(py)2] 
(17), compared to the predominantly 1,2-intrastrand cross-links formed by 
cisplatin, may contribute to the former’s high potency towards cancer cells.  
(iii) Unlike the widened and flattened features in cisplatin–DNA complexes, the 
minor groove in the P–DNA complex is widened at one end and deepened at the 
other end of the platinated site. The distinctive structure of the trans interstrand P–
DNA complex with more bending (67°) and less unwinding (20°) is closer to 
intrastrand cisplatin–DNA adducts (bent by 83.2° and unwound by 36°) than 
interstrand cisplatin–DNA adducts (bent by 60° and unwound by 81°) or 
transplatin interstrand cross-links (bent by 26° and unwound by 12°). The analysis 
of the δ torsion angles indicates a more A-DNA-like C3'-endo conformation at the 
platinated site for the P–DNA complex than for the interstrand cisplatin–DNA 
complex (PDB 1A2E). The combination of the structural features described here 
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offers numerous possibilities for specific interactions with proteins that may help 
rationalize to the striking differences in cellular repair mechanisms and apoptosis 
pathways and influence the loading of DNA and RNA polymerases in the 
promoter region of genes. 
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Chapter 6 
Perspectives and Future Work 
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Herein, the major advances and conclusions in computer-aided drug design of 
photoactivated platinum complexes within this thesis are summarised. Future 
work for a better understanding of the mechanism of action as well as efficient 
drug design and discovery to achieve greater potency and desirable 
pharmacological properties is outlined. 
6.1 Concluding Remarks 
A variety of platinum complexes have proven successful as anticancer agents in 
the clinic and in clinical trials. In spite of revolutionary leaps forward in 
understanding cancer pathogenesis, relatively little progress has been made in 
exploiting these insights into etiology (i.e. the causative mechanisms of disease) to 
prevent the disease and, equally important, to treat it. Most of the anticancer 
treatments in widespread use today were developed prior to 1975, at a time when 
the development of therapeutics was not yet informed by the genetic and 
biochemical mechanisms of cancer pathogenesis. Death rates for cancer have 
begun to fall, because of early detection and surgical removal of growths that have 
advanced through only the early stages of tumour progression. However, mortality 
caused by the more advanced tumours that have invaded and begun to metastasize 
has changed little in recent decades.
188
 Among a number of strategies of therapy, 
photoactivated platinum compounds offer both temporal and spatial control over 
drug activation and have remarkable potential to increase selectivity for cancer 
cell lines and to reduce some of the noxious side-effects associated with 
conventional chemotherapeutics.
35,36,159
  
Numerous experimental and theoretical studies have been carried out on metal-
based drugs and their in vivo mechanisms of action.
6,11,31,32,40,189-191
 However, the 
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research on photoactivated metal complexes is still in its infancy.
35,36,159,161,192,193
 
Many important issues such as the principles that govern the power and frequency 
of radiation, structures of metal complexes, properties in excited states, and the 
induced photopathways and photoproducts as well as solvent effects are not fully 
understood. 
In this thesis, DFT/TDDFT has been used as a tool to help tune the coordination 
environment of platinum(IV) complexes to achieve desirable photochemical 
properties and furthermore LFMM/LFMD has been employed to study novel 
distortions induced by DNA platination which are important for understanding the 
mechanism of action of a new class of photoactive platinum anticancer drugs. In 
Chapter 3, exploration of trans influences, the nature of OR
−
 and (pseudo)halogen 
ligands, electron-withdrawing/donating/delocalizing substituents on the N-ligands, 
and intramolecular H-bonds by TDDFT shows that the design of platinum(IV) 
complexes with absorption bands shifted towards longer wavelengths (~330 nm) 
can be achieved by introducing intramolecular H-bonds involving the OH ligands 
and 2-hydroxyquinoline or by iodido ligands, and the direction of metal-ligand 
electron transfer can be controlled. Furthermore, mesomeric electron-withdrawing 
substituents on pyridine result in low-energy absorption with significant intensity 
in the visible region. The comparison of the optimised structures shows that, in 
general, Pt(IV) complexes with Pt−L bond distances closer to their Pt(II) products 
are more likely to undergo photoreduction with longer-wavelength light. The 
molecular orbitals analysis shows that the distinct makeup of the molecular 
orbitals in electronic transitions for cis/trans-{Pt(N3)2} isomers result in different 
photoproducts. 
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Ligand field molecular mechanics (LFMM) parameters for Pt–guanine 
interactions are derived to enable the square-planar geometry of the platinum 
fragment to be generated automatically rather than be imposed by artificial forces 
(see Chapter 4), and are applied to the first ligand field molecular dynamics 
(LFMD) simulations of bifunctional DNA adducts of the anticancer drug cisplatin 
to validate our protocols before advancing to a possible major DNA photoproduct 
of the novel platinum(IV) complex trans,trans,trans-[Pt(N3)2(OH)2(py)2] (17) (py 
= pyridine) (see Chapter 5). LFMM gives an excellent description of the local Pt 
coordination which is in good agreement with experimental and QM/MM 
structures. LFMD also accurately reproduces the experimentally-observed 
structures of intrastrand and interstrand platinum–DNA complexes. The major 
photoproduct from complex 17 can form an interstrand crosslink on the DNA 
duplex dodecamer, d(C1C2T3C4T5C6G7*T8C9T10C11C12)• 
d(G13G14A15G16A17C18G19*A20G21A22G23G24), where the trans-{Pt(py)2}
2+
 
fragment is coordinated to G7 and G19. This adduct has a widened minor groove at 
one end and deepened minor groove at the opposite end of the platinated site, and 
exhibits a global bend of ~67° and an unwinding of ~20°. The unusual structural 
features associated with this interstrand trans-[Pt(py)2(Gua)2]
2+
 cross-link offer 
many possibilities for specific protein–DNA interactions, which suggests possible 
mechanisms for the high potency of this photoactivated complex. LFMM/LFMD 
appears to provide a reliable way to model local and global conformational 
distortions induced by binding of various platinum complexes, particularly highly 
strained systems involving critical conformational changes. It will be interesting 
to model the other forms of interstrand crosslinks using LFMD in future work.  
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Both experimental and theoretical works suggest that the photochemistry of 
platinum complexes is complex and thus not simple to predict, and that 
photoproducts can be complicated to characterise, and must therefore be 
investigated thoroughly to elucidate the pathways. Future work will focus on 
applying LFMD to the study of sequence-dependent reactions of DNA with 
platinum-based anticancer drugs and their photoproducts, and to the design of 
metal-containing complexes that exhibit speciﬁcity with respect to duplex DNA 
and also between diﬀerent G-quadruplexes. 
6.2 Future Work: Rational Design of Metal-Based Complexes with 
Selectivity for Duplex and Quadruple DNA 
In order for drug targeting to be selective and effective, it is not enough for metal-
based complexes to bind to duplex or quadruplex DNA. New 
metallopharmaceuticals must also target selectively one duplex/quadruplex over 
another. LFMD simulations could be used for the docking of metal complexes to 
specific DNA sequences and structures and to compute relative kinetic and 
thermodynamic free energies for the binding of metal complexes to DNA with 
desirable sequences and structures, as well as to predict transition structures of 
metal–DNA adducts and DNA conformational changes upon metal binding. 
In DNA-drug docking, the drug is brought (manually or, in some cases, 
automatically) into the vicinity of the binding site and oriented so that electrostatic 
and van der Waals interactions (computed via appropriate molecular mechanics 
energy expressions) between the drug and DNA are optimized. Accurate docking 
calculations can be very difficult and require an extremely fast computer because 
both drugs and nucleic acids are relatively flexible molecules that mutually adjust 
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their conformations in the process of binding to maximize steric and chemical 
complementarity. Alternatively, to speed up the calculation, one or both 
components can be frozen. For example, the active site can be fixed and a set of 
precalculated drug conformations docked to give a series of ‘poses’ each of which 
has a ‘score’. Such calculations are very quick but potentially of low accuracy.  
Ideally, I would like to compute the binding free energy. Free energy calculations 
using molecular dynamics or Monte Carlo simulations provide a direct link 
between the microscopic structure and fluctuations of the model system and its 
most important macroscopic thermodynamic property, and thus show great utility 
for guiding molecular design. Free-energy perturbation and thermodynamic 
integration calculations provide rigorous means to compute free-energy changes 
so that accurate prediction of metal-biomolecule binding affinities can be 
achieved.
194
 The fundamental difficulty in free energy calculations lies in 
obtaining adequate sampling of conformations. Because of the ruggedness of the 
energy landscapes of nucleic acids and proteins, many energy barriers cannot be 
crossed spontaneously in simulations spanning even a few nanoseconds. In 
addition, due to the inherently very short elementary simulation time step, ~2 fs, 
molecular dynamics simulations are presently limited to relatively short total 
simulation times, on the order of nanoseconds to microseconds. However, with the 
ongoing significant advances in hardware and software, as well as techniques to 
enhance sampling, the evaluation of the kinetic and thermodynamic reactivity of 
metal–DNA interactions could become a powerful tool in the design and synthesis 
of new potent metallopharmaceuticals with sequence-dependent selectivity for 
duplex DNA and with accurate targeting of the loops and grooves of G-
quadruplexes. In addition, the characterization of transition states is essential if the 
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chemical processes are under kinetic control. As LFMM employs Morse potential 
to model metal-ligand bonds, transition states of metal-ligand interactions can be 
computed if proper parameters, such as the change of charges, are provided. 
6.3 Future Work: the Study of the Interactions between Various 
Metal Ions and DNA/Proteins  
Not only do platinum complexes bind to DNA, but they can also interact with 
proteins involved in replication, transcription, repair, and chromatin structure. 
Many of these proteins communicate with each other to mediate drug uptake, 
signal transduction, and gene expression, which further affect anticancer activity 
of platinum-based drugs. Better information about the structures and the reactivity 
of platinum complexes with a variety of proteins will be valuable for elucidating 
the molecular mechanism of these compounds and further improving drug design. 
On the other hand, LFMM force field can be extended to adenine and other 
transition metals, such as Ruthenium, Osmium, Rhodium, Iridium, and Gold. 
Careful parameterisation is required to ensure that the preference of guanine over 
adenine and of AG 1,2-intrastrand crosslinks over the analogous GA adducts, and 
periodic trends of metal-ligand bonds can be reproduced.  
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Appendix 1 
 
Table A1-1. Comparison between Calculated and Experimental Bond Distances 
(in Å ) and Angles (in deg) for trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] and cis, 
trans, cis-[Pt(N3)2(OH)2(NH3)2] 
Complex  BP86/DZT
a
 BP86/TZP
b
 Experiment 
trans, trans, trans-
[Pt(N3)2(OH)2(NH3)2] Pt-N3 2.088 2.090 2.046 
 Pt-NH3 2.051 2.057 2.036 
 Pt-OH 2.050 2.047 2.006 
 Pt-N-N 116.3 117.2 117.2 
 N-N-N 175.6 174.7 174.5 
cis, trans, cis-
[Pt(N3)2(OH)2(NH3)2] Pt-N3 2.052 2.053 2.037 
 Pt-NH3 2.108 2.116 2.033 
 Pt-OH 2.049 2.046 2.006 
 Pt-N-N 115.5 116.3 116.3 
 N-N-N 175.5 174.8 172.9 
     
 Rmsd 
(Å ) 0.044 0.046 
 
 Rmsd 
(°) 1.5 0.9 
 
a
 BP86 functional in combination with the uncontracted triple-ζ+polarisation 
(TZP) STO basis sets.
 b
 BP86 functional in conjunction with the uncontracted 
double-ζ+polarisation (DZP) STO basis sets. 
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Table A1-2. Comparison of intense bands λmax between calculated electronic 
transitions with scalar and two-component (spin-orbital coupling) relativistic 
TDDFTs using SAOP potentials and experimental UV-Vis spectrum for trans, 
trans, trans-[Pt(N3)2(OH)2(NH3)2], cis, trans, cis-[Pt(N3)2(OH)2(NH3)2], and trans, 
trans, trans-[Pt(N3)2(OH)2(NH3)(pyridine)] (1). 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)2] 
 nm 1/cm eV kcal/mol transition Oscillator 
Strength 
experiment 285 35088 4.35 100.32   
scalar 
295 33924 4.21 96.99 11 0.341 
237 42245 5.24 120.79 19 0.192 
scalar + 
COSMO
a
 
301 33269 4.13 95.12 10 0.218 
282 35419 4.39 101.27 11 0.207 
225 44508 5.52 127.26 19 0.231 
two-component 293 34104 4.23 97.51 47 0.313 
cis, trans, cis-[Pt(N3)2(OH)2(NH3)2] 
 nm 1/cm eV kcal/mol transition Oscillator 
Strength 
experiment 256 39063 4.84 111.68   
scalar 
277 36046 4.47 103.06 13 0.134 
271 36944 4.58 105.63 14 0.156 
two-component 277 36083 4.47 103.17 55 0.114 
trans, trans, trans-[Pt(N3)2(OH)2(NH3)(pyridine)] (1) 
 nm 1/cm eV kcal/mol transition Oscillator 
Strength 
experiment 289 34602 4.29 98.93   
scalar 
312 32025 3.97 91.57 17 0.119 
293 34112 4.23 97.53 21 0.261 
two-component 
311 32200 3.99 92.07 71 0.115 
292 34280 4.25 98.01 87 0.225 
a
 scalar relativistic TDDFT in combination with COSMO. 
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Figure A1-1. Fully optimized structures of the platinum(IV) complexes. Bond 
lengths are given in Å . 
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Appendix 2 
 
Table A2-1. New LFMM/MMFF94 and LFMM/AMBER94 charge schemes for dGuo(Pt)
+
 derived from CHelpG charges of cis-
[Pt(NH3)2(Cl)(dGuo)]
+
. 
  QM    mmff94   new new 
Label Atom dGuo dGuo(Pt)+ (dGuo(Pt)+)-dGuo  dGuo dGuo(Pt)+ (dGuo(Pt)+)-dGuo (dGuo(Pt)+)-dGuo dGuo(Pt)
+
 
1 N1 -0.894 -0.888 0.006  -0.490 -0.490 0.000 0.006 -0.484 
2 C2 1.006 1.094 0.088  0.560 0.560 0.000 0.088 0.648 
3 N3 -0.772 -0.776 -0.004  -0.576 -0.576 0.000 -0.004 -0.580 
4 C4 0.402 0.548 0.146  -0.026 -0.026 0.000 0.146 0.120 
5 C5 -0.026 -0.328 -0.302  0.141 0.141 0.000 -0.302 -0.161 
6 C6 0.794 0.888 0.094  0.716 0.716 0.000 0.094 0.810 
7 N7 -0.56 -0.147 0.413  -0.565 -0.012 0.553 0.413 -0.152 
8 C8 0.235 0.168 -0.067  0.037 0.037 0.000 -0.067 -0.030 
9 N9 -0.268 -0.231 0.037  0.048 0.048 0.000 0.037 0.085 
10 N10 -0.944 -1.042 -0.098  -0.850 -0.850 0.000 -0.098 -0.948 
11 O11 -0.609 -0.657 -0.048  -0.570 -0.570 0.000 -0.048 -0.618 
12 H12 0.445 0.457 0.012  0.370 0.370 0.000 0.012 0.382 
13 H13 0.388 0.458 0.07  0.400 0.400 0.000 0.070 0.470 
14 H14 0.403 0.466 0.063  0.400 0.400 0.000 0.063 0.463 
15 H15 0.147 0.157 0.01  0.150 0.150 0.000 0.010 0.160 
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      Amber94   new new 
      dGuo dGuo(Pt)+ (dGuo(Pt)+)-dGuo (dGuo(Pt)+)-
dGuo 
dGuo(Pt)
+
 
      -0.505 -0.505 0.000 0.006 -0.499 
      0.743 0.743 0.000 0.088 0.831 
      -0.664 -0.664 0.000 -0.004 -0.668 
      0.181 0.181 0.000 0.146 0.327 
      0.199 0.199 0.000 -0.302 -0.103 
      0.492 0.492 0.000 0.094 0.586 
       -0.573 -0.573 0.000 0.413 -0.160 
      0.074 0.074 0.000 -0.067 0.007 
      0.058 0.058 0.000 0.037 0.095 
      -0.923 -0.923 0.000 -0.098 -1.021 
      -0.570 -0.570 0.000 -0.048 -0.618 
      0.352 0.352 0.000 0.012 0.364 
      0.423 0.423 0.000 0.070 0.493 
      0.423 0.423 0.000 0.063 0.486 
      0.200 0.200 0.000 0.010 0.210 
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Table A2-2. LFMM parameter values for platinum complexes. The atom types employed are the same as AMBER94. 
Morse         
  r0 (Å ) D0 (kcal/mol) α (1/Å )     
Pt+2 CL- 2.49079 52 1.44416     
Pt+2 HYDR 1.67686 75 2.08984     
Pt+2 N3 2.31653 46 1.63273     
Pt+2 BR- 2.55103 52 1.5331     
Pt+2 P 2.34522 53 1.94219     
Pt+2 OH2 2.33859 57 1.16197     
Pt+2 S 2.51364 52 1.54781     
Pt+2 NC 2.26093 60 1.67828     
Pt+2 NB 2.24093 60 1.72828     
Pt+2 C 2.05 75 2.0898     
         
   
   
 ALL 
(kcal/mol) 
n      
Pt+2 HYDR 247 2      
Pt+2 CL- 1850 4      
Pt+2 N3 2800 6      
Pt+2 BR- 2580 4      
Pt+2 P 4155 4      
Pt+2 OH2 2800 6      
Pt+2 S 770 4      
Pt+2 NC 2400 6      
Pt+2 NB 2400 6      
Pt+2 C 247 2      
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[esig]      1/cm 1/cm 1/cm 
Pt+2 CL- 0 0 0 0 0 0 1.65E+06 
Pt+2 HYDR 0 0 0 0 0 0 147000 
Pt+2 N3 0 0 0 0 0 610000 0 
Pt+2 BR- 0 0 0 0 0 0 1.66E+06 
Pt+2 P 0 0 0 0 380000 0 0 
Pt+2 OH2 0 0 0 0 0 400000 0 
Pt+2 S 0 0 0 0 0 1.02E+06 0 
Pt+2 NC 0 0 0 0 0 0 1.33E+06 
Pt+2 NB 0 0 0 0 0 0 1.33E+06 
Pt+2 C 0 0 0 0 0 0 147000 
         
[epix]      1/cm 1/cm  
Pt+2 CL- 0 0 0 0 0 175000 0 
Pt+2 HYDR 0 0 0 0 0 0 0 
Pt+2 N3 0 0 0 0 0 0 0 
Pt+2 BR- 0 0 0 0 0 80000 0 
Pt+2 P 0 0 0 0 -92000 0 0 
Pt+2 OH2 0 0 0 0 0 0 0 
Pt+2 S 0 0 0 0 0 0 0 
Pt+2 NC 0 0 0 0 0 0 0 
Pt+2 NB 0 0 0 0 0 0 0 
Pt+2 C 0 0 0 0 0 0 0 
         
[epiy]      1/cm 1/cm 1/cm 
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Pt+2 CL- 0 0 0 0 0 175000 0 
Pt+2 HYDR 0 0 0 0 0 0 0 
Pt+2 N3 0 0 0 0 0 0 0 
Pt+2 BR- 0 0 0 0 0 80000 0 
Pt+2 P 0 0 0 0 -92000 0 0 
Pt+2 OH2 0 0 0 0 0 190000 0 
Pt+2 S 0 0 0 0 93115 0 0 
Pt+2 NC 0 0 0 0 0 0 590000 
Pt+2 NB 0 0 0 0 0 0 590000 
Pt+2 C 0 0 0 0 0 0 0 
         
[exds]      1/cm 1/cm 1/cm 
Pt+2 CL- 0 0 0 0 0 0 445000 
Pt+2 HYDR 0 0 0 0 0 0 155000 
Pt+2 N3 0 0 0 0 0 121000 0 
Pt+2 BR- 0 0 0 0 96000 0 0 
Pt+2 P 0 0 0 0 150000 0 0 
Pt+2 OH2 0 0 0 0 0 0 163000 
Pt+2 S 0 0 0 0 91000 0 0 
Pt+2 NC 0 0 0 0 0 135000 0 
Pt+2 NB 0 0 0 0 0 135000 0 
Pt+2 C 0 0 0 0 0 0 155000 
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Table A2-3. LFMM-Optimized and QM/MM
a
 M–L Bond Lengths (in Å ) for double-stranded Pt Complexes.  
 LFMM  QM/MM 
 Pt Pt Pt Pt  Pt Pt Pt Pt 
1 2.037 2.040 2.014 2.005  2.019 2.016 2.035 2.045 
2 2.008 2.000 2.030 2.032  2.014 2.024 2.027 2.039 
3 2.012 1.998 2.030 2.027  2.026 2.016 2.023 2.036 
4 2.011 1.999 2.031 2.029  2.016 2.025 2.038 2.027 
5 2.012 2.001 2.030 2.040  2.018 2.029 2.037 2.033 
6 2.015 2.003 2.030 2.053  2.025 2.026 2.024 2.047 
7 2.014 2.002 2.042 2.034  2.021 2.030 2.032 2.038 
8 2.023 2.006 2.052 2.064  2.031 2.019 2.037 2.065 
9 2.032 2.011 2.063 2.070  2.031 2.022 2.047 2.064 
10 2.011 2.000 2.027 2.033  2.020 2.025 2.024 2.035 
11 2.011 1.999 2.028 2.031  2.017 2.026 2.026 2.032 
12 2.012 1.998 2.025 2.029  2.019 2.028 2.019 2.031 
13 2.011 1.999 2.029 2.034  2.020 2.025 2.028 2.036 
a 
Gkionis, K.; Platts, J. A., J. Biol. Inorg. Chem. 2009, 14 (8), 1165.
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Table A2-4. The computed low energy LFMM and QM frequencies (cm
−1
) for 
cis-[Pt(NH3)2(Cl)(dGuo)]
+
 in Figure 4-1. 
ADF LFMM
16 23
35 35
43 41
45 62
65 74
84 89
95 115
114 134
118 137
125 160
134 164
155 178
161 189
177 195
195 218
207 223
211 250
222 261
235 282
245 286
251 307
275 317
292 327
308 345
314 352
324 360
336 367
339 377
370 386
394 418
422 451
429 484
440 499
455 544
457 561
470 572
506 579
572 585
592 601  
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Appendix 3 
 
Table A3-1. Molecular dynamics simulation protocol used in MOE simulations. 
1A84
1782 H2O
22 Na+
md step sub step time step/ps time/ps ensemble thermostat constraint
emin 1 pt/DNA
heating 1 10 NVT, 0K to 150KBerendsen pt/DNA
2 10 NVT, 150K to 300KBerendsen pt/DNA
equilibration 1 0.002 100 NVT, 300K NHA pt/DNA
opt 1 none
production 0.002 5000 NVT, 300K NHA none
1A2E
1532 H2O
18 Na+
md step sub step time step/ps time/ps ensemble thermostat constraint
emin 1 pt/DNA
heating 1 10 NVT, 0K to 150KBerendsen pt/DNA
2 10 NVT, 150K to 300KBerendsen pt/DNA
equilibration 1 0.002 100 NVT, 300K NHA pt/DNA
opt 1 none
production 0.002 5000 NVT, 300K NHA none
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Table A3-2. Molecular dynamics simulation protocol used in DL_POLY simulations. 
1A2E
General settings:
cut rvdW delR shake tol ewald precision no link Berendsen NVT or NPT Verlet leap-frog
12.0 A 12.0 A 0.5 A 1.00E-08 1.00E-06
Sim ensemble T /K p / atm tau T / ps tau p / ps timestep / ps steps equilibration scale only water bonds frozen
1 NPT 300 1 0.01 0.1 0.0005 50000 50000 1 +
2 NPT 300 1 0.1 0.3 0.001 10000 10000 1 +
3 NPT 300 1 0.3 0.4 0.001 10000 10000 1 +
4 NPT 300 1 1 1 0.001 10000 10000 1 +
5 NPT 300 1 2 2 0.001 5000 5000 1 +
6 NPT 300 1 0.2 0.2 0.002 50000 50000 1 +
7 NPT 300 1 0.5 0.5 0.002 50000 0 1 +
8 NPT 300 1 1 1 0.002 50000 0 1 +
9 NPT 300 1 2 2 0.002 50000 0 1 +
10 NPT 300 1 2 2 0.002 3000000 0 1 +
2 Cl-
18 Na+
3941 H2O
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1A2E DE-PLATINATED
General settings:
cut rvdW delR shake tol ewald precision no link Berendsen NVT or NPT Verlet leap-frog
12.0 A 12.0 A 0.5 A 1.00E-08 1.00E-06
Sim ensemble T /K p / atm tau T / ps tau p / ps timestep / ps steps equilibration scale only water bonds frozen
1 NPT 300 1 0.1 0.5 0.0001 50000 50000 1 +
2 NPT 300 1 0.1 0.2 0.0005 5000 5000 1 +
3 NPT 300 1 0.1 0.1 0.001 5000 5000 1 +
4 NPT 300 1 0.5 0.1 0.001 50000 50000 1 +
5 NPT 300 1 1 1 0.001 50000 50000 1 +
6 NPT 300 1 2 2 0.001 50000 50000 1 +
7 NPT 300 1 2 2 0.002 3000000 50000 1 +
18 Na+
3941 H2O  
  
  
1
7
1
 
P-DNA
General settings:
cut rvdW delR shake tol ewald precision no link Berendsen NVT or NPT velocity Verlet
12.0 A 12.0 A 0.5 A 1.00E-08 1.00E-06
Sim ensemble T /K p / atm tau T / ps tau p / ps timestep / ps steps equilibration scale only water bonds frozen
1 NPT 300 1 0.3 0.3 0.0005 50000 50000 1 +
2 NPT 300 1 0.3 0.3 0.001 50000 50000 1 +
3 NPT 300 1 0.5 0.5 0.002 100000 100000 1 +
4 NPT 300 1 0.5 0.5 0.002 100000 0 0 +
5 NPT 300 1 0.2 0.2 0.002 500000 500000 1 +
6 NVT 450 0.2 0.003 5000 5000 1 ---
7 NVT 300 0.2 0.002 50000 50000 15 +
8 NVT 450 0.2 0.003 5000 5000 1 ---
9 NVT 300 0.2 0.002 50000 50000 15 +
10 NVT 450 0.2 0.003 5000 5000 1 ---
11 NVT 300 0.2 0.002 50000 50000 15 +
12 NPT 300 1 0.5 0.5 0.002 250000 250000 1 +
13 NPT 300 1 0.5 0.5 0.002 250000 250000 1 +
14 NPT 300 1 1 1 0.002 250000 250000 25 +
15 NPT 300 1 2 2 0.002 250000 250000 25 +
16 NPT 300 1 2 2 0.002 250000 250000 25 +
17 NPT 300 1 2 2 0.002 250000 250000 100 +
18 NPT 300 1 2 2 0.002 3000000 3000000 100 +
22 Na+ 2 Cl- --- means all bonds except (Pt-L) bonds 
3400 H2O  were frozen to reference value
  
1
7
2
 
 
 
  
Figure A3-1. The potential energy U(r) of 1A84 at time t in kcal/mol during LFMD simulations using DommiMOE. 
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Figure A3-2. The potential energy U(r) of 1A2E at time t in kcal/mol during LFMD simulations using DommiMOE. 
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Figure A3-3. The average LFMD structure derived from simulations of 
deplatinated 1A2E with periodic boundary conditions. 
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